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ABSTRACT 
 
Central nervous system (CNS) disorders are increasing over the last years as a 
consequence of a continuously aged population growth. Despite scientific advances, current 
therapeutics are often not thrived, which raises the increasing need for successful ways to 
reach CNS and achieve fruitful treatments. Additionally, the blood-brain barrier (BBB) is a 
unique membrane involving the brain, able to create such restrict CNS environment. 
Therefore, regarding CNS disorders incidence, failing therapeutics and BBB-related 
responsibility, the development of in vitro BBB models that mimic the physiologic BBB is a 
key factor for the study of newly developed drug/gene delivery systems, namely their 
interaction with BBB and permeability. Simultaneously, the production of effective platforms 
to circumvent BBB protective functions is leading this research field. 
Drug efflux pumps at the BBB interface, as P-glycoprotein (P-gp), act as a noteworthy 
barrier that prevents the effectiveness of CNS disorders treatments, due to their ability to 
strongly limit the perfusion of compounds into the brain. Over the past decades, new 
approaches towards overcoming the BBB and its efflux transporters have been proposed, 
with limited degree of success. Small interfering RNA (siRNA) has been taking place in this 
topic as consequence of its targeting competence to specifically silence a protein of interest 
in a post-transcriptional way. Therefore, siRNA is used as a promising approach to 
selectively silent target proteins, improving the ability of drugs to reach the brain. 
As important as the efficient protein silence is the transport of siRNA to its anatomical 
site of action. Nanotechnology and bioengineering joined to carry siRNA to the desired 
location, protecting the oligonucleotide circulation, directing its transport, and promoting 
intracellular delivery. Recent research on functionalization strategies offers distinct chemical 
tools to bind specific ligands to the surface of nanosystems, enabling them to obtain targeted 
functions. The selection of proper ligands is promoting the BBB surpassing likelihood of 
siRNA-loaded systems. 
Gathering these previous ideas, the main aim of this thesis was to develop targeted 
and safe nanosystems, able to modulate the drug efflux at the BBB via siRNA against P-gp. 
The first part of this approach was focused on the development of a non-cellular based BBB 
model where permeability experiments could be performed in a simple and fast way, 
obtaining a high throughput screening tool, also used for in vivo permeability prediction. 
Phospholipid vesicle-based permeability assay (PVPA) method was used to produce such 
model, and then, to assess passive transcellular-like permeability of siRNA, free and loaded 
into nanoparticles. Both polymeric poly(lactic-co-glycolic acid) (PLGA) and lipid (solid lipid 
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nanoparticles, SLN) nanoparticles encapsulating siRNA were developed. Slightly negative (-
10 mV) and monodisperse populations around 140 nm were obtained and their effect on 
siRNA permeability through the BBB-PVPA model was assessed. The permeability of siRNA 
has increased from 3.7  10-6 cm s-1 (free siRNA) to 5.5  10-6 cm s-1 and 6.9  10-6 cm s-1 
after encapsulation into polymeric and lipid nanoparticles, respectively. 
Then, the nanoparticulate-based systems were improved through the assessment of 
several materials and functionalization techniques. A PLGA-based polymer and a lipid, both 
amine terminated, were added to the previously formulation systems in order to improve their 
surface functionalization through carbodiimide and maleimide chemical approaches. 
Concurrently, the surfactant previously used, poly(vinyl alcohol), was replaced for Tween80, 
as this last one was easier to remove from nanoparticles surface, enhancing the functional 
groups availability and therefore exhibiting their mainly negative charge. Therefore, polymeric 
PLGA nanoparticles presented mean size around 115 nm, negatively charged surface (-30 
mV) and 50% of siRNA association efficiency, while SLN, also negatively charged (up to -21 
mV), presented 150 nm of mean size and association efficiency up to 52%. The release 
profile of siRNA from nanoparticles was sustained, reaching around 60% of released siRNA 
after 24h in physiological conditions. As well, the safety of nanoparticles was demonstrated 
assessing the metabolic activity of brain endothelial cells, found to be generally above 80%, 
up to 24h of incubation. To enhance transcellular permeability, nanoparticles were 
functionalized on the surface with a peptide-binding transferrin receptor (TfR), in a site-
oriented manner, obtaining mean sizes between 321 and 506 nm and surface charge within 
the range -10 to -40 mV. Such modification was confirmed by 1H nuclear magnetic resonance 
(1H NMR), and their targeting ability against human brain endothelial cells was demonstrated 
by fluorescence microscopy and flow cytometry. The interaction of TfR-targeted 
nanoparticles with brain endothelial cells increased 3- and 4-fold compared to non-modified 
SLN and PLGA nanoparticles, respectively. 
While the interaction with endothelial cells of functionalized and non-functionalized 
PLGA nanoparticles were evident and detected through fluorescence microscopy, minor 
differences were found between functionalized and non-functionalized SLN. These data may 
indicate an inefficient SLN functionalization, either due to a low yield binding chemistry 
process itself, or due to the lack of correct peptide availability for its receptor. Therefore, 
polymeric systems seemed to be more benefic that lipid ones, which justifies the selection of 
PLGA-based nanoparticles for the next project step. 
Finally, the functionality of TfR-targeted PLGA nanoparticles via different peptide 
linkage bridges (carbodiimide and maleimide) was assessed on a human BBB cell-based 
model. Beyond their ability to improve siRNA permeability through the BBB by 2-fold, it was 
shown that, 96h post transfection, TfR-peptide functionalized PLGA nanoparticles via 
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maleimide chemistry successfully induced reduction of P-gp messenger RNA (mRNA) 
expression up to 52%, compared to non-functionalized systems. Subsequently, the 
permeability of rhodamine 123, as a P-gp substrate, through the human BBB model, was 
determined upon the treatment of endothelial cells with siRNA-loaded TfR-peptide 
functionalized PLGA systems, resulting in an increase up to 27% in permeability in three 
hours of assay. This suggested a positive and marked biologic effect of the siRNA-induced 
P-gp down-regulation. 
Overall, a BBB-targeted polymeric nanosystem was developed for delivery of siRNA 
against P-gp. Functionalized siRNA-loaded PLGA nanoparticles showed to be successful in 
silencing P-gp as a BBB efflux transporter and, consequently, in enhancing the blood-to-brain 
in vitro permeability of a P-gp substrate. Hence, drug efflux modulation at the BBB level was 
attained, bringing hope to CNS disorders treatments, since drugs could reach brain in higher 
and therapeutic concentrations. Additionally, being P-gp commonly over expressed at tumor 
cells, this polymeric system has the potential to be applied to cancer when properly 
functionalized to those cells. 
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RESUMO 
 
Com o contínuo envelhecimento da população, as perturbações relacionadas com o 
sistema nervoso central (CNS) têm vindo a aumentar ao longo dos anos. Apesar dos 
avanços científicos, as terapias existentes até à data não são suficientemente eficazes para 
travar o avanço das doenças relacionadas com o CNS, o que gera uma necessidade de 
desenvolver tratamentos mais dirigidos e eficientes. Adicionalmente, a barreira hemato-
encefálica (BBB) é uma membrana única que envolve o cérebro e cria o ambiente restrito 
característico do CNS. Assim, tendo em conta a incidência das perturbações do CNS, os 
insucessos terapêuticos e a responsabilidade relacionada com a BBB, o desenvolvimento de 
modelos in vitro da BBB que mimetizem esta barreira fisiológica torna-se preponderante no 
desenvolvimento de novos sistemas de entrega de fármacos/genes, nomeadamente na sua 
interação com a BBB e permeabilidade. Simultaneamente, esta área de investigação tem 
sido liderada pela produção de formas eficazes de contornar as funções protetoras da BBB. 
As bombas de efluxo de fármacos existentes na BBB, tal como a glicoproteína-P (P-
gp), são barreiras bioquímicas que previnem a eficácia dos tratamentos de distúrbios do 
CNS, devido à sua forte capacidade de limitar a perfusão de compostos para o interior do 
cérebro. Ao longo das últimas décadas, foram propostas novas abordagens no sentido de 
modular a passagem de fármacos pela BBB e controlar os seus transportadores de efluxo, 
embora com sucesso limitado. Como consequência das propriedades relacionadas com o 
específico silenciamento de proteínas de interesse ao nível da pós-transcrição, o RNA de 
interferência (siRNA) tem assumido uma especial preponderância nesta área da 
investigação. Desta forma, o siRNA é usado como uma abordagem promissora para 
silenciar seletivamente proteínas alvo, aumentando a probabilidade dos fármacos 
alcançarem o cérebro. 
Tão importante quanto o eficaz silenciamento proteico é o transporte do siRNA para 
o seu local de ação pretendido. Assim, a nanotecnologia e bioengenharia uniram-se, 
protegendo a circulação sanguínea dos oligonucleótidos, conduzindo o seu transporte para 
os locais-alvo e promovendo a entrega intracelular. Os recentes estudos relacionados com 
estratégias de funcionalização oferecem várias ferramentas químicas para conjugar ligandos 
moleculares específicos à superfície de nanossitemas, o que possibilita o seu 
direcionamento ativo. Desta forma, a seleção dos ligandos apropriados promove a 
probabilidade de sistemas transportadores de siRNA atravessarem a BBB. 
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Reunindo as ideias anteriores, o principal objetivo desta tese consistiu no 
desenvolvimento de nanossistemas para encapsular siRNA, seguros e direcionados, 
capazes de modular o efluxo de fármacos na BBB através de siRNA contra a P-gp. 
Inicialmente procedeu-se ao desenvolvimento de um modelo não celular de BBB. Os 
objetivos deste modelo prendiam-se com a possibilidade de testar, de um modo simples e 
rápido, a permeabilidade de compostos. Assim, uma ferramenta de rastreio e avaliação, 
também usada para a previsão da permeabilidade in vivo, foi obtida. Este modelo de 
permeabilidade baseado em vesículas fosfolipídicas (PVPA) foi otimizado e posteriormente 
testado para avaliar a permeabilidade passiva transcelular de siRNA, tanto livre como 
encapsulado. Foram desenvolvidas nanopartículas poliméricas de ácido poli(lático-co-
glicólico) (PLGA) e lipídicas (nanopartículas lipídicas sólidas, SLN) com siRNA encapsulado. 
O efeito das nanopartículas desenvolvidas, ligeiramente negativas (-10 mV) e com 
populações monodispersas de cerca de 140 nm, na permeabilidade do siRNA através do 
modelo BBB-PVPA foi avaliado. Detetou-se um aumento na permeabilidade do siRNA, 
desde 3.7  10-6 cm s-1 (siRNA livre) até 5.5  10-6 cm s-1 e 6.9  10-6 cm s-1 após 
encapsulação em nanopartículas poliméricas e lipídicas, respetivamente. 
De seguida, o sistema baseado em nanopartículas foi melhorado através do teste de 
vários materiais e técnicas de funcionalização. Componentes matriciais das nanopartículas 
modificados com grupos amina terminal foram adicionados aos sistemas já produzidos, de 
forma a promover a funcionalização da sua superfície através de duas abordagens químicas 
distintas, tanto por cardodiimida como maleimida. Simultaneamente, o surfactante 
previamente usado foi substituído por Tween80, caracterizado por ser mais facilmente 
removido da superfície das nanopartículas, promovendo a disponibilidade dos grupos 
funcionais, que assim expõem as suas cargas substancialmente negativas. 
Consequentemente, as nanopartículas poliméricas apresentaram tamanho médio de cerca 
de 115 nm, com superfície negativamente carregada (-30 mV) e com 50% de eficiência de 
associação de siRNA, enquanto as SLN, também carregadas negativamente (até -21 mV), 
apresentaram 150 nm de tamanho médio e eficiência de associação até aos 52%. A 
libertação controlada do siRNA foi verificada, alcançando cerca de 60% de libertação das 
nanopartículas após 24h em condições fisiológicas. Mais ainda, a segurança das 
nanopartículas foi garantida, uma vez que a atividade metabólica de células endoteliais 
cerebrais, quando em contacto com todas as nanopartículas em concentrações crescentes, 
esteve geralmente acima dos 80%, até 24h de incubação. Com vista a melhorar a 
permeabilidade transcelular, as nanopartículas foram funcionalizadas com um péptido que 
se liga ao recetor da transferrina (TfR), atingindo tamanhos médios entre 321 e 506 nm, e 
cargas de superfície entre -10 e -40 mV. Ensaios de ressonância magnética nuclear 1H (1H 
NMR) confirmaram esta modificação de superfície, e a capacidade das nanopartículas se 
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direcionarem para células da BBB humana foi demonstrada por microscopia de 
fluorescência e citometria de fluxo. A interação entre os sistemas funcionalizados e as 
células aumentou 3- e 4-vezes quando comparado aos mesmos sistemas não 
funcionalizados de SLN e PLGA, respetivamente. 
Apesar das diferenças de interação com as células endoteliais entre as 
nanopartículas de PLGA funcionalizadas e não funcionalizadas terem sido notórias através 
de microscopia de fluorescência, o mesmo não aconteceu relativamente às SLN. Estes 
resultados indicam a possível ineficácia na funcionalização das SLN, que poderá estar 
relacionado com o baixo rendimento do processo de ligação química, ou dever-se à falta de 
péptido, espacial e corretamente disponível, para o seu recetor. Deste modo, os sistemas 
poliméricos pareceram ser mais benéficos que os lipídicos, razão pela qual foram 
selecionados para prosseguir no desenvolvimento do projeto de tese. 
Por fim, as nanopartículas funcionalizadas com o péptido anti-TfR, através da 
implementação da ligação carbodiimida ou maleimida, foram avaliadas num modelo celular 
de BBB humana. Para além da sua capacidade de duplicar a permeabilidade do siRNA 
através da barreira, foi evidenciado que, 96h após a transfeção, as nanopartículas 
funcionalizadas via maleimida induziram eficazmente a redução da expressão do RNA 
mensageiro (mRNA) da P-gp até 52%, em relação aos sistemas não funcionalizados. 
Subsequentemente, a permeabilidade da rodamina 123, como substrato da P-gp, foi 
determinada através do modelo de BBB humana, após incubação das células endoteliais 
com as nanopartículas de PLGA funcionalizadas. No final de três horas de ensaio, a 
permeabilidade da rodamina 123 aumentou até 27%, o que sugere a existência de um efeito 
biológico positivo e notável, através da regulação negativa da P-gp induzida por siRNA. 
De uma forma geral, foram desenvolvidos nanossitemas poliméricos, direcionados 
para a BBB, para a entrega de siRNA anti-P-gp. As nanopartículas funcionalizadas e 
carregadas com siRNA mostraram conseguir silenciar a P-gp como um transportador de 
efluxo da BBB e, consequentemente, potenciar a permeabilidade sangue-cérebro de um 
substrato da P-gp. Desta forma, foi alcançada a modulação do efluxo de fármacos ao nível 
da BBB, o que traz esperança para o tratamento das perturbações do CNS, já que os 
fármacos poderão alcançar o cérebro em concentrações mais elevadas e potencialmente 
terapêuticas. Visto que a P-gp é comummente sobre expressa em células cancerígenas, o 
sistema polimérico desenvolvido poderá ser aplicado a condições tumorais, desde que 
adequadamente funcionalizado para essas mesmas células. 
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1. Central nervous system disorders 
 
The number of people aged 60 years and over has tripled since 1950, reaching 600 
million in 2000 and surpassing 700 million in 2006. It is projected that the combined senior 
and geriatric population will reach 2.1 billion by 2050 (United Nations, 2007). As the effects of 
ageing on the brain and cognition are widespread and have multiple etiologies, the 
increasing incidence of brain disorders is real and expected. The World Health Organization 
has indicated that central nervous system (CNS) disorders are the major medical challenge 
of the 21st Century (Research And Markets, 2007). Disorders of the CNS are numerous, 
diverse, frequently severe, and affect a large portion of the world population. These diseases 
can debilitate conditions that significantly affect the morbidity and mortality of modern society. 
Neurodegenerative diseases including Alzheimer's diseases, Parkinson's diseases and 
amyotrophic lateral sclerosis – which symptoms are related to loss of movement, memory, 
and dementia due to the gradual loss of neurons – are constantly and rapidly increasing as 
population ages. As well, brain tumors constitute a severe and unsolved clinical condition 
and are a common cause of cancer-related death. 
Longer life expectancy should be followed by better quality of life, however, current 
therapies to CNS disorders (which are mainly incident on old-age population) do not 
positively correspond to their expectations (Bhaskar et al., 2010). Neurodegenerative 
diseases, deeply associated with aging, are usually linked to a loss of brain and spinal cord 
cells. As examples, in Alzheimer's and Parkinson's diseases the neuronal damage occur due 
to abnormal protein processing and accumulation, which results in gradual cognitive and 
motor deterioration (Gilmore et al., 2008). 
According to Brain Tumor Research website statistics (Farm, 2014), brain tumors kill 
more children and adults under the age of 40 than any other cancer, and only 18.8% of those 
diagnosed with brain tumor survive beyond five years, compared to 50% average survival 
prognostic for all cancers. Moreover, the incidence of brain metastases has increased over 
the last decade mainly due to improved treatment of primary peripheral cancers resulting in 
increased patient survival, as well as due to the development of newer tools to image and 
diagnostic tumors of the CNS (Agarwal et al., 2011). Among the different ways to treat 
cancer, such as surgery and radiotherapy (which uses high-energy particles or waves to 
destroy or damage cancer cells, that arise the possibility to damage also normal cells, reason 
why this treatment must be carefully planned to minimize side effects), tumor therapy is 
usually based on the interplay between chemotherapeutic and antiangiogenic agents 
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(Murthy, 2007). In general, treatment of many aging disorders and tumors require drugs 
acting on the CNS, highlighting the need and importance to reach CNS on a therapeutic 
concentration. Simultaneously, the field of nanomedicine is rapidly expanding and promises 
revolutionary advances to the diagnosis and treatment of devastating human diseases 
(Gilmore et al., 2008). 
 
2. Obstacles to brain diseases treatment 
 
Drug delivery to the CNS represents a challenge in developing effective treatments 
for neurodegenerative diseases and brain tumors due to the unique and complicated 
environment imposed by the CNS itself. There are protective barriers which restrict the 
passage of foreign substances into the brain, namely the blood-brain barrier (BBB), the blood 
cerebrospinal fluid barrier (BCSF), and other specialized CNS barriers as the arachnoid 
barrier  (Abbott et al., 2010; Bhaskar et al., 2010). Therefore, an important part of this CNS 
challenge is overcoming the natural tendency of the BBB to block drug transport. This barrier, 
a tightly packed layer of endothelial cells surrounding the brain (Bhaskar et al., 2010), is 
designed to protect and prevent high-molecular weight molecules in blood from entering the 
brain by filter harmful compounds from the brain back to the bloodstream. As so, since the 
BBB cannot recognize therapeutic compounds, high doses must be administered to have a 
drug therapeutic concentration at the brain, with increased risks of adverse side effects 
(Murthy, 2007). 
Due to the difficulty of physically active molecules overcome BBB and reach CNS, it 
becomes crucial to understand the structural composition as well as how the factors that 
regulate permeability of the substances across the BBB act. Morphologically, the BBB is 
mainly constituted by brain endothelial cells, which form the cerebral microvascular 
endothelium, paving the luminal side (the blood capillary side). This cell layer is in close 
association with basement membrane and neighboring cell types, which include pericytes, 
astrocytes, neurons and microglia in the abluminal membrane. Together, these various cell 
types form the neurovascular unit that is essential for the health and function of the CNS 
(Figure 1.1). Endothelial cells release a number of diffusible factors that are able to affect 
neural precursors and to promote stem-cell renewal (Cardoso et al., 2010). On the other 
hand, pericytes play an important role on the integration of endothelial cells and astrocytes 
functions at the neurovascular unit (Armulik et al., 2010; Fisher, 2009); and astrocytes are 
crucial on the induction of BBB integrity and functions, namely by the secretion of factors 
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such as basic fibroblast growth factor (Abbott et al., 2006). Moreover, neurons are a key 
factor on BBB cerebral flow and vessel dynamics (Cardoso et al., 2010; Choi and Kim, 
2008a; Weiss et al., 2009). Lastly, the exact mechanisms of how microglia influences BBB 
properties are still unknown, however it is clear that they are playing an important role in 
immune response of the CNS and consequently in the BBB integrity (Choi and Kim, 2008b). 
Besides this cellular network, several molecular and receptor structures are present 
on the surface of the endothelial cells (Figure 1.2), able to mediate the transport of solutes 
and other substances including drugs in and out of the brain. Therefore, BBB is also 
responsible for leukocyte migration and maintenance of brain microenvironment 
homeostasis, which is crucial for neuronal activity and proper functioning of CNS. The 
transport of solutes and other substances across BBB is also dependent on intercellular 
junctions affecting the paracellular permeability (Wilhelm and Krizbai, 2014). Tight junctions 
(TJs) consist of an extreme complex of integral proteins spanning the intercellular cleft, 
junctional adhesion molecules and cytoplasmic accessory proteins bound to the actin 
cytoskeleton. Specifically, claudins form the primary seal of TJ, determining TJ integrity. 
Occludins are the dynamic regulatory proteins responsible for TJ regulation and subsequent 
transendothelial electrical resistance (TEER) enhancement, and paracellular permeability 
restriction. Together, claudins and occludins form the extracellular component of TJs (Abbott 
et al., 2006). Furthermore, adherent junctions are located near the basolateral side of 
endothelial cells, holding them together and giving the tissue structural support (Abbott et al., 
2010). Besides junctions, as special characteristics of BBB that limit drug uptake, there is 
also a lack of fenestrations, low endogenous pinocytotic activity  and metabolic barriers 
(enzymes and diverse transport systems) (Ballabh et al., 2004). Other important 
characteristic of in vivo BBB is the shear stress over the surface of the cells, which is a 
tangential force generated by the blood flow. Shear stress (SS) promotes the differentiation 
process and maintenance of BBB phenotype (Cucullo et al., 2011). 
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Figure 1.1. Blood-brain barrier cellular structure and morphology. The neurovascular unit is a complex 
cellular system that includes highly specialized endothelial cells, a high concentration of pericytes 
embedded in the endothelial cell basement membrane; astrocytic endfeet associated to the 
parenchymal basement membrane, neurons and immune cells. Adapted from Abbott, 2013. 
 
Next to the BBB, BCSF is the second important feature of the CNS, formed by the 
epithelial cells of the choroid plexus. BCSF mainly regulates the exchange of molecules 
between the blood and cerebrospinal fluid, controlling the penetration within the interstitial 
fluid of the brain parenchyma (Bhaskar et al., 2010; Gilmore et al., 2008; Mahringer et al., 
2011). Moreover, another interface, the avascular arachnoid epithelium, has a relatively small 
surface that is the main reason why it is not a significant surface for exchange between blood 
and CNS (Abbott et al., 2010). Some other CNS barriers, like blood tumor barrier and blood 
retina barrier, may also play a role in drug transport (Bhaskar et al., 2010). 
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Figure 1.2. Mechanisms present at the BBB that mediate the transport from blood to brain (Nagpal et 
al., 2013). 
 
3. Blood-brain barrier and drug efflux 
 
As already mentioned, BBB is an endothelial dynamic interface that shields the CNS 
from exposure to circulating toxins and potentially harmful chemicals (Hawkins and Davis, 
2005). This protective barrier controls the influx and efflux of a wide variety of substances, 
excluding therapeutic drugs from entering the brain, and thus, at the same time, maintains a 
favorable environment for the CNS and becomes an obstacle for drugs intended to treat CNS 
diseases (Agarwal et al., 2011; Bhaskar et al., 2010). The ability of a substance to penetrate 
the BBB or be transported across BBB is dependent on its physiochemical properties, as 
small size, liposolubility and customizable surface, which are examples of favorable 
properties. The cerebral pharmacological efficacy of any drug depends on its CNS uptake 
which, in turn, depends on a combination of factors, including CNS physical barriers and the 
affinity of the substrate for specific transport systems located at both sides of these 
interfaces. In this context, efflux transporters present at the BBB are one of the main 
limitations of brain penetration as well as the main responsible for intra- and extra-cellular 
distribution of a variety of endogenous and exogenous compounds. Active efflux transport or 
carrier mediated efflux involve extrusion of drugs from the brain in the presence of efflux 
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transporters. This type of transport causes the active efflux of drugs from brain back to blood 
(Bhaskar et al., 2010). Therefore, one strategy to improve the efficacy of CNS drugs would 
be the modulation of transport proteins mainly responsible for the drug efflux, being 
responsible for their improved passage across the BBB (Mahringer et al., 2011). 
 
3.1. Drug efflux transporters 
 
A key element of the BBB function is the expression of ATP-binding cassette (ABC) 
drug efflux transporters in the luminal membrane of brain microvessel endothelial cells, which 
besides restrict the entry of many compounds into the brain, also plays a major role on the 
maintenance of brain homeostasis and detoxification. Among these ABC transporters, are 
the P-glycoprotein (multi-drug resistance 1 (Mdr1) gene product, P-gp), breast cancer 
resistance protein (BCRP), and members of the multi-drug resistance related proteins (Mrp1, 
2, 4 and 5). These proteins collectively hamper brain uptake of a huge variety of lipophilic 
xenobiotics, potentially toxic metabolites and also drugs. Several other transport proteins and 
receptors are expressed at the BBB, such as the non-ABC transporters Oat3 (organic anion 
transporter) and Oatp2 (organic anion transporting polypeptide that handles steroid and drug 
conjugates, certain opioid peptides, and the cardiac glycoside, digoxin) that, when coupled to 
the appropriate ion gradients, are capable of driving organic anions into the endothelial cells 
(Agarwal et al., 2011; Bauer et al., 2005; Hermann and Patak, 2011; Mahringer et al., 2011). 
A deeply studied export pump is P-gp, a 170 kDa phosphorylated glycoprotein 
expressed in multiple cell types within the brain parenchyma, including astrocytes and 
microglia. Its highest activities seem to be in the luminal plasma membrane of the capillary 
endothelium (Mahringer et al., 2011). Mdr1 is often over expressed in tumor cells, which 
contributes to the multi-drug resistant phenotype commonly seen in cancer (Fisher et al., 
2007). The fact that Mdr1 messenger RNA (mRNA) and P-gp are highly expressed in multi-
drug resistant cells, while P-gp has a long turnover time, make this target very attractive to 
inhibit with antisense or small interference RNA (siRNA) oligonucleotides (Fisher et al., 
2007). Moreover, in vivo dosing studies in Mdr1-knockout mice show greatly increased 
plasma-to-brain ratios (5-fold to 50-fold) for a large number of drugs that are P-gp substrates 
(Schinkel et al., 1996), which indicates the relevance of P-gp efflux system (Bauer et al., 
2005). 
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Another example that highlights P-gp efflux mechanism, by decreasing the effect of 
drugs which are its substrates, was studied by using morphine on rats-induced peripheral 
inflammatory pain (Sanchez-Covarrubias et al., 2014). This condition results in increased 
expression and activity of P-gp and, consequently, there is a significant reduction in CNS 
uptake of morphine (since morphine is a P-gp substrate) and reduced morphine analgesic 
efficacy. Considering this, researchers induced peripheral inflammatory pain and examined 
the administration of diclofenac on BBB transport of morphine via P-gp, as well as on its 
analgesic and anti-inflammatory efficacy. Diclofenac, a non-steroidal anti-inflammatory drug, 
is commonly administered in conjunction with opioids (i.e. morphine) during pain therapy, and 
have been reported to modulate P-gp (Akanuma et al., 2010). Authors observed a significant 
decrease in brain morphine uptake in injured animals. Moreover, in situ brain perfusion 
studies showed that not only pain induction but also diclofenac treatment alone increased P-
gp efflux activity which results in decreased morphine brain uptake (Sanchez-Covarrubias et 
al., 2014). Robillard and colleagues investigated in vivo the tissue distribution of the human 
immunodeficiency virus protease inhibitor atazanavir in wild-type (WT) mice and P-gp/BCRP-
knockout mice. In this study, some WT mice were pre-treated with a P-gp/BCRP inhibitor, 
elacridar. In P-gp and Bcrp knockout mice, authors demonstrated a significant increase in 
atazanavir brain concentration of 5.4-fold compared to those in WT mice (p < 0.05). 
Moreover, elacridar-treated WT mice showed a significant increase in atazanavir brain 
concentration of 12.3-fold compared to those in vehicle-treated WT mice. These in vivo 
results show how P-gp (as well as BCRP) is involved in limiting the ability of atazanavir to 
permeate mice brain (Robillard et al., 2014). Also Liu and co-workers studied P-gp 
consequences as an efflux transporter. A novel anti-Parkinson’s disease (PD) candidate 
drug, which is a synthetic squamosamide derivative (FLZ), has shown poor BBB penetration, 
but the main reason for that (if caused by P-gp and/or BCRP) was still unclear. Therefore, in 
vitro permeability experiments of FLZ were carried out on BBB models (one mimicking 
physiological, and other PD pathological-related BBB properties). In PD models, both 
expressions of P-gp and BCRP were significantly greater, which is associated with the lower 
BBB permeability of FLZ in pathological model, compared with physiological model. 
Transport studies were also performed, and obtained data have shown that only P-gp blocker 
effectively inhibited the efflux of FLZ. Thus, from this study it is possible to conclude that P-gp 
is the main responsible for poor brain penetration of FLZ and low BBB permeability (Liu et al., 
2014). 
The BCRP (72 kDa (Paturi et al., 2010)) mainly transports sulphated conjugates of 
drugs and sterols (Hori et al., 2005), which largely corresponds to cationic and uncharged 
substrates (Bauer et al., 2005). Its function is regulated by steroid hormones, particularly 
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estrogens. In brain capillaries from male and female rats and mice, BCRP-mediated transport 
was rapidly and reversibly reduced after short term exposure to nanomolar concentrations of 
17β-estradiol (Mahringer et al., 2011). 
Multi-drug resistance related protein 4 (Mrp4; 150 kDa (Sauna et al., 2004)) shares 
many features with P-gp and BCRP, including broad substrate affinity and expression at the 
BBB (Lin et al., 2013). Regarding the difficulty to evaluate the role of Mrp4 at the BBB (since 
most drugs are also substrates of P-gp and/or BCRP), Lin and co-workers created a mouse 
strain in which all these alleles were inactivated. Hence, they used these animals to assess 
inactivated alleles impact on brain delivery of camptothecin analogues (as gimatecan and 
itinotecan active metabolite SN-38), an important class of antitumor agents, substrates of 
these transporters. They were able to observe that additional deficiency of Mrp4 in P-
gp;BCRP-/- mice significantly increased the brain concentration of all camptothecin 
analogues by 1.2-fold (gimatecan) and 5.8-fold (SN-38). The presence of P-gp or Mrp4 alone 
was sufficient to reduce the brain concentration of SN-38 to the level in WT mice. From this 
study, it is possible to conclude that Mrp4 limits the brain penetration of camptothecin 
analogues and teams up with P-gp and BCRP to form a robust cooperative drug efflux 
system. This intensive action limits the usefulness of selective ABC transport inhibitors to 
enhance drug entry for treatment of intracranial diseases (Lin et al., 2013). 
Regarding BBB composition features, namely these drug efflux transporters, only a 
small class of drugs or small molecules (molecular mass of < 400-500 Da) with high lipid 
solubility are actually able to across the BBB (Bhaskar et al., 2010). Thus, conventional 
pharmacological drugs or chemotherapeutic agents are incapable to pass through the 
barrier. 
 
4. Blood-brain barrier in vitro models 
 
BBB represents a critical obstacle in the treatment of the neurological disorders as 
preventing most of the pharmaceutical solutions being successful (Nagpal et al., 2013). 
Therefore, nowadays, there is a huge interest on the development of effective solutions to 
overcome this barrier and treat brain diseases. Thus, the development of a close in vitro 
system is an important step for the evaluation of new drugs and drug delivery systems to 
cross the BBB. However, as a unique environment, BBB is very difficult to mimic. 
Considering that a single factor could be enough to change BBB fundamental properties, so 
far no in vitro model can faithfully reproduce all the properties and characteristics of the in 
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vivo BBB (Cardoso et al., 2010). Nonetheless, improve existing BBB models and/or creating 
new ones is a challenging aim to several researches groups. 
Several options could be selected in order to mimic BBB, from non-cellular to cell-
based models. Distinct type of apparatus (static or dynamic) could be established, as well as 
used with cells from different origins (as endothelial cells, astrocytes, neurons), as primary 
cells or immortalized cell lines, in monoculture or co-culture. Usually, the final purpose needs 
and the available facilities, time and resources determine which kind of model researchers 
select to reproduce. 
 
4.1. Non-cellular based models 
 
There exists an increasing demand for in vitro models. However, so far, there is no 
such thing as a perfect model; all of them have some drawbacks and deficiencies. 
Complexity, time-consuming, high costs, absence of some in vivo features or lack of 
accuracy are just a few examples. Investigators continue to explore the membrane model 
world, searching for a more reliable but still cost effective bio-relevant model approach. 
Usually, cell-based models are relatively costly to maintain and time-consuming, mainly due 
to culturing times. Therefore, models based on non-cellular membranes arise as attractive 
alternatives. Artificial membranes based on parallel artificial membrane permeability assay 
(PAMPA) and phospholipid vesicle-based permeation assay (PVPA) constitute effective 
models for passive and transcellular-like permeability (Buckley et al., 2012). These models 
are particularly interest for poorly soluble drugs permeability studies, since they are 
transported through the evaluated transcellular route. Generally, non-cellular based models 
are relatively cheap and offer the opportunity for high throughput analysis, where a fast 
screening of large numbers of compounds could be performed (Buckley et al., 2012). 
 PAMPA, a membrane model based on lipids, was first developed to predict 
transcellular absorption of drug in the intestine, but its potential was rapidly underlined and 
several variants with different lipid compositions have been generated (Buckley et al., 2012), 
including the BBB-PAMPA (Wohnsland and Faller, 2001). Nonetheless, PVPA membranes 
are prepared through the deposition of liposomes on a porous filter, reaching a tight barrier 
comprised of phospholipid bilayers sandwiches (Buckley et al., 2012). This is a more recently 
developed intestinal artificial model, which has already demonstrated a good correlation with 
in vivo data for drugs transported by passive diffusion (Flaten et al., 2006). Although it is 
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most suitable for passive permeability studies, it can be applied for the prediction of the 
extent of oral drug absorption for new entities in early drug development. Interestingly, 
electrical resistance and permeability of a model drug (calcein) were used to confirm barrier 
integrity, as cellular-based models usually do (Flaten et al., 2008). Moreover, the possibility 
to change the lipid composition and adapt the protocol in order to mimic different barriers was 
already executed for skin (Engesland et al., 2013), leaving the opportunity and an open gap 
for other desired barriers. 
 
4.2. Cell-based models 
 
 In the last decades, most of the current successful cell-based BBB in vitro models 
were based on primary cell cultures due to their high TEER values and low cellular passage. 
However, there may be a limitation on the availability of the primary cells resulting from 
animals’ low accessibility, while these cells are also more susceptible to internal and external 
contaminations than immortalized cell lines. In addition, this approach has high costs and 
requires time-consuming and special skills for the cellular isolation (Wilhelm and Krizbai, 
2014). On the other hand, immortalized cell lines offer a considerable number of advantages. 
They are reliable (using trusted well-established sources), consistent (cell source is 
controlled), long-lasting (it is important that cell features do not disappear over time), 
accessible (cells are available to be purchased at any time) and preparation time and cost 
are reduced (Zhang et al., 2011). Despite lacking certain BBB features and having lower 
TEER, there is no doubt that immortalized cell lines are an emergent solution to reproduce 
the in vitro BBB models (Cardoso et al., 2010). 
 Until current ages, mouse and rat brain endothelial cell lines are the most common to 
use (Cardoso et al., 2010; Li et al., 2010). Less studied but still used are porcine and bovine 
origins (Wilhelm and Krizbai, 2014). Human brain endothelial cells became available during 
the early 1980s and were revealed as crucial for the study of the BBB developmental and 
pathophysiological processes. The best characterized human cell line in this field is the 
cerebral microvascular endothelial cell line (hCMEC/D3) which has been shown to retain 
important BBB characteristics at least until the 35th passage. Briefly, hCMEC/D3 shows a 
stable phenotype, the expression of endothelial cell markers and ABC-transporters. Human 
specimens are undoubtedly the best model, since they are the only ones that faithfully 
reproduce the human BBB characteristics (Wilhelm and Krizbai, 2014). 
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 As mentioned previously, brain endothelial cells are the main component of BBB; 
nonetheless, other cell types also play an important role both in the function and regulation of 
BBB characteristics. Therefore, in vitro models could be improved and have an increased 
complexity when other cell types as astrocytes/glial cells, pericytes, and even neurons are 
included. To study the BBB models efficiency, several barrier properties should be analyzed, 
such as TEER and permeability of certain molecules (Wilhelm et al., 2011). 
 
4.2.1. Monoculture models 
 Semi-permeable membranes devices as Transwell® (further discussed in the Figure 
1.4 A) enable the study of BBB cell culture models. Using this approach, different properties 
can be assessed within the same device, as drug permeability and TEER. However, some 
disadvantages include cell adhesion with a random pattern at semi-permeable membranes, 
which provokes the so-called "edge effect" with the possible subsequent TJ absence (Naik 
and Cucullo, 2012; Santaguida et al., 2006). 
 A simplified view of the BBB, as monolayer of highly specialized brain microvascular 
endothelial cells on a Transwell® apparatus, is the most used idea for a BBB model. For this 
monoculture system, cells from various sources (bovine, rodent, porcine, non-human 
primate, and human) are seeded on the upper (luminal) surface of the membrane, immersed 
in their specific growth media. Transwell® apparatus have a microporous membrane interface 
that allows for nutrient exchange and the passage of cell-derived and exogenous 
substances, but does not allow cell movement across the two compartments, upper and 
lower (Naik and Cucullo, 2012). Brain endothelial cells from rat (as RBE4 (Vilas-Boas et al., 
2014; Wilhelm et al., 2011) and GP8 (Demeuse et al., 2004)) and mouse (b.End3 (Shi et al., 
2014)) are extensively cultured on monolayers as BBB plain models. Besides these non-
human cell lines, the already mentioned hCMEC/D3 has been of growing importance (Abbott, 
2013; Wilhelm et al., 2011). 
 However, monoculture is a basic reconstruction of the BBB which therefore lacks 
several vital features necessary for the development of real BBB properties in vitro. These 
type of models do not have natural physiological stimuli as cell-to-cell interaction with 
perivascular astrocytes and other parenchymal cells (e.g. neurons), intraluminal SS, and 
circulating blood cells. These lacking properties significantly limit the vascular endothelium 
capability to develop and/or maintain the in vivo intrinsic BBB properties and functions. 
Moreover, besides these limitations, this disadvantage could also accelerate endothelial 
dedifferentiation, promoting the consequent loss of BBB characteristics (Naik and Cucullo, 
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2012). All of these lead to the development of more complex BBB models, incorporating 
different type of cells in order to reproduce more closely the neurovascular unit (Abbott, 
2013). 
 
4.2.2. Co-culture models 
 All previous described cells can be used in combination to obtain different and 
improved co-cultures models (Figure 1.3). From these, generally, the ones that better mimic 
in vivo BBB anatomical conditions bring into play brain endothelial cells with astrocytes 
and/or pericytes. 
 Different cells could need different medium composition. Hence, if co-culture is 
intended, determine how different media or their combination affect cell morphology and 
culture consistency is crucial. 
 
Figure 1.3. In vitro cell-based co-cultured BBB models using three types of cells (endothelial cells, 
pericytes, astrocytes, and/or neurons) in different arrangements (A to F). Adapted from Wilhelm and 
Krizbai, 2014. 
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 Co-culture of endothelial cells with glial cells/astrocytes 
 Glial cells ability to induce BBB properties is the main reason why they are broadly 
used nowadays in co-culture with endothelial cells (Wilhelm et al., 2011), mostly for drug 
delivery studies (Zhang et al., 2011). Usually, primary glial cells or the immortalized C6 cell 
line, which has been intensively used for the study of gliomas, are cultured (Abbott, 2013; 
Wilhelm et al., 2011). On semi-permeable plate filters, astrocytes are usually seeded on the 
abluminal side and release factors which promote BBB characteristics such as: formation of 
more strict inter-endothelial tight junctions, increased expression of brain endothelial marker 
enzymes, transporters and efflux systems (Naik and Cucullo, 2012). 
 Studies indicate that co-culture of bovine endothelial cells and astrocytes promote an 
increase in TEER data and decrease in permeability values, comparing with endothelial cells 
monoculture (Zysk et al., 2001). As with bovine cells, also similar results were obtained with 
rat or mouse endothelial cells and astrocytes. To achieve good TEER values, direct contact 
between endothelial cells and astrocytes is necessary (Wilhelm et al., 2011). The robustness 
of a BBB model was also achieved through the incorporation of astrocytes-derived acellular 
extracellular matrix, which was derived from the lyses and decellularization of rat astrocytes 
(Zhang et al., 2011). 
 Co-culture of endothelial cells with pericytes 
 At the in vivo BBB, endothelial cells and pericytes have a close contact, so this co-
culture mixture could be very reliable. It is still unknown which type of pericytes plays a 
decisive role, but it has been established that there is an intrinsic relation between pericytes 
and the formation and maintenance of the cerebral microvasculature structure and functions 
(Ribeiro et al., 2010). Corroborating this, in vitro studies already shown an increase of TEER 
due to the addition of pericytes (Hayashi et al., 2004; Santaguida et al., 2006), indicate that 
direct contact between these cells leads to the tightest barrier formed (Hayashi et al., 2004). 
Furthermore, pericytes have been also shown to induce Mrp 6 expression (Berezowski et al., 
2004) in endothelial cells. 
 Co-culture of endothelial cells with neurons 
 More recently, it has been proved that neurons induce the production of BBB related 
enzymes in cultured cerebral endothelial cells (Tontsch and Bauer, 1991). The co-culture of 
rat brain endothelial cells with cortical neurons has shown that a direct contact between them 
is not necessary for the induction of occludin (one of the TJ proteins) expression (Cestelli et 
al., 2001). 
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 Triple co-culture 
 A combination of three different cells is also possible but not so usual due to the 
complexity of such model. Still, most common triple co-cultures associate pericytes or 
astrocytes on the bottom side of Transwell® inserts plus endothelial cells seeding on the 
upper side (Wilhelm et al., 2011). The presence of both pericytes and astrocytes is frequently 
described as advantageous since brain endothelial cells express higher levels of TJ proteins 
and greater tightness (Nakagawa et al., 2009). 
 A multi-culture human cell system study with endothelial cells, astrocytes, and 
pericytes in a three-dimensional (3D) configuration, based on Transwell® filters, has also 
been performed. Mono-, co-, and tri-cultivation were investigated to find the most effective 
model (Hatherell et al., 2011). Authors conclude that co-cultivation of astrocytes with 
endothelial cells produced the most successful model, as determined by TEER values that 
were significantly higher than for the pericyte co-culture. Nevertheless, pericytes co-culture 
improved TJ formation, but did not improve the model to such an extent when grown in tri-
cultivation with astrocytes (Hatherell et al., 2011). 
 
4.3. Blood-brain barrier apparatus 
 
 Various factors intrinsic to in vivo environment are crucial to maintain an optimally 
functioning BBB (Prabhakarpandian et al., 2013). Several in vitro BBB apparatus have been 
developed and can be distinguished into two main groups: static and dynamic systems. The 
main difference is related to the fluid flow of dynamic systems that results in SS over the cells 
surface (Booth and Kim, 2012), which is an essential characteristic of the in vivo BBB. 
 
4.3.1. Static models 
 The semi-permeable plate filters, with a side-by-side diffusion support, are the best 
and most well known bi-dimensional static model. This system consists of a microporous 
semi-permeable membrane that separates the luminal (vascular) and the abluminal 
(parenchymal side) compartments, and is submerged in feeding medium (Naik and Cucullo, 
2012; Santaguida et al., 2006). Such apparatus, characterized for its easiness to establish 
cultures and low cost (Cucullo et al., 2008; Naik and Cucullo, 2012; Santaguida et al., 2006), 
is indicated to study permeability of drugs across BBB. However, the semi-permeable 
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membranes cannot reproduce the physiological tangential force generated by the blood flow 
(SS) across the apical surfaces affecting the structure and function of endothelial cells 
(Cucullo et al., 2011; Naik and Cucullo, 2012; Prabhakarpandian et al., 2013). Shear stress 
promotes the differentiation process and maintenance of BBB phenotype; without it the cells 
lose their BBB properties (Cucullo et al., 2008; Naik and Cucullo, 2012). In addition, lacking 
antimitotic influences by laminin and flow, cell cycle rate tends to increase, causing an 
uncontrolled growth of endothelial cells in a multilayer manner (Naik and Cucullo, 2012; 
Santaguida et al., 2006). 
 
4.3.2. Dynamic in vitro (DIV) models 
 Although Transwell® apparatus (Figure 1.4 A) cannot mimic the intraluminal blood 
flow that is essential for the formation and differentiation of the BBB, dynamic models use 
physical stimuli to create SS. Replicating both functionally and anatomically the brain 
microvasculature, these models create quasi-physiological conditions (Ribeiro et al., 2010; 
Santaguida et al., 2006). 
 The first attempt to dynamically mimic BBB was performed by Bussolari and co-
researchers through the use of a purpose-built cone and plate viscometer (Bussolari et al., 
1982). This apparatus allowed them to expose cells to a quasi/uniform laminar or pulsatile 
SS. However, due to the turbulence presented by the created flow, it did not faithfully 
reproduce the flow experienced in vivo. Nonetheless, this was the first step to produce 
dynamic BBB models. The realized importance of SS as a vital component of any in vitro 
model was increasing, so researchers decided to focus on the development of new 
generations of dynamic in vitro systems as the dynamic in vitro model of the BBB (DIV-BBB; 
Figure 1.4 B) (Naik and Cucullo, 2012; Ribeiro et al., 2010). 
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Figure 1.4. Schematic representation of the Transwell
®
 and the DIV-BBB systems. (A) The static 
Transwell
®
 system consists of cells grown on microporous membranes, and allows the study of 
bidirectional transport across the BBB. (B) A bundle of porous polypropylene hollow fibers is 
suspended in the DIV-BBB chamber. These fibers are in continuity with a medium source through a 
flow path consisting of gas-permeable silicon tubing. ECS stands for extracellular space. Adapted from 
Cucullo et al., 2008. 
 
 This system allows the use of co-cultures and creates intraluminal flow through 
artificial capillary-like structural supports (hollow fibers) (Cucullo et al., 2008; Naik and 
Cucullo, 2012). Endothelial cells are cultured in the lumen of hollow-fibers inside a sealed 
chamber and are exposed to flow while, for example, astrocytes are seeded in the 
extraluminal compartment to promote cellular stimuli. The intraluminal flow is generated by a 
pulsatile pump, which can be regulated (through the diameter of the hollow fibers and the 
viscosity of the medium) to produce SS levels and intraluminal pressure physiologically 
comparable to that observed in capillaries in vivo (Naik and Cucullo, 2012; Ribeiro et al., 
2010). DIV-BBB has several significant advantages, namely low permeability to intraluminal 
polar molecules, high TEER, expression of specialized transporters, ion channels, and efflux 
systems (Naik and Cucullo, 2012). Nonetheless, disadvantages are also present since this 
system is not intended to be used in drug permeability studies, requires more time and 
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technical skills to be established, and a high cell load is required to start the process (Naik 
and Cucullo, 2012). Moreover, its design does not allow for visualization of the intraluminal 
compartment to assess morphological and/or phenotypic changes of the vascular 
endothelium. Also, in contrast to conventional static BBB models, this apparatus is not 
designed for a high throughput pharmaceutical study (Naik and Cucullo, 2012). 
 Studies performed with DIV-BBB demonstrated that the co-culture of brain endothelial 
cells with astrocytes when under dynamic conditions developed a more stringent barrier as 
demonstrated by high TEER (15- to 20-fold higher values (Cucullo et al., 2008)) and a 
selective permeability (Santaguida et al., 2006). 
 After DIV-BBB, other models based on culturing cells using tri-dimensional 
extracellular matrix supports were created (Nagpal et al., 2013; Ong et al., 2010). These 3D 
systems enable close interactions between cells as well as the formation of quasi-
physiological biochemical gradient exposure. Furthermore, these apparatus could also be 
used to study specific roles of various extracellular proteins in cell differentiation. Despite 
dynamic models clear advantages, their drawbacks are also assured, as more expensive and 
less convenient than static models (Montesano et al., 1983; Naik and Cucullo, 2012). 
 
4.3.3. Microfluidic models 
 Another example of dynamic models recently developed to mimic BBB is the 
microfluidic-BBB (MicroBBB) (Yeon et al., 2012). This apparatus is a polymeric multi-layered 
device with a membrane in between which separates the top and bottom channel. This 
system not only allows cell culturing procedure, permeability tests and TEER measurements 
(Booth and Kim, 2012; Griep et al., 2013), but also enables monitoring cell migration in a 3D 
environment (Naik and Cucullo, 2012). When compared to the models previously discussed, 
MicroBBB presents more advantages including rapid and low-cost fabrication; controlled and 
repeated environment with realistic microcirculatory dimensions; physiological fluid flow and 
SS; and a very thin culture membrane which decreases the distance between co-cultured 
cells (Booth and Kim, 2012; Griep et al., 2013; Wilhelm et al., 2011). However, the top-
bottom architecture of this model limits simultaneous real-time visualization of both vascular 
and neuronal sides of BBB (Wilhelm et al., 2011). Another key feature of this model is related 
to its ability to monitor changes in barrier function, which occur in response to various 
environmental stimuli namely diseases (Booth and Kim, 2012; Griep et al., 2013; 
Prabhakarpandian et al., 2013). 
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 A microfluidic chip was studied by Griep and colleagues when using hCMEC/D3 cells 
and exposure to fluid SS. The BBB chip study showed that hCMEC/D3 cultures had 
comparable TEER values (36.9 ± 0.9 Ωcm2) with the well-established Transwell® assay (28.2 
± 1.3 Ωcm2). Furthermore, when cells were exposed to SS, barrier tightness increased up to 
120 Ωcm2 (Griep et al., 2013). In another 3D microfluidic work, hCMEC/D3 cells were co-
cultured with astrocytes. Authors have shown that application of SS facilitates TJ formation in 
the endothelial monolayer, with and without the presence of astrocyte in the surrounding 
matrix (Partyka et al., 2017). Moreover, in several different MicroBBB studies, tighter 
endothelial membranes with a lower permeation of tested molecules, as well as an up 
regulation of TJ proteins and/or P-gp was demonstrated, compared to Transwell® BBB 
systems (Prabhakarpandian et al., 2013; Wang et al., 2016). 
 
5. How to overcome the blood-brain barrier 
 
 Concerning reaching brain limitations, several administration strategies may be used, 
which can be divided into two categories: local delivery (such as intraparenchymal and 
intraventricular) (Alam et al., 2010)) and systemic delivery (such as intravenous and 
intranasal). Generally, the local route constitutes an invasive approach, enabling drug 
delivery directly into the parenchymal space (intraparenchymal (De Boer and Gaillard, 2007)) 
or into the cerebral ventricle (intraventricular (Alam et al., 2010)). While direct injection can 
be an effective modality for local delivery in some cases (e.g., in some tumors), it is not 
efficient for brain metastasis or neurodegenerative diseases, which require therapeutic 
agents to be widely spread in the brain. Moreover, BBB disruption could also be used to 
directly deliver substances to the brain (Pardridge, 2005), using certain chemicals or applying 
energy (ultrasonic waves or electromagnetic radiations (Cho et al., 2016)), which exposes 
brain to infection and damage (Alam et al., 2010). Simultaneously, the potential partial 
irreversibility of the disruption of BBB compromises its protective role to the CNS. These 
restrictions are the main reasons for lack of successful strategies that can allow localized and 
controlled delivery of drugs across the BBB to the desired site of injury (Bhaskar et al., 2010). 
On the other hand, intravenous delivery is the most commonly used route to administrate 
large doses of drugs (Huynh et al., 2006) since, although drug availability is affected by its 
exposure to peripheral organs and rapid clearance, it avoids first-pass metabolism and has 
the great potential to deliver drugs to almost all neurons in the brain (almost all neurons have 
their own brain capillary for oxygen and nutrient supply) (Alam et al., 2010; Pardridge, 2003). 
The intranasal route is based on the principle that drugs exit nose sub-mucosa space into the 
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brain compartment. Advantages of this route came from nasal epithelium high permeability, 
avoidance of first-pass metabolism and self-administration. However, this administration 
damages the nasal mucosa and decreases the quantity of drug available (Alam et al., 2010; 
Nagpal et al., 2013). Thus, the existence of few safe and effective therapeutic options for 
many devastating and pervasive brain disorders encourages the raising of drug delivery 
systems of colloidal dimensions. 
 
5.1. Common strategies 
 
 To overcome the BBB, without compromising its integrity, four main strategies have 
been applied, namely direct transporter inhibition, targeting signaling pathways that control 
transporter regulation (function and/or expression), targeting inflammatory and stress 
pathways in order to modify the transporter synthesis, and direct down-regulation of efflux 
transporters expression and/or transport activity (Agarwal et al., 2011). 
 Of all the xenobiotic efflux pumps highly expressed in brain capillary endothelial cells, 
P-gp handles the largest fraction of commonly prescribed drugs and thus is an obvious target 
for manipulation. Some mechanisms by which P-gp activity in the BBB can be modulated 
are, regarding the strategies mentioned: (i) direct inhibition by specific competitors, (ii) 
functional modulation, and (iii) transcriptional modulation. All have proved potential to 
specifically reduce P-gp function and thus selectively increase brain permeability of its 
substrates. 
 The first approach is related to the modification of pump function by inhibitors and 
intracellular signals. Several relatively specific P-gp inhibitors have been developed and 
tested (Kemper et al., 2003; Kemper et al., 2004). This option depends on numerous issues, 
as the inhibitor affinity and reversibility, which could become serious problems (Bauer et al., 
2005). The first P-gp inhibitor was found by chance in 1981 by Tsuruo et al., who showed 
that verapamil, a calcium channel blocker, inhibits P-gp-mediated drug efflux in resistant 
tumor cells. Then, a variety of inhibitors were developed that differ in potency, selectivity, and 
side effects (Avendano and Menendez, 2002; Pleban and Ecker, 2005). However, until now, 
only a few compounds have been tested for their potential to enhance drug delivery to the 
brain (Agarwal et al., 2011). Due to their similarities, P-gp and BCRP have an overlap in 
substrate specificity. Concerning this, there are some evidences that demonstrate, for some 
compounds, inhibition of either BCRP or P-gp alone is not sufficient to increase delivery into 
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the brain (Agarwal et al., 2011). Thus, it became also important to study the combined impact 
of these two efflux transporters on the delivery of drugs across the BBB. 
 The first proof-of-principle that P-gp inhibition can be used to treat brain cancer came 
from a study in nude mice with intracerebrally implanted human glioblastoma. In this study, 
Fellner et al. identified P-gp as the major factor in limiting the anti-cancer therapeutic 
paclitaxel from crossing the BBB and permeating into the CNS. Consistent with this, treating 
glioblastoma-bearing mice with paclitaxel had no effect on tumor size but pre-treating mice 
with the P-gp inhibitor valspodar increased paclitaxel brain levels and reduced tumor size by 
90% (Fellner et al., 2002). 
 Some studies already showed that absence of both P-gp and BCRP resulted in an 
effect that was significantly larger than the combined effects from the single transporter 
knockout mice. These findings suggest that inhibition of either P-gp or BCRP can be 
compensated by the respective other transporter, and that both transporters “cooperate” with 
each other in preventing chemotherapeutic drugs from entering the brain. Furthermore, for 
the majority of drugs, P-gp is the dominant transporter, rather than BCRP. Given the synergic 
effect of P-gp and BCRP at the BBB, developing compounds that are potent inhibitors of both 
transporters may prove beneficial. As so, elacridar is a dual P-gp/BCRP inhibitor that has 
undergone extensive preclinical and clinical evaluation (Agarwal et al., 2011; Hyafil et al., 
1993) – a phase I study was performed where the lowest effective dose of elacridar to obtain 
maximum oral bioavailability of topotecan was determined, as well as the optimal schedule of 
co-administration of both drugs (Kuppens et al., 2007). 
 The second approach, ideally, is the transiently and specific decrease of efflux to the 
blood through rapid regulation of transporter function. Two signaling pathways have been 
identified that could potentially be used to down-regulate P-gp transport activity at the BBB – 
one involves inflammatory mediators through protein kinase C beta I, the other one involves 
vascular endothelial growth factor signaling (Agarwal et al., 2011). The last one results in a 
reversible loss of P-gp function without a decrease in export protein expression. Depression 
of P-gp activity by this factor is associated with phosphorylation of caveolin-1, a signal known 
to trigger caveolin-dependent endocytosis (Mahringer et al., 2011). As well, various signaling 
pathways have been shown to down-regulate BCRP. As an example, it was demonstrated 
that estrogens play a role in BCRP regulation – estrone and 17β-estradiol reverse BCRP-
mediated drug resistance (Agarwal et al., 2011; Imai et al., 2002). 
 The third idea regards the alteration of the transporter synthesis due to enhanced or 
inhibited transcription and translation. This topic is related with the possibility of use 
inflammatory and stress pathways to lower P-gp expression at the BBB. Several promoter 
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elements have been found so far, as pregnane X receptor ligands, but it is not clear to what 
extent P-gp expression can be down-regulated by removing them from the diet. In contrast to 
inflammation and inflammatory mediators (as interleukin-6, interleukin-1b, and tumor 
necrosis factor-α) which reduces transporter expression (Hartmann et al., 2002; McRae et 
al., 2003), cellular stress (e.g., exposure to heavy metals, reactive oxygen species, and some 
chemotherapeutics as well as heat stress) up-regulates expression of P-gp (Bauer et al., 
2005). 
 The forth strategy related to directly down-regulate efflux transporters expression 
and/or transport activity constitute a new and promising approach which takes advantage of 
siRNA and is here further discussed. 
 
5.2. siRNA mechanism and targets 
 
 There is a potential therapeutic exploitation of gene regulation based on RNA 
interference. Its endogenous regulatory mechanisms rely on the sequence specific 
interaction between siRNA and mRNA. Therefore, these mechanisms can be activated via 
the delivery of siRNA to the cell interior, which is a short double stranded RNA that guides 
sequence specific mRNA degradation, and highly result in specific inhibition of gene 
expression through degradation of target mRNA (Dorsett and Tuschl, 2004). 
 RNA interference was first discovered in Caenorhabditis elegans when it was 
observed that injected double stranded RNA was far more potent at limiting gene expression 
than either sense or antisense strands alone (Fire et al., 1998). The RNA interference 
mechanism of action starts by cleavage of the RNA two strands into short ~21 nucleotide 
RNA sequences by an endonuclease called Dicer (Zamore et al., 2000). These short 
sequences, the siRNAs, are rapidly taken up into an enzyme complex, RNA induced 
silencing complex (RISC), that degrades the mRNA through guidance to a specific target 
mRNA resulting in specific gene silencing (Fuest et al., 2009; Hammond et al., 2000). At 
RISC (Nascimento et al., 2014), one siRNA strand is taken into the effector complex, the 
catalytic subunit Argonaute2, and then serves as a template, guiding the hydrolysis of 
complementary or near complementary mRNA sequences (Fountaine et al., 2005; Martinez 
and Tuschl, 2004). 
 Moreover, since it is very specific, siRNA technology is considered to be a useful 
approach to study the role of various proteins in neuronal physiology. Even better than the 
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old methods of generating knockout mice who lack the target protein (Morrison et al., 1996) 
or generating conditional knockdown or knockin mice that only remove or express the protein 
following a specific treatment (Christophorou et al., 2005; Perez-Martinez et al., 2012). 
However, as all existing strategies, the use of siRNA could also have some drawbacks 
important to mention. Among them is poor cellular uptake and instability under physiological 
conditions, therefore successful siRNA therapy needs the development of drug delivery 
systems. Besides, the saturation of the endogenous RNA interference pathway, silencing of 
unwanted genes known as off-target effects and the activation of innate immunity may also 
arise from siRNA approach (Sioud, 2015; Xu and Wang, 2015). 
 Regarding siRNA mechanism, it becomes clear how this molecule can be used as a 
unique strategy to directly down-regulate efflux transporters expression and increase the 
chances to overcome BBB and reach brain treatments. On a small study, siRNA was used to 
target P-gp in mouse brain capillary endothelial cells. siRNA was administrated intravenously 
(once/day during 4 days) and it resulted in a significant reduction of the P-gp-labeled area in 
the hippocampal hilus and parietal cortex. P-gp expression proved to be down-regulated in 
these brain regions by 31 and 16%, respectively (Figure 1.5). This was the first preliminary 
evidence that a down-regulation of P-gp can be achieved in brain capillary endothelial cells 
by administration of siRNA in vivo. Furthermore, since just 2 day-treatment was not able to 
down-regulate BBB P-gp in a significant manner, authors conclude that this down regulation 
could only be achieved with a prolonged treatment (Fuest et al., 2009). 
 
 
Figure 1.5. P-gp-labeled area of the hilus and the parietal cortex of control mice and mice treated with 
siRNA targeting Mdr1 for four consecutive days. * p < 0.05. Adapted from Fuest et al., 2009. 
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 Besides the most known and studied P-gp, other brain-related proteins have been 
siRNA targets. Hori and colleagues specifically silence the rat ABC transporter BCRP in brain 
capillary endothelial cells by transfection of siRNA. They were able to reduce BCRP mRNA 
between 55 to 79%, as well as protein levels. Additionally, BCRP-mediated mitoxantrone 
efflux transport was suppressed by the introduction of siRNA into cells. Authors also verified 
that used siRNA did not affect the mRNA levels of other ABC transporters, suggesting that it 
can selectively silence BCRP at the BBB (Hori et al., 2005). Different studies also suggest 
the siRNA efficiency with other targets as the non-ABC transporter Oat3 (Hino et al., 2006), 
and the TJ protein claudin-5 (Campbell et al., 2008). 
 siRNA has already proven to be a promising strategy for the treatment of Huntington's 
disease, a progressive neurodegenerative disease caused by an expansion of a trinucleotide 
repeat in the Huntingtin gene, as it can specifically decrease the expression of the toxic 
mutant Huntingtin (HTT) protein. In order to locally and transiently disrupt the BBB to improve 
siRNA efficiency, focused ultrasound combined with intravascular delivery of microbubble 
contrast agent was used in the brain of adult rats. This technique is based on the application 
of concentrated acoustic energy to the target location and simultaneously systemic 
administration of a microbubble contrast agent. Then circulating microbubbles begin to 
oscillate, which leads to mechanical changes in the blood vessel wall and a transient 
increase in the permeability of the BBB (Hynynen et al., 2001). Following this, siRNA against 
HTT gene treatment leads to a significant 32% reduction of HTT protein expression (which is 
similar to decreases observed in other studies (Rodriguez-Lebron et al., 2005)) in a dose 
dependent manner (Burgess et al., 2012). 
 
5.3. siRNA delivery 
 
 Delivery is considered a hurdle for the development of siRNA-based therapeutics 
(Aagaard and Rossi, 2007). Therefore, several strategies had been proposed, including 
delivery of the siRNA precursor, short hairpin RNA, which is introduced in cells encoded on 
viral vectors. Although highly efficient and with a low rate of degradation and turnover, 
compared to siRNA short hairpin RNA has some disadvantages as safety concerns (some 
viral vectors are related to putative insertional mutagenesis), limited loading viral vectors 
capacity, and high production costs (Grimm et al., 2006). Therefore, non-viral vectors arise 
as promising alternatives able to deliver siRNA and other nucleic acids into cells, potentially 
resulting in their functional expression (Gao et al., 2011). 
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 Chemical stabilization and conjugation with functional molecules can be used to 
improve the stability and permeability of siRNA (Lorenz et al., 2004; Muratovska and Eccles, 
2004; Turner et al., 2007). However, the lack of cellular specificity could be an issue. In the 
case of P-gp, which is not only localized in brain capillary endothelial cells, but also in many 
other tissues including the gut (Watkins, 1997), its non-selective expression modulation by 
siRNA will enhance exposure of sensitive tissues to harmful xenobiotics (Fuest et al., 2009; 
Loscher and Potschka, 2005). Regarding these topics, among the different approaches 
explored in recent years to overcome this limitation are nanoparticle-based systems, ranging 
from polymer particles to liposomes and inorganic systems as gold nanoparticles. In addition, 
different examples and types of nanoparticles were studied, proving their role on ease drug 
transport across the BBB (Murthy, 2007). 
 Nanoparticles have long been noticed to pass through the BBB, which is related to 
their advantageous properties as small size, customizable surface, improved drug solubility, 
targeted drug delivery and multifunctionality. These provide a substantial advantage for drug 
and gene delivery systems across the BBB, which is the first step for effective treatments of 
many CNS disorders (Bhaskar et al., 2010). Regarding toxicity, polymeric and liposomal 
nanoparticles are probably the least problematic since typically they are made from or 
covered with natural or highly biocompatible components (Murthy, 2007). 
 To improve siRNA safe delivery to the CNS, the proper design of nanosystems needs 
to be considered to enhance BBB crossing, endosomal escape and siRNA efficiency 
(O'Mahony et al., 2013; Perez-Martinez et al., 2012). As an example, chitosan nanoparticles 
were assessed as a siRNA delivery system to silence P-gp in an in vitro BBB model. 
Transfection of rat brain endothelial cells with siRNA loaded in chitosan nanoparticles 
mediated effective knockdown of P-gp, since P-gp mRNA levels reduced to approximately 
20% compared to the untreated cells. As well, a subsequent decrease in P-gp substrate 
efflux was detected, resulting in increased cellular delivery and efficacy of the model drug 
doxorubicin (Malmo et al., 2013). 
 Another strategy used to silence HTT gene were modified amphiphilic β-cyclodextrins 
(CDs), based on naturally occurring oligosaccharide molecules, as siRNA neuronal carriers 
(Godinho et al., 2013). CDs form particles with a diameter between 100 and 350 nm, which 
were stable up to 6h in artificial cerebrospinal fluid. 24h post transfection, these complexes 
were able to reduce the expression of the HTT gene by 51% in rat striatal cells and 78% in 
human Huntington’s disease primary fibroblasts. Additionally, HTT protein levels were found 
to be reduced by 35% 72h post transfection in the rat model. In order to investigate 
knockdown efficiency in vivo, mice were treated with HTT naked siRNA, CD-HTT-siRNA (CD 
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loaded with HTT targeted siRNA), or CD-NS-siRNA (CD loaded with non-silencing siRNA). 
CD-HTT-siRNA was able to significantly reduce the expression of the HTT gene in vivo 
since, 4h post injection, HTT gene expression was reduced by 85%, which was maintained 
up to seven days (Figure 1.6). Both naked siRNA and NS siRNA did not have any effect on 
HTT gene expression levels (Godinho et al., 2013). Authors concluded that the potential 
application of these β-CDs as siRNA carriers for CNS delivery is not restricted to 
Huntington’s disease, but applicable to other neurodegenerative diseases (Godinho et al., 
2013). 
 
 
Figure 1.6. HTT gene expression in the mouse brain mediated through CD-HTT-siRNA. Mice were 
injected with vehicle (white), HTT naked siRNA (light grey), CD-HTT-siRNA (grey), and CD-NS-siRNA 
(dark grey) nanoparticles. RNA was extracted at different time points and HTT mRNA relative 
expression was assessed. p < 0.001, compared to vehicle treated animals (Godinho et al., 2013). 
 
 In order to achieve stable and non toxic lipoplexes able to carry siRNA, Khatri and 
colleagues evaluated them as a transport system for siRNA targeted to RRM1 (enzyme 
responsible for development of resistance to gemcitabine in cancer cells). A cationic lipoplex 
composed by a mixture of different lipids was tested. Cell uptake studies and gene 
expression assays have confirmed intracellular availability of siRNA. Lipoplexes showed 
higher cellular uptake (5- to 6-fold) than that obtained with naked siRNA. Consequently, 
siRNA-loaded lipoplexes obtained 27% RRM1 gene expression while naked siRNA had 84%, 
on tested cancerous cells (Khatri et al., 2014). 
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 The combination of two systems could be advantageous, like Peddada and co-
workers tested. A complex consisting of an anionic co-polymer and a cationic liposome was 
theirs idea to carry an antisense oligonucleotide against the apoptosis inhibitor Bcl-2. The 
siRNA complexes improved the gene silencing effect in human ovarian cancer cells, reducing 
its expression to 40% of the untreated control. In vivo studies showed that, after 
intraperitoneal injection in mice, a greater amount of siRNA is delivered to ovarian tumor 
xenografts using this delivery system, compared to the siRNA-loaded liposome complex. 
These results highlight the importance of the hydrophilic-lipophilic balance of the transport 
system in achieving stability and cellular uptake (Peddada et al., 2014). 
 Other proteins were evaluated as siRNA targets, such as: green fluorescent protein 
(GFP) (Kumar et al., 2007), Rho-associated kinase (ROCK) (Liu et al., 2013), phosphatase 
and tensin homolog (PTEN) protein highly expressed in pyramidal neurons (Rungta et al., 
2013), glutamate ionotropic from aspartate receptor (GRIN1) (Rungta et al., 2013), 
interleukin-10 (IL10) (Pradhan et al., 2014), depicted on Table 1.1. 
 
5.4. siRNA/drug co-delivery 
 
 In order to create an even more efficient system, the combination of siRNA and drugs 
in the same formulation could be really advantageous, since it would have distinct ways to 
act. Several works have already been performed taking the advantage of this possible 
synergic effect. Polymeric functionalized micelles with a nose-to-brain delivery system are an 
example where authors investigated the combined therapeutic effects on a rat model of 
malignant glioma. siRNA against Raf-1 (which plays a role in cell proliferation and apoptosis) 
and camptothecin anticarcinogenic drug were loaded in the same system, that was then 
functionalized with a trans-activator protein (TAT) to brain delivery (Kanazawa et al., 2014). 
siRNA- and siRNA/drug-loaded functionalized systems have promoted cell death in rat 
glioma cells after high cellular uptake. The mean survival period of rats treated with naked 
siRNA solution (18.4 days) was not significantly different from that of untreated rats (16.6 
days). However, the mean survival period of rats treated with siRNA-loaded functionalized 
nanoparticles was 20.4 days, for siRNA control/drug-loaded functionalized nanoparticles 20.6 
days, and for both siRNA and drug-loaded functionalized nanoparticles was 28.4 days. This 
last case was significantly greater than any other option (Figure 1.7). The highest therapeutic 
effect was promoted by the additive effects of drug and siRNA co-delivery (Kanazawa et al., 
2014). 
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Figure 1.7. Effect of intranasal administration of Raf-1-siRNA complexed with camptothecin-loaded 
micelles on the survival of intracranial glioma-bearing rats. Adapted from Kanazawa et al., 2014. 
 
6. Brain Targeting 
 
 Nanoparticles have several different flexible properties that can be modified according 
to their aim, which make them advantageous carriers to transport drugs/genes through the 
organism and also, due to their ability to be functionalized, to target specific environments, 
tissues or organs. In order to have an efficient delivery upon administration, nanoparticles 
surface can be coated with polyethylene glycol (PEG), surfactants or target molecules 
(Wohlfart et al., 2012), among other options. Nanoparticles structure and features will define 
the drug/gene release kinetics and characteristics. Furthermore, the internalization of 
nanoparticles in different cells depends on their physicochemical properties, such as size and 
surface charge. 
 Functionalization of nanocarriers is one of the most important steps and challenges in 
formulating nanocarriers for drug/gene delivery. Effective and highly specific conjugation 
strategies are used to attach biomolecules to nanoparticles surface (Bhaskar et al., 2010); 
and there are numerous ways to functionalize nanocarriers according to its final goal. 
Targeting mechanisms could be either passive (as the enhanced permeability and 
retention effect) or active (a non-invasive way to transport drugs to pre-determined target 
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cells using site-specific ligands (Bhaskar et al., 2010)).The main advantage of active 
targeting is the increase of the amount of drug/gene in the targeted tissue, thereby increasing 
the pharmacological response and reducing systemic side effects (De Boer and Gaillard, 
2007). There are several ways (Figure 1.8) further described that can be followed, 
individually or in combination, to develop a BBB targeted effective system. 
 
Figure 1.8. Possible strategies used to functionalize nanoparticles, directing them to the brain. 
 
6.1. Surface properties 
 
 Nanoparticles surface properties are the key factor for a successful brain delivery. Not 
only surface charge but also hydrophobicity influence the adsorption of blood proteins into 
the systems surface, influencing nanoparticles clearance, cellular uptake, and transcytosis 
rate (Gessner et al., 2002). The surface charge need to be assessed according to the 
permeability through the BBB and consequent brain distribution profiles, as well as to their 
toxicity and BBB-related integrity. Part of the research community agrees that neutral and 
slightly negative particles have no effect on BBB integrity, while high concentrations of 
anionic or cationic systems disrupt it (Lockman et al., 2004). Despite their immediate toxic 
effect at the BBB, cationic nanoparticles may promote their transport across this barrier due 
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to the adsorption to BBB cells, which are negatively charged, through electrostatic 
interactions (Alam et al., 2010). 
 
6.2. Stealth properties 
 
 Usually, unmodified nanoparticles are rapidly adsorbed, mainly by opsonins, and 
eliminated from the organism by the macrophages of the reticuloendothelial system (Wohlfart 
et al., 2012). Therefore, coating nanoparticles surface with proper hydrophilic and non-ionic 
surfactants (Araujo and Kreuter, 1999), such as polysorbate 80, or the attachment of 
biocompatible coatings as PEG (Brigger et al., 2002) prolong nanoparticles blood circulation. 
Consequently, the body distribution can be modified significantly, which in some cases might 
improve brain delivery (Bhaskar et al., 2010). 
 In the nanotechnology field, surfactants act especially as stabilizers and/or coating 
agents. Generally, nanoparticles coated with proper surfactants show decreased hepatic 
uptake, increased blood levels, and some revealed increased drug levels in the brain (Wilson 
et al., 2008). Thus, it is commonly accepted that right coating could have an impact on the 
delivery to the BBB. Among the surfactants already investigated as coatings, the most 
promising is the polysorbate 80, which proved to be effective as a brain delivery enhancer in 
different types of systems, such as those based on poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles (Tahara et al., 2011) and lipid nanoparticles (Azhari et al., 2016; Goppert and 
Muller, 2005). The incorporation of PEG on the nanoparticles surface is a widespread 
technique for delivery systems, namely the intravenously administered ones. PEG is not 
recognized as a foreign material by macrophages in blood, and can therefore increase the 
half-life of carriers (Murthy, 2007; Perez-Martinez et al., 2012), enhancing the ability to cross 
the BBB by promoting their exposition to receptors (Schlachetzki et al., 2004). 
 
6.3. Ligands 
 
 Another strategy applied to enhance nanoparticles ability to cross the BBB is based 
on transporter-mediated delivery. Conjugation of nanoparticles to ligands that recognize 
receptors expressed at the BBB is done to take advantage of native physiological BBB 
nutrient transport systems (Gabathuler, 2010). Peptides and small molecules may use 
CHAPTER I 
32 
 
specific transporters expressed on endothelial cells to promote nanoparticles uptake. Thus, 
only drugs/systems that closely mimic the endogenous carrier substrates would be 
transported into the brain (Allen et al., 2003; Chen and Liu, 2012; Gabathuler, 2010). In this 
way, biomolecules as peptides, proteins and antibodies have been extensively used as 
ligands (targeting molecules) to selectively direct drugs/genes. These molecules act by 
recognizing and binding to target receptors or antigens. This approach is predominantly used 
in circumstances that these receptors/antigens are over expressed or selectively expressed 
by particular cells or tissue components. The most important concepts and the basis of 
binding targeting molecules to nanoparticles are: the ligand should selectively bind to the cell 
surface receptors on the targeted cells; the receptor should only be expressed on the target 
cells, or the expression should be higher at the target cells than in the non-target cells; and 
the modified nanoparticle should be stable enough in the systemic circulation to reach target 
cells in an effective concentration. In addition, targeting ligands can be conjugated on the 
surface of nanocarriers either by covalent or non-covalent linkage (Juillerat-Jeanneret, 2008). 
 One of the most prominent candidates to use at nanoparticles surface are cell-
penetrating peptides (CPP), such as TAT, that facilitate intracellular delivery (Bhaskar et al., 
2010). CPPs are generally peptides of less than 30 amino acids (Lindgren and Langel, 
2011). They have an enormous potential for diagnostic and therapeutic applications due to 
their low cytotoxicity and the tremendous variety of cargo that can be loaded (Lindgren and 
Langel, 2011). Recently, Liu and co-workers made a polymer core-shell system with TAT 
molecules anchored on its surface to antibiotic delivery. The results shown that the 
nanoparticles with TAT improved their cellular uptake by endothelial cells (Liu et al., 2008). In 
order to deliver siRNA for use in neurodegenerative diseases, Malhotra and co-workers 
synthesized PEG coated chitosan, with further conjugation of PEG tip with a TAT. 
Nanoparticles were tested to deliver a functional siRNA against the Ataxin-1 gene in an in 
vitro established model of a neurodegenerative disease – spino cerebellar ataxia. This 
disorder is characterized by an over expression of this ataxin protein, and a loss of cells from 
the cerebellum and spinal cord affecting motor coordination, posture and balance. The 
results indicated a successful suppression of the ataxin protein 48h post transfection, as 
siRNA loaded on these systems was able to down-regulate more its target than bare siRNA 
(Malhotra et al., 2013). 
 Glutathione (GSH) is a peptide that is being used to brain-targeting. It is an 
endogenous tripeptide that possesses antioxidant properties and plays a central role in the 
detoxification of intracellular metabolites. GSH receptor is abundantly expressed at the BBB 
and thus is able to mediate safe targeting and enhanced delivery of drugs to the brain 
(Georgieva et al., 2014). Gaillard and colleagues showed an improved drug brain delivery by 
CHAPTER I 
33 
 
using GSH PEGylated (GSH-PEG) liposomes. They studied these liposomes in healthy rats 
and observed that drug plasma circulation and brain uptake were significantly increased after 
encapsulating in GSH-PEG liposomes. Similarly, in vivo results with an autoimmune 
encephalomyelitis model rat showed that, while free drug had no effect, when loaded in 
GSH-PEG liposomes significantly reduced the disease clinical signs. In addition, the 
targeting by itself led to a significant more effective treatment compared non-targeted 
PEGylated liposomes (Gaillard et al., 2012). 
 Besides previously reported peptides, proteins are also utilized as targeting agents. 
However, proteins have some clear disadvantages since they are more difficult to modify to 
generate derivatives. Moreover, due to the presence of the tertiary structure in proteins, they 
often undergo physical degradation, which may interfere with the molecular recognition 
(Majumdar and Siahaan, 2012). 
 Transferrin receptor (TfR) has been widely studied and has shown to be a promising 
molecular probe for targeted drug delivery. Transferrin receptors are known to be expressed 
in the luminal membrane of the capillary endothelium of the BBB, among other body regions. 
Drug targeting to the TfR, which mediates cellular uptake of iron, can be achieved by using 
the endogenous ligand transferrin itself, or by using antibodies/peptides directed against the 
TfR (Gabathuler, 2010; Moos and Morgan, 2000). Pardridge and co-researchers worked with 
OX-26, an antibody against the TfR. Their data have shown that drug targeting and delivery 
to the brain is promoted by this additional system component (De Boer and Gaillard, 2007; 
Pardridge et al., 1991). 
 Another biomolecule used to functionalize nanoparticles is the apolipoprotein E 
(ApoE) that is involved in the transport of lipids into the brain by the low density lipoprotein 
(LDL) receptors, which is essential to maintain cholesterol homeostasis (Vance and Hayashi, 
2010). Besides ApoE binding to various receptors on the BBB, it also binds to receptors in 
other CNS regions (De Boer and Gaillard, 2007). Therefore, nanoparticles could be modified 
with ApoE in order to improve their uptake mechanism and brain translocation (Michaelis et 
al., 2006), which are regulated by LDL receptors (Gabathuler, 2010). 
 Magnetic nanoparticles are also used to transport siRNA to brain. Veiseh and 
colleagues studied a cancer-cell specific magnetic nanosystem for siRNA delivery and 
simultaneous non-invasive monitoring through magnetic resonance imaging (Veiseh et al., 
2010). Their nanosystem was composed by a superparamagnetic iron oxide nanoparticle 
core coated with PEG-grafted chitosan and polyethylenimine. It was loaded with siRNA 
(against GFP) and functionalized with a tumor-targeting peptide (chlorotoxin, CTX). Rat 
glioma cells were treated with targeted and non-targeted nanovectors, and nanoparticles-
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siRNA-CTX were internalized 2-fold more than non-targeted systems, which highlights that 
functionalized systems readily binds to glioma cells through the affinity of CTX to its receptor. 
Moreover, the knockdown transgene expression of GFP in GFP+ cells were evaluated and 
found to be enhanced when cells were treated with targeted nanoparticles (62% reduction in 
GFP expression). These results suggest how receptor-mediated cellular internalization 
affects an enhanced knockdown (Veiseh et al., 2010). 
 Some examples of previous works developed through the production of functional 
systems that act as siRNA carriers have been here described and are summarized on Table 
1.1. 
 Nanoparticles are important not only due to their ability to be functionalized and 
improve the delivery to target cells/tissues, but also, and most significantly, thanks to their 
multifunctional properties. These systems can work as both diagnostic and therapeutic 
platforms. In vivo imaging of nanomaterials is an exciting recent field that can provide real-
time tracking of those nanocarriers, monitoring drug delivery. With multifunctional systems, 
the field of brain imaging is being improved, since it became possible to monitor events at the 
molecular and cellular levels, as well as to track the development of neurological diseases 
and cancerous formations (Bhaskar et al., 2010). 
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Table 1.1. Examples of enhanced siRNA delivery via nanosystems. 
Nanosystem Target Main results References 
Peptide RVG FITC GFP siRNA delivered specifically to neuronal 
cells 
(Kumar et al., 
2007) 
Chitosan nanoparticles P-gp P-gp mRNA levels 20% reduced 
compared to the untreated cells 
(Malmo et al., 
2013) 
Amphiphilic 
cyclodextrins 
HTT HTT expression reduced by 85%, 4h 
post injection 
(Godinho et al., 
2013) 
Nanoparticles 
complexes PEG-PEI 
ROCK-II Expression of ROCK-II mRNA inhibited 
by 20% 
(Liu et al., 2013) 
TAT-PEGylated 
chitosan nanoparticles 
Ataxin-1 Target protein suppressed, 48h post 
transfection 
(Malhotra et al., 
2013) 
Lipid nanoparticles PTEN 
GRIN1 
Expression reduced by 72% and 51%, 
compared with non-injected control 
(Rungta et al., 
2013) 
Pathogen-mimicking 
microparticles 
IL10 Significantly enhanced DCs Th1/Th2 
cytokine ratio 
(Pradhan et al., 
2014) 
Copolymer and 
liposome combination 
Bcl-2 Gene expression reduced to 40% of the 
untreated control 
(Peddada et al., 
2014) 
Cationic lipoplex RRM1 Increased cellular uptake (6 higher 
than with naked siRNA); reduced gene 
expression (27%; 84% with naked 
siRNA) 
(Khatri et al., 
2014) 
CTX-magnetic 
nanoparticles 
GFP GFP expression reduced by 62% for 
nanoparticles-siRNA-CTX, compared to 
35% for nanoparticles-siRNA 
(Veiseh et al., 
2010) 
Abbreviations: Bcl-2, apoptosis inhibitor; CTX, chlorotoxin; DCs, dendritic cells; FITC, fluorescein 
isothiocyanate; GFP, green fluorescent protein; GRIN1, glutamate ionotropic from aspartate receptor; 
HTT, Huntingtin protein; IL10, interleukin-10; PEG, polyethylene glycol; PEI, polyethyleneimine; PTEN, 
phosphatase and tensin homolog; ROCK, Rho-associated kinase; RRM1, ribonucleoside-diphosphate 
reductase large subunit; RVG, rabies virus glycoprotein; TAT, trans-activator protein; Th1, T helper 1 
cells; Th2, T helper 2 cells 
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7. Concluding highlights 
 
 As neurological disorders numbers arise, the need for effective treatments increases. 
CNS distinctive environment and BBB defensive functions enhance the reaching-brain 
complexity. Therefore, the development of a feasible and truthful in vitro BBB model where 
blood-to-brain permeability could be assessed is fundamental for a successful study of drug-
BBB interaction. Concurrently, siRNA, as a key to several approaches that silence specific 
genes associated to BBB protective role, turned out to be a promising and hopeful way to 
surpass BBB. To transport and target siRNA to attain its final goal, nanotechnology systems 
are used. By targeting these systems surface to the brain, their capacity to reach the target 
cells increase, which improves their efficacy. As well, off-target and harmful systemic side 
effects decrease. 
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1. Overview 
 
Nowadays, ageing population is widespread across the world and constitutes a 
potential factor for raising the incidence of brain disorders in modern society. It is most 
advanced in the highly developed countries, but also growing faster in less developed 
regions. Increasing life expectancy and declining fertility rates are the greatest causes for 
such epidemiologic data. Consequently, a number of brain-related disabilities as stroke, 
dementia, memory impairments and changes in levels of neurotransmitters and hormones 
are having an increasing importance in order to keep quality of life levels high. 
Therefore, the CNS, where all central actions are coordinated and neuromodulators 
are produced, and the BBB, as the brain protective membrane, are the main subjects to 
study and to try to overcome, so the likeliness of a successful treatment could be improved. 
siRNA, due to its strong specificity on temporarily silencing a particular gene, became 
a great biomolecular way to down-regulate efflux transporters such P-gp presented at the 
BBB. These transporters act as efflux systems pumping drugs from brain back to blood, 
decreasing the efficiency of most therapies. Adding nanotechnology to the line, siRNA-
loaded nanoparticles protect the oligonucleotide from harsh conditions as enzymatic 
degradation, which results in a biodegradable system with siRNA increased bioavailability. 
As well, through surface modification, these systems could act as “Trojan horses”, improving 
siRNA accumulation in the desired site of action, simultaneously decreasing harmful side-
effects. 
In the present thesis, two main institutions had collaborated: the Institute for Research 
and Innovation in Health (i3S) at the University of Porto (Portugal) and the Department of 
Physics, Chemistry and Pharmacy from the University of Southern Denmark (Denmark). At 
i3S, the group has a broad experience in the development of drug/gene delivery systems 
based on lipids and polymers, additionally to an expertise in receptor-targeted nanoparticles 
surface modification. The main interests of the group are to overcome the physiological 
barriers, as the BBB, and develop systems to efficiently and in a target way deliver 
drugs/genes, decreasing the effects in the surrounding tissues. The group from the University 
of Southern Denmark is known for the development of non-cellular based membrane models 
that mimic in vivo protective membranes. Liposomes are used to resemble cellular 
membranes through a fast method, which was demonstrated to be effective, with outputs 
similar to the ones obtained via in vitro based models. Their research interest areas are also 
drug solubility and dissolution, drug delivery systems namely liposomes, and drug release. In 
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close partnership and through a great team work, these two main groups with minor 
interventions from the Faculty of Sciences from the University of Porto (Portugal), had 
combined their expertise to enable the fulfillment of the work reported in this thesis, 
dedicated to the development of a targeted siRNA delivery biomaterial to modulate the drug 
efflux at the BBB. 
 
2. Aims 
 
The present thesis aims to expose the current knowledge regarding CNS and its 
affecting disorders. In this scope, BBB and its over-protective function were essential topics 
here discussed. Since the main aim of this thesis project was to develop a safe and targeted 
nanoparticulate-based system able to modulate the drug efflux at the BBB, siRNA against P-
gp was introduced in the approach (Figure 2.1). Therefore, besides physicochemical 
characterization, the permeability through BBB models (non-cellular and cellular-based) of 
developed formulations and their safety were evaluated. Finally, the ultimate objective was to 
use the targeted system as a BBB permeation enhancer for P-gp substrates. 
The specific objectives of this thesis were: 
i) To investigate the feasibility of a BBB non-cellular based model supported by 
phospholipid vesicles that mimic cellular membranes, its structure and how a model 
drug interacts with and permeates through it; and further test the influence of lipid and 
polymeric nanoparticles on the permeability of siRNA through the developed model 
(Chapter III). 
ii) To improve the siRNA delivery systems previously developed by 
functionalization of their surface with a BBB targeting peptide, and additional 
investigation of the influence of distinct biomaterial compositions and peptide binding 
approaches on their efficiency and safety as carrier systems, and interaction with 
human brain endothelial cells (Chapter IV). 
iii) To assess the most promising BBB targeted nanoparticles on the siRNA 
permeation across a human brain cell-based monolayer, as well as further evaluation 
of their effect on P-gp expression and consequent drug efflux modulation through the 
permeability of a model P-gp substrate (Chapter V). 
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iv) To integrate precedent chapters by developing an overall discussion leading to 
the main conclusions of the work and its future perspectives (Chapter VI). 
 
 
 
 
Figure 2.1. Schematic representation of the normal BBB behavior (top) and the ultimate aim of this 
thesis project (bottom). 
 
 
 
 
  
CHAPTER III 
 
 
 
A new approach for a blood-brain barrier model based on 
phospholipid vesicles: membrane development and siRNA-
loaded nanoparticles permeability 
 
 
 
 
 
 
 
 
 
 
This chapter was based on the following published paper: 
- Gomes, M.J., Dreier, J., Brewer, J., Martins, S., Brandl, M. and Sarmento, B. 2016. A new 
approach for a blood-brain barrier model based on phospholipid vesicles: membrane 
development and siRNA-loaded nanoparticles permeability. J Membrane Sci. 503: 8-15. 
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1. Abstract 
 
Worldwide incidence of central nervous system (CNS) disorders is rising along with 
the age of population, making it an increasingly relevant subject. Protecting the CNS is the 
blood-brain barrier (BBB) which, consequently, hampers the success of current therapies by 
blocking drugs access to brain. Thus, developing innovative CNS treatments and improving 
the ability to cross BBB is urgent. Therefore, a BBB model where permeability experiments 
could be performed in a simple and fast way is crucially necessary to obtain high throughput 
screening tools. This is where phospholipid vesicle-based permeability assay (PVPA) method 
opportunity arises. Through this technique, a non-cellular based BBB model able to assess 
passive transcellular-like permeability was developed based on phospholipid vesicles that 
mimic cellular membranes. This model could be also used as a tool for in vivo permeability 
prediction. Simultaneously, use of small interfering RNA (siRNA) to specifically silence efflux 
proteins present at BBB surface could be a useful advantage to circumvent BBB blockage. 
To improve siRNA delivery to brain and increase its ability to permeate BBB, lipid and 
polymeric nanoparticles were tested and their effect was observed by measuring siRNA 
permeability through the BBB-PVPA model.  The permeability of siRNA significantly 
increased from 3.7  10-6 cm s-1 (free siRNA) to 5.5  10-6 cm s-1 and 6.9  10-6 cm s-1 after 
encapsulation into polymeric and lipid nanoparticles, respectively. 
 
KEYWORDS: Blood-brain barrier, artificial membrane, phospholipid, permeability, 
nanoparticles 
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2. Introduction 
 
Nowadays, along with aging population, central nervous system (CNS) disorders are 
arising as an important theme due to their worldwide increasing incidence, frequently severe. 
Current therapies are not successful to treat these diseases (Bhaskar et al., 2010), mainly 
because drugs cannot reach the brain due to blood-brain barrier (BBB) protective 
morphology (Gilmore et al., 2008). BBB is a layer of endothelial cells very tightly bound to 
each other (tight junctions, TJ) that block the transport of drugs from blood to brain (Bhaskar 
et al., 2010). Besides TJ, efflux systems, such as P-glycoprotein (P-gp), are also 
characteristic of brain endothelial cells and limit drug uptake (Agarwal et al., 2011). 
Therefore, since the prevalence of brain diseases is raising, to find CNS treatments is 
needed, thus, improving the ability to cross BBB is urgent. Consequently, BBB studies are 
required, as well as the need for a BBB model where experiments could be performed. 
Phospholipid vesicle-based permeability assay (PVPA) is a simple in vitro model with 
passive transcellular-like permeability used as a tool for in vivo permeability prediction 
(Flaten et al., 2006b). The vesicle-based model is a tight barrier of liposomes, representing a 
much simpler and easier method to mimic the BBB compared to cell based approaches. This 
tool is made of a layer of phospholipid vesicles well compacted in a membrane filter, as 
developed by us (Flaten et al., 2009; Flaten et al., 2006a; Flaten et al., 2006b; Flaten et al., 
2008). PVPA has similarities with cell-based systems since on a monoculture BBB model 
brain endothelial cells are seeded above the Transwell® membrane (Wilhelm and Krizbai, 
2014). As well, on the BBB-PVPA model, liposomes that mimic brain endothelial cellular 
membranes are placed on the top of a Transwell® system-like (insert plus membrane filter). 
Small and large liposomes form a bilayer of phospholipid vesicles well compressed to create 
a membrane capable to mimic BBB tightness (TJ between BBB cells). All extracellular factors 
and cell-to-cell communications do not exist on the phospholipid-based model. Moreover, 
efflux systems present at this biological barrier are not mimicked on PVPA model. Therefore, 
since BBB-PVPA model lacks morphological features and the availability of active transport 
proteins, only passive transcellular-like diffusion is addressed. On the other hand, this 
disadvantage could become a plus as it could arise a way to differentiate between active and 
passive transport (Flaten et al., 2006b), by comparison of PVPA and cell-based models. 
Despite non-cellular models limitations, PVPA membranes could be an alternative and/or 
complement to cellular models since they are easier to develop, less time consuming, can be 
simply adaptable to what is desired, and thus they could be an easy way to do a first fast 
screening before moving to cell-based models. 
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Our working hypothesis was that the PVPA barrier earlier introduced as an intestine 
model (Flaten et al., 2009; Flaten et al., 2006a; Flaten et al., 2006b; Flaten et al., 2008) 
should be adapted in order to better mimic passive transcellular-like diffusion at the BBB. For 
that, we prepare a model with a biomimetic bilayer lipid composition to achieve a tighter 
barrier, indicated by higher transendothelial electric resistance (TEER) values than the ones 
observed with the PVPA barrier so far (~600 Ωcm2 (Fischer et al., 2011)), and appropriate 
permeability of well-known compounds (e.g. verapamil, theophylline and calcein) by 
comparison with values reported for other BBB models. 
The well-known parallel artificial membrane permeation assay (PAMPA) composition 
has been already modified positively for the prediction of BBB penetration (BBB-PAMPA (Di 
et al., 2009)). This model uses a multi-well plate for the donor chambers and 
membrane/receptor compartments are placed on top. The membrane used on PAMPA is a 
lipid-infused artificial membrane located between donor and receptor compartments. 
However, previous studies (Flaten et al., 2006b) revealed that the PAMPA model was less 
strong, reliable and robust than the PVPA model, as probably the liposome layer of the PVPA 
model resembles better the membrane of cells. Consequently it is expected that the BBB-
PVPA will be a more reliable and robust model to predict brain permeation than the BBB-
PAMPA. Beyond non-cellular based models, membranes made of cells are common as BBB 
models. Human brain endothelial cells (hCMEC/D3 cell line) are regularly used for static BBB 
cell based models, either in monoculture (Weksler et al., 2013) as well as in co-culture 
(Hatherell et al., 2011). 
On the other hand, as efflux transporters are the main system that denies the access 
of drugs to CNS, one possible strategy to improve the efficacy of CNS drugs could be the 
modulation of these transporter proteins responsible for their passage across the BBB 
(Mahringer et al., 2011). Here is where siRNA arises as a useful tool to specifically silence 
these efflux proteins, as for example the siRNA against P-gp used in this study (Gomes et 
al., 2015). Briefly, siRNA guide chain, once at the cytoplasm of brain endothelial cells, has 
the ability to find its complementary mRNA chain and degrade it (Fuest et al., 2009; 
Nascimento et al., 2014). In this case, P-gp mRNA is the target thus the product of mRNA 
translation will decrease, resulting in P-gp down-regulation. 
The main aims of this study were the development of a BBB non-cellular based model 
supported by phospholipid vesicles that mimic cellular membranes, and test the permeability 
of siRNA through the optimized in vitro BBB model. Furthermore, to improve its delivery and 
increase its ability to permeate BBB, siRNA-loaded nanosystems (solid lipid nanoparticles 
(SLN) and polymeric PLGA nanoparticles) were evaluated. Nanoparticles (NPs) have 
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advantageous features – small size, customizable surface, improved solubility, targeted drug 
delivery – that provide them the promising capacity to reach and cross the BBB, which could 
also improve the same capacity for what they incorporate (Bhaskar et al., 2010). Lastly, the 
created barrier and its overall structure were observed, as well as how calcein as a model 
drug interacts/permeates through it. 
 
3. Materials and Methods 
 
3.1. Materials 
 
Phosphatidylcholine from soybean (S100) and egg phosphatidylethanolamine (EPE) 
were purchased from Lipoid, phosphatidylserine from Corden Pharma, and cholesterol from 
Sigma. Other reagents were purchased from Sigma: all drugs – calcein, verapamil and 
theophylline, and PVA (mol wt 30000-70000, 87-90% hydrolyzed). From VWR, chloroform, 
methanol and ethyl acetate were purchased. Nitrocellulose filter 650 nm (DAWP 14250), 24-
well plates (Millicell® 24), and filters 800 nm and 400 nm (Isopore membrane filters, 0.8 μm 
ATTP02500 and 0.4 μm HTTP02500) were purchased from Millipore. siRNA-FITC against P-
gp was purchased from Santa Cruz Biotechnology, Witepsol E-85 from Gattefossé, PLGA 
5004A from Corbion Purac, and Lissamine™ Rhodamine B 1,2-Dihexadecanoyl-sn-Glycero-
3-Phosphoethanolamine Triethylammonium Salt (rhodamine DHPE) from Invitrogen. 
 
3.2. Methods 
 
3.2.1. Preparation of barriers 
Since PVPA model may easily be modified with respect to lipid composition in order 
to better resemble the BBB (Engesland et al., 2013), BBB-PVPA with different lipid 
compositions were produced in order to find the most suitable composition in terms of TEER 
and appropriate permeability of verapamil, theophylline and calcein. It is essential to mimic 
the lipid composition of brain capillaries, and not the overall lipid composition of the brain. 
Therefore, the average percentages (mol/mol) for each lipid present on the composition of 
brain endothelial cell lines were previously determined (Kramer et al., 2002a; Kramer et al., 
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2002b) and are here described: phosphatidylcholine (PC; 22.3%); cholesterol (CHO; 21.8%); 
phosphatidylethanolamine (PE; 14.2%); phosphatidylserine (PS; 10.5%); cholesterol ester 
(9.3%); sphingomyelin (6.7%); fatty acids (6.6%); phosphatidylinositol (4.2%); triglycerides 
(3.5%); cardiolipin (0.9%). According to these values, the lipids that exist in larger quantities 
were chosen, and different lipid mixtures were made (maintaining their proportionality) to 
develop distinct PVPA-barriers, assess their behavior, and select the one that better mimics 
BBB. Therefore, PC+PE, PC+CHO, PC+PE+PS and PC+PE+PS+CHO were studied, as well 
as just PC, which is the major BBB component, also acting as control and a primitive BBB 
model. 
The BBB-PVPA was prepared according to the procedure earlier described and 
stored for up to 2 weeks at -80º C in accordance with previous stability studies (Flaten et al., 
2009; Flaten et al., 2006a; Flaten et al., 2006b; Flaten et al., 2008; Flaten et al., 2007). In 
brief, liposomes were prepared by film extrusion method. To make 2 x 24-well plates, a total 
lipid mass of 2.16 g was weighted to a round bottom flask where 7.2 mL of 
chloroform/methanol (2:1) was added. To produce the different lipid mixtures tested, lipids 
where weighted proportionally. After lipids dissolution, film formation was promoted by 
rotavapor (55°C, 150 rpm, with N2 circulation). Then, liposome dispersion (6% w/v) was 
prepared by adding to the lipid film 10% ethanol in PBS and shaking the mixture until 
everything is dispersed. The 24-well plates were prepared by welding a nitrocellulose filter to 
the well plate by heat press HP60-250-ESM for 32 seconds. To prepare the barriers, 
liposome dispersions were extruded through filters with pore size 800 nm (large liposomes) 
and 800 + 400 nm (small liposomes), and were then deposited on a filter support through 
centrifugation. The liposomes were added in consecutive steps, first the smaller liposomes 
and then the larger ones. First, 182 μL of small liposomes were added to each insert of a 24-
well plate with a membrane filter on the bottom, then first centrifugation was done at 600  g, 
25°C, 4 min. After the addition of the same amount of small liposomes, second centrifugation 
was done at 600  g, 25°C, 10 min. The excess of liposomes still on the insert was discarded 
by dabbing them on a tissue and, with the lid on, plates were placed in an oven (Binder, Buch 
& Holm) at 50°C for 45 min. After they reached room temperature, large liposomes (182 μL) 
were added to each insert and the third centrifugation was done at 600  g, 25°C, 30 min. 
Plates were covered with tissue paper and turned upside down, and the forth centrifugation 
was performed at 20  g, 25°C, 5 min. Finally, barrier plates were stored at -80°C for at least 
1h. 
Labeled barriers were produced following the same protocol as the non-labeled ones, 
but with 0.2 mol% of labeled phospholipid (rhodamine DHPE, that stays within the lipid 
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matrix), which was weighted and mixed at the beginning with the lipids, maintaining the total 
weight (Flaten et al., 2006a). 
 
3.2.2. Nanoparticle production and characterization 
Nanoparticles (lipid and polymeric) were prepared through a modified solvent 
emulsification evaporation method, based on the water-in-oil-in-water (w/o/w) double 
emulsion technique (Fonte et al., 2014; Soares et al., 2013). Twenty milligrams of polymer 
(PLGA) or lipid (Witepsol E-85) were dissolved in ethyl acetate (500 μL). Then, 100 μL of 
siRNA-FITC solution in RNAse free water (13.55 ng μL-1) was added to the organic solution 
and homogenized for 90 s using a Vibra-Cell™ ultrasonic processor. The primary emulsion 
(w/o) formed was then added into 2 mL of the surfactant solution, 2% of PVA in deionized 
water, and homogenized again for 60 s. The second emulsion formed (w/o/w) was finally 
added to 6 mL of the same surfactant solution and was left under magnetic stirring at 300 
rpm for at least 3 h for ethyl acetate evaporation. 
After production, the nanoparticles were characterized regarding their average 
particle size, polydispersity index (PdI) and average zeta potential by electrophorethic light 
scattering using a Malvern Zetasizer Nano ZS instrument (Malvern Instruments Ltd). For 
these measurements, samples were diluted in MilliQ-water. To determine the association 
efficiency (AE) of the developed nanosystems, the amount of siRNA-FITC associated to the 
nanoparticles was calculated by fluorescence (ex. 494 nm, em. 517 nm). This calculation 
was made by the difference between the total amount of siRNA used to prepare the systems, 
and the amount that remained in the aqueous phase after nanoparticles isolation by 
centrifugation (50,000  g, 4°C for 20 min (PLGA NPs) or 14h (SLN)), according to the 
following equation (Sarmento et al., 2006): 
 
 
 
Surface morphology (shape and size) of nanoparticles was evaluated by scanning 
electron microscopy (SEM). Nanoparticles were resuspended and purified three times with 
distilled water by ultracentrifugation in a Beckman Avanti J-26 XP ultracentrifuge (Beckman 
Coulter) at 20,000  g for 15 min at 4°C, to remove the dissolved surfactant. Then, samples 
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were mounted onto metal stubs and vacuum-coated with a layer of gold/palladium before 
observation in the SEM microscope, using a FEI Quanta 400 FEG SEM, and analyzed with 
INCA Electronic Data System (EDS). EDS used in conjunction with the SEM apparatus is 
INCA Energy 350 (Oxford Instruments). 
 
3.2.3. Permeation assay 
To finish the preparation of barriers, a freeze-thaw cycle was used to promote fusion 
of liposomes and hence produce a tight barrier. Therefore, plates were thawed in the oven at 
65°C (40 min without lid, then 20 min with lid), and after reached room temperature they were 
ready for the permeation experiment. All permeation experiments were performed until reach 
steady state, at sink conditions. Wells (receptor chamber) were filled with 800 μL of PBS pH 
7.4 (mimicking brain) and the inserts (donor chamber) with 400 μL of PBS pH 7.4 (mimicking 
blood). Inserts were moved to the wells for an incubation period of 30 min. Then, resistance 
(TEER) was measured (Millicell® ERS, Millipore). For drug permeation assays, buffer was 
removed from the donor compartments and replaced for a drug solution with a known 
concentration (calcein 10 mM / verapamil 10 mM / theophylline 10 mM). Inserts were moved 
to new wells filled with 800 μL PBS pH 7.4, and light contact was avoided from now on. 
Further, inserts were moved to new wells according to these time points: 1h, 1h30, 2h, 2h30, 
3h, 3h30, 4h, 4h30 and 5h. The resistance was measured again immediately after these 5h. 
Samples (200 μL) were taken from all wells (at each time point) to a titer plate (Microplate 
Costar 96) where the drug that crossed the membrane over time was quantified. The 
concentration of drug in solution was quantified using UV/Vis spectrophotometer for 
absorbance of verapamil (284 nm) and theophylline (271 nm), and for fluorescence of calcein 
(ex. 485 nm, em. 520 nm). 
The apparent permeability (Papp) of each drug in solution was calculated by the 
following equation: 
 
 
 
where dm/dt is the permeated mass over time, c0 the initial concentration at the donor 
chamber, and A the surface area of the membrane (0.6 cm2) (Kanzer et al., 2010). 
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The protocol followed for the permeation of free-siRNA or siRNA-loaded NPs was 
similar. However, donor compartments were filled with 400 μL RNAse free water (blank for 
free siRNA-FITC), or free siRNA-FITC (167 ng mL-1), or empty-NPs (blank for the respective 
siRNA-loaded NPs), or siRNA-FITC-loaded NPs. Moreover, time points were different: 1h, 
2h, 3h, 4h and 5h; and when 200 μL were taken from the receptor compartment to a titer 
plate, the same volume of fresh buffer was added. siRNA-FITC that crossed the barrier over 
time was quantified through fluorescence with a plate reader. Papp was calculated for free-
siRNA, siRNA-SLN and siRNA-PLGA using the same equation described before. 
 
3.2.4. Confocal studies 
After the preparation of the barriers and their freezing at -80°C, plates were thawed in 
the oven at 65°C (40 min without lid, then 20 min with lid), and after reach room temperature 
they were ready for the confocal experiment. Inserts of labeled barriers were filled with 400 
μL PBS or 400 μL calcein 10mM. The wells were filled with 800 μL PBS pH 7.4 or 800 μL 
calcein 10mM, respectively. After an incubation period of 3h, donor compartments were 
discarded and the insert membrane was seen at the confocal microscope. 
The images were recorded on a Zeiss confocal LSM 510 with an femtosecond Ti:Sa 
laser used as excitation source (Broadband Mai Tai XF W25 with a 10 W Millennia pump 
laser, Spectra Physics). Fluorophores were excited at 810 nm (multi photon excitation), 
emission was recorded with a bandpass filter 500-530 nm (for calcein, green) and a 
bandpass filter 565-615 nm (for Lissamine rhodamine B, red). 
 
3.2.5. Statistical analysis 
For the data analysis one-way analysis of variance (ANOVA) was performed to 
compare multiple groups. Differences between groups were compared with a post hoc test 
(Tukey’s honestly significant difference). Results are reported as mean ± standard deviation 
from a minimum of three independent experiments. Differences were considered significant 
at * p < 0.05, ** p < 0.01, or *** p < 0.001. All statistical analyses were performed with the 
software PASW Statistics 20 (IBM Corporation). 
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4. Results and Discussion 
 
4.1. Permeability and TEER of barriers made from different lipid mixtures 
 
In order to mimic the BBB lipid composition, its most common lipids and 
phospholipids were chosen to prepare different barriers according to the PVPA method: 
PC+PE, PC+CHO, PC+PE+PS, PC+PE+PS+CHO. A schematic illustration of the PVPA 
barrier structure is depicted on Figure 3.1, where an insert and a well are represented as a 
Transwell® system-like, along with small and large liposomes deposited on the membrane 
filter. To assess these different barriers in terms of usefulness as a BBB model, TEER values 
were monitored (Figure 3.2). Also, the permeability of three drugs (calcein, theophylline and 
verapamil), which have distinct intrinsic properties and permeability behaviors, was 
determined (Figure 3.3). 
 
 
 
Figure 3.1. Schematic illustration of phospholipid vesicle-based barrier structure on a Transwell
®
 
system-like. 
 
Our working hypothesis was based on the premise: the more similar the lipid mixture 
is to brain endothelial cells lipid composition, theoretically the closer its barrier tightness will 
be to the one shown by BBB. TEER is generally regarded as a good indicator of barrier 
tightness (Bates et al., 2015). TEER was measured, for each type of membrane, before and 
after permeability experiments (5h; Figure 3.2). 
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Figure 3.2. Transendothelial electrical resistance (TEER) of all studied barriers which were made of 
distinct phospholipid mixtures. TEER was measured on the beginning and at the end of permeability 
studies. PC: phosphatidylcholine; PE: phosphatidylethanolamine, PS: phosphatidylserine, CHO: 
cholesterol. 
 
Most PVPA-barriers made of lipid mixtures resulted in lower TEER-values than the 
pure PC-barrier. The exception was the mixture of PC and PE, which resulted in significantly 
higher TEER-values indicating enhanced barrier tightness as compared to the pure PC-
barrier. This observation may be explained by different effects. First, cholesterol is known to 
make phospholipid bilayers stiffer and less flexible (Dols-Perez et al., 2014; Khajeh and 
Modarress, 2014). Higher stiffness of the vesicles may negatively affect their packing density 
during barrier preparation. On the other hand, PS is known to induce a strong net charge to 
the vesicles (Mitkova et al., 2014), which also may negatively affect their packing density 
during barrier preparation, due to charge-charge-interactions. Lastly, mixtures with higher 
number of lipids result in different type of liposomes (different size and charge), which would 
be more unstable, and not able to pack so well with each other. This could cause disruption 
of the interactions between different liposomes, promoting less tight membranes and lower 
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TEER. Thus, PC+CHO, PC+PE+PS and PC+PE+PS+CHO present a loss of barrier 
tightness, which is not in accordance with one of the main BBB features. 
Moreover, the differences observed between TEER values before and after the 
permeability assay could be related to that experiment, since the permeation of tested drugs 
may open some spaces within the barrier, decreasing its TEER. 
For the permeability assays, three different model drugs were selected. Calcein 
(622.55 g mol-1; a Biopharmaceutics Classification System  class III compound), a hydrophilic 
charged marker commonly used as an indicator of trans-bilayer permeability (Patel et al., 
2009), was used since it is well studied on this field and therefore is easy to correlate 
(Fischer et al., 2011; Flaten et al., 2008; Kanzer et al., 2010). Theophylline (180.164 g mol-1; 
a BCS class I drug which Log P (octanol/water) is -0.02 (Hansch et al., 1995)), and verapamil 
(454.602 g mol-1; a BCS class I drug which Log P (octanol/water) is 3.8 (Yoshida et al., 
2010)) were chosen as standard drugs since, despite their hydrophilic character, present 
different values of coefficient O/W, being verapamil more hydrophobic than theophylline. 
Therefore, these drugs have different expected behavior on crossing a phospholipid 
membrane (Di et al., 2003). Theophylline is a drug used in therapies for respiratory diseases 
since it acts both as a competitive non-selective phosphodiesterase inhibitor (Essayan, 2001) 
and as a non-selective adenosine receptor antagonist, explaining many of its cardiac effects. 
Verapamil acts by blocking voltage-dependent calcium channels and is used in the treatment 
of hypertension, angina pectoris, cardiac arrhythmia, and most recently, cluster headaches 
(Bleier et al., 2015). 
Permeability for these molecules was determined for all lipid mixtures-based 
membranes developed (Figure 3.3), simultaneously with the evaluation of TEER values. We 
further tested our working hypothesis that a barrier composed of a mixture of lipids (mainly 
PC+PE, based on TEER results), which better resembles the BBB lipid composition than just 
PC, would be more proper for the prediction of drugs permeability through the BBB than a 
pure PC barrier. Permeability results corroborate resistance data for PC+CHO, PC+PE+PS 
and PC+PE+PS+CHO, since such high permeability obtained for these mixtures are related 
to less tightness and compact barrier observed by TEER. Likewise, corroborating this 
hypothesis, calcein (which is the largest molecule tested and indicates lipid vesicle leakage) 
permeability increased on these multiple lipids mixtures. Thus, these mixtures were 
discarded to continue our studies as BBB models candidates. We could not see any 
significant difference between PC+PE and PC alone. However, for the same lipid mixture, 
verapamil crosses in a deeper extend than theophylline, which was expected due to the 
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improved interaction between a hydrophobic membrane and the most hydrophobic used drug 
rather than other more hydrophilic. 
 
 
Figure 3.3. Permeability of calcein, theophylline and verapamil through different barriers made of 
distinct phospholipid mixtures. PC: phosphatidylcholine; PE: phosphatidylethanolamine, PS: 
phosphatidylserine, CHO: cholesterol. 
 
Literature values for the permeability of verapamil and theophylline through other BBB 
models (as in vitro cell-based or PAMPA) were determined and set to be from 3.23 ± 0.54  
10-5 cm s-1 to 3.35 ± 0.45  10-5 cm s-1 on a used BBB cellular model (MDCKII-MDR1 
monolayer) and 3.43 ± 0.71  10-5 cm s-1 on PAMPA (Carrara et al., 2007), for verapamil. For 
theophylline, values of 8.8 ± 2.0  10-6 cm s-1 on brain endothelial cells monoculture (bEnd.3 
cell line) (Dhanikula et al., 2009) were described. These values are within the obtained 
PVPA-data range (5.2  10-6 – 2.2  10-5 cm s-1 for verapamil and 3.8  10-6 – 1.6  10-5 cm s-
1 for theophylline), having the same order of magnitude. Moreover, permeability for verapamil 
is higher than for theophylline, as cell-based or PAMPA models also demonstrated before. 
The innovation provided by PVPA method is, therefore, highlighted by these results, since it 
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enables the development of membrane models in a faster and easier fashion than 
conventional existing models, while retaining similar permeability values. 
At flow conditions, on BBB models such as Dynamic in vitro (DIV) systems (system 
that mimics blood flow by creating intraluminal flow through artificial capillary-like structural 
supports (hollow fibers) (Naik and Cucullo, 2012)), steady state is achieved after 2 weeks, 
when TEER reaches 1200 Ωcm2 (Cucullo et al., 2008). On the other hand, static systems as 
Transwell® models just require 1 week to steady state but TEER could only reach 60-80 
Ωcm2 (15- to 20- fold lower values) (Cucullo et al., 2008). With PVPA method, the highest 
TEER values are obtained in the same day of production, an advantage considering fast high 
throughput analysis. Furthermore, the lipid mixture PC+PE reaches even higher TEER than 
on flow conditions (keeping this value high enough after permeability experiments), in much 
less time. 
In order to select the model that better mimics BBB, permeability and resistance 
values were evaluated and compared to other reported BBB models. Although permeability 
values were very similar between PC and PC+PE, TEER values for the mixture PC+PE were 
significantly higher than for PC. These higher TEER values are more often obtained with 
dynamic systems, which mimic better the BBB, rather than static models. Therefore, since 
this is an intended characteristic to achieve a better BBB model, this mixture was selected as 
the best one, still continuing to do all further experiments with PC barrier also. Besides its 
higher TEER, PC+PE is already more complex than just PC, and has the two main 
phospholipids present in the BBB. 
 
4.2. Selected BBB model structure 
 
As long as the liposomes are stable, which could be addressed through the proven 
barrier stability and integrity (with TEER results), we believe that the liposomes stay as 
vesicles organized on/above the filter material, mainly through adsorption of their bilayers to 
each other. Still, to track their structure, the two types of barriers composed of PC+PE and 
PC only were then labeled and visualized by confocal microscopy (Figure 3.4 A). Further, 
calcein was added to the apical side of these membranes to assess its permeability 
pathways (Figure 3.4 B). 
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Figure 3.4. (A) BBB model (PC+PE) labeled with Lissamine rhodamine B. (B) BBB barrier (PC) 
labeled with Lissamine rhodamine B assessing calcein permeability. Large scale bar is 20 μm; small 
scale bar is 10 μm. 
 
Figure 3.4 A shows the labeled barrier, it was possible to observe the BBB structure 
through the filaments created by the membrane filter and the barrier developed above it. For 
the calcein permeation assessed in the labeled BBB barrier (Figure 3.4 B), a much larger 
amount was found on the apical side of the barrier surface, and only a small amount crossing 
the barrier, which was expected due to its very low permeability values (Figure 3.3), in 
accordance to previous studies (Flaten et al., 2006a). Similar location of calcein was 
observed for PC+PE model (data not shown). 
The interaction between BBB model and calcein, as the largest hydrophilic molecule 
here used able to indicate lipid vesicle leakage, highlighted the integrity and stability (for at 
least three hours) of the created barrier. 
 
4.3. Nanoparticles characterization 
 
After the development and selection of a BBB model, it was used to test the 
permeability of siRNA and siRNA-loaded NPs. Two types of nanoparticles were produced, 
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namely lipid (SLN) and polymeric (PLGA), as systems to transport siRNA to the BBB. The 
mean size and zeta potential properties of developed nanoparticles are depicted on Table 
3.1. To promote BBB crossing, a size below 200 nm is desired in order to avoid rapidly 
uptake by reticuloendothelial system (Chen et al., 2004). Therefore blood circulation time is 
increased, as well as the contact time with the BBB (Chen et al., 2004; Kaur et al., 2008). 
This requisite was accomplished, with monodisperse and slightly negative populations. 
Moreover, the siRNA association efficiency of siRNA-loaded nanoparticles was also 
measured and calculated. Association efficiency between 53 and 56% was obtained, which 
constitutes a promising result since siRNA is very hydrophilic. Data related to nanoparticles 
characterization revealed similarities among produced nanoparticles, both SLN and PLGA, 
loaded and unloaded. 
 
Table 3.1. Physicochemical characteristics of SLN and PLGA nanoparticles, both empty and siRNA-
loaded. 
NP system 
Mean size 
[nm] 
PdI Zeta Potential [mV] 
Association 
Efficiency [%] 
SLN 139.3 ± 1.3 0.127 ± 0.023 -10.1 ± 0.5 - 
siRNA-loaded SLN 137.3 ± 3.2 0.129 ± 0.024 -10.0 ± 1.0 53.1 ± 1.1 
PLGA 142.9 ± 1.0 0.093 ± 0.018 -8.2 ± 0.1 - 
siRNA-loaded PLGA 144.0 ± 1.4 0.121 ± 0.024 -10.1 ± 0.7 56.5 ± 1.8 
PdI, polydispersity index 
 
SEM analysis was also performed to obtain more information about the particle size 
and morphology. All evaluated nanoparticles exhibited a spherical shape (Figure 3.5) and a 
smooth surface, regardless of their composition. Nanoparticles sizes observed by SEM were 
shown to be similar to those obtained by Zetasizer measurements. However, it has been 
reported that solvent removal that occurs during SEM sample preparation may cause 
changes that can influence particle shape and size (Das and Chaudhury, 2011). 
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Figure 3.5. SEM images of (A) PLGA nanoparticles, and (B) siRNA-loaded PLGA nanoparticles. The 
scale bar shown below the images corresponds to 1 μm. 
 
4.4. siRNA permeability 
 
To evaluate the permeability of siRNA and the influence of nanoparticles, free-siRNA, 
siRNA-loaded SLN and siRNA-loaded PLGA nanoparticles were added to the apical side of 
both PC barrier and BBB selected model (PC+PE). The permeability values are depicted on 
Figure 3.6. 
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Figure 3.6. Permeability of free-siRNA and siRNA-loaded NPs (both SLN and PLGA) through the 
selected BBB model (PC+PE) and the control barrier (PC). PC: phosphatidylcholine; PE: 
phosphatidylethanolamine. 
 
Permeability had the lowest value for free-siRNA, however, as a hydrophilic 
compound, it still had some permeation through the BBB model, which could be explained by 
its very small size. Both types of nanoparticles significantly increased siRNA transport across 
the barrier, since nanoparticles themselves permeate the lipid barrier, releasing then the 
siRNA. SLN were more efficient than PLGA nanoparticles, due to their hydrophobic lipid 
composition, which presented higher affinity to lipid membranes made of liposomes. 
However, no differences between results obtained for PC or PC+PE were observed. 
The percentages of siRNA that crossed the membrane were similar for PC and 
PC+PE, close to 10% of free-siRNA, 14% of siRNA-PLGA, and 19% of siRNA-SLN. 
Concerning these values, it is clear the improvement of siRNA penetration through a BBB 
model membrane, from 10% to 19%, highlighting the influence of nanoparticles as a carrier 
and a siRNA permeability promoter. Other previous studies also emphasize the importance 
of siRNA carriers, stressing the significance of choosing the adequate carrier, as Khatri and 
colleagues who observed that siRNA loaded cationic lipoplexes increased siRNA cellular 
uptake (in two different lung cancer cell lines) by five to six fold compared to naked siRNA 
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(Khatri et al., 2014). In another study, chitosan nanoparticles improved siRNA uptake in 
RBE4 cells (commonly used as a BBB model), which was monitored by fluorescence (Malmo 
et al., 2013). Moreover, Godinho and co-workers evaluated cellular uptake of a fluorescently 
labeled siRNA loaded in amphiphilic-cyclodextrins nanoparticles through a rat neuronal in 
vitro model. After 48 h post transfection, up to 38% of cells were found to be positive for 
fluorescent siRNA complexes. In contrast, no significant uptake was observed in cells treated 
with naked siRNA (Godinho et al., 2013). Therefore, as these cell-based studies also 
highlight, nanocarriers are crucial to potentiate siRNA efficiency since they promote its 
uptake thus increasing its permeability across cellular membranes. 
Permeability through these barriers can be related and caused by charge (siRNA, 
nanoparticles and barrier are negative) and hydrophobicity (siRNA is hydrophilic; 
nanoparticles and barrier are hydrophobic). Opposite charges attract each other, as well as 
similar hydrophobicity surfaces. Interactions between different charges and hydrophobic 
surfaces influence the affinity increase/decrease and therefore may control the permeability. 
In this study, all the present elements are negative, so there is no great advantage from that, 
and therefore effects of charge on penetration are negligible. As the BBB-PVPA barrier, 
human BBB also carries a negative charge due to its glycosaminoglycan composition (Li and 
Fu, 2011). So, regarding charge consequences, created barrier mimics BBB at this level, 
which also validates a direct comparison between these membranes. Moreover, since PVPA 
membranes study passive transcellular-like permeability, produced nanoparticles (both SLN 
and PLGA) may cross this artificial BBB through the liposomes (transcellular-like pathway). 
Nanoparticles are believed to interact with liposomes from the barrier, being able to stay 
between them and thus go through them. Especially SLN, they may merge with the lipids in 
the barrier, which could then promote siRNA release. Furthermore, that could also affect the 
barrier tightness, another possible explanation for the decrease of resistance after the 
permeability experiment. 
Therefore, nanoparticles were able to interact with BBB-PVPA liposomes, passively 
crossing the barrier through them, revealing capability to interact with BBB-like cellular 
membranes. As so, siRNA would have the possibility to act in these cells down-regulating the 
expression of P-gp. Consequently, any P-gp substrate drug that is desired to achieve the 
brain in a therapeutic concentration will benefit of this transient opportunity. Improving siRNA 
permeability by using nanoparticles could be the trigger to make all this process more likely 
to occur, ending with numerous drug reaching brain advantages. 
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5. Conclusions 
 
The main innovative key in this work holds up to the phospholipid-vesicle based 
method to create membranes as a non-cellular based technique. This enables the 
development of membranes according to the desired lipid content. It has several advantages 
when compared to cell-based methods such as: easy to reproduce, less expensive, less time 
consuming, no contamination problems. Moreover, it is an excellent way for high throughput 
screening of permeability properties of potential drug/nanosystem candidates early in the 
development process, leading to a pre-selection of the best drug/nanosystem before 
continue to in vitro and in vivo studies. Our non-cellular based BBB model could be used as 
another model to compare results and can easily be improved/adapted (as shown in this 
study) by using other lipids or adjusting the production protocol. Also, it could be simply 
modified to mimic other type of barriers. Since it has no active transport, it evaluates only 
passive transport which could then be compared with passive and active transports that 
occur in other models in vitro/in vivo in order to verify the influence of both types of transport. 
One of the main objectives of barriers developed through this method is to enable results 
extrapolation and prediction. 
The first goal of this work was to develop a non-cellular based BBB model. Although 
permeability studies with both drugs and siRNA do not indicate a difference between barriers 
made of PC and PC+PE, TEER values are clearly different and may influence the barrier 
behavior in other conditions, namely the permeability to other drugs. Thus, the mixture 
PC+PE was selected as the one that better mimics BBB. 
As obtained permeability data suggest, similar values could be achieved by using 
BBB-PVPA method and cell-based models. Consequently, phospholipid-based method could 
lead to avoid cell based experiences with early drugs/nanosystems which could not be good 
enough yet. This underlines that PVPA, as a simple system, could be an easy way to do a 
first fast screening before moving to cell-based models. Therefore, it could be a faster and 
less expensive option. 
Regarding siRNA permeability through the selected BBB model and the influence of 
nanosystems, nanoparticles were found to act as an efficient carrier since they significantly 
improve siRNA permeability through the BBB model. This indicates the importance of using 
siRNA delivery nanosystems. Moreover, these nanoparticles were shown to be promising 
enough to be further tested on a cell-based model. 
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1. Abstract 
 
Blood-brain barrier is a tightly packed layer of endothelial cells surrounding the brain 
that acts as the main obstacle for drugs enter the central nervous system (CNS), due to its 
unique features, as tight junctions and drug efflux systems. Therefore, since the incidence of 
CNS disorders is increasing worldwide, medical therapeutics need to be improved. 
Consequently, aiming to surpass blood-brain barrier and overcome CNS disabilities, 
silencing P-glycoprotein as a drug efflux transporter at brain endothelial cells through siRNA 
is considered a promising approach. For siRNA enzymatic protection and efficient delivery to 
its target, two different nanoparticles platforms, solid lipid (SLN) and poly(lactic-co-glycolic 
acid) (PLGA) nanoparticles were used in this study. Polymeric PLGA nanoparticles were 
around 115 nm in size and had 50% of siRNA association efficiency, while SLN presented 
150 nm and association efficiency up to 52%. The siRNA release profile was assessed and 
verified as sustained, reaching around 60% after 24h. Nanoparticles surface was 
functionalized with a peptide-binding transferrin receptor, in a site-oriented manner. This 
surface modification was confirmed by NMR, and their targeting ability against human brain 
endothelial cells was successfully demonstrated by fluorescence microscopy and flow 
cytometry. The interaction of modified nanoparticles with brain endothelial cells increased 3-
fold compared to non-modified lipid nanoparticles, and 4-fold compared to non-modified 
PLGA nanoparticles, respectively. These nanosystems, which were also demonstrated to be 
safe for human brain endothelial cells, without significant cytotoxicity, bring a new hopeful 
breath to the future of brain diseases therapies. 
 
KEYWORDS: Blood-brain barrier; Functionalization; Nanoparticles; siRNA; TfR-peptide 
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2. Introduction 
 
Currently, there is a huge and increasing incidence of central nervous system (CNS) 
disorders, which emphasizes such disorders as the major medical challenge of the 21st 
century, as indicated by the World Health Organization (ResearchAndMarkets, 2007). CNS 
disorders affect a large portion of population worldwide involving frequent and rare disorders, 
with unknown etiology or already identified causes, but the great majority is very disabling 
and not yet curable. From brain cancer to amyotrophic lateral sclerosis and diseases like 
Alzheimer’s, Parkinson or Huntington’s, there are numerous distinct disorders, characterized 
as unsolved clinical conditions, that lead to the same need, i.e., drug reaching brain in 
therapeutic concentrations, with few side effects and through a minimally invasive way 
(Gomes et al., 2015). This therapeutic gap is related to the complex CNS environment and its 
protective barriers, being, therefore, identified as the main challenge for the development of 
an efficient brain therapy. 
Blood-brain barrier (BBB) is one of the most relevant CNS barriers that restrict the 
passage of foreign substances into the brain by blocking drug/molecules transport. This 
biological membrane is mainly comprised by brain endothelial cells forming a cerebral 
microvascular endothelium, which presents molecular and receptor structures able to 
mediate the transport of substances in and out of the brain (Abbott et al., 2010). Additionally, 
the BBB holds tight junctions between adjacent endothelial cells which make this barrier very 
tight, and exhibits a lack of fenestrations and low endogenous pinocytotic activity (Abbott et 
al., 2010; Bhaskar et al., 2010). As one of the central contributors for brain penetration 
limitations are drug efflux systems, present at the luminal membrane of BBB. These are 
transporters that cause the efflux of many compounds, including drugs, from brain back to 
blood (Bhaskar et al., 2010). Among these systems is the P-glycoprotein (P-gp), which is a 
phosphorylated glycoprotein present in several tissues namely at the luminal plasma 
membrane of the capillary endothelium (Mahringer et al., 2011). Due to their described roles, 
drug efflux systems are considered to be a very attractive target to inhibit, in order to improve 
drug passage across the BBB, thus increasing the efficacy of CNS therapies (Fisher et al., 
2007; Mahringer et al., 2011). 
In order to study how to circumvent obstacles that difficult brain entrance, a feasible 
BBB in vitro model is crucial. Immortalized cell lines, as hCMEC/D3 (human brain endothelial 
cells), are commonly used as a human BBB model (Weksler et al., 2013). Surpass this 
compactly packed layer of endothelial cells, specifically drug efflux systems, will potentiate 
drug reaching brain ability. With this purpose, small interfering RNA (siRNA) arises as a 
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promising option for drug efflux systems temporary silence, since efflux systems known 
inhibitors have issues – as the inhibitor affinity and reversibility – that could become serious 
problems (Bauer et al., 2005). By directly down-regulate efflux transporters expression and/or 
transport activity, siRNA could be the key for these brain “over protective” issues. Despite 
siRNA large potential, efficient methods for its delivery must be devised. Nanomedicine, as 
an expanding and promising field for innovative advances to the diagnosis and treatment of 
devastating and pervasive diseases (Gilmore et al., 2008), could be a great ally for that 
approach. Nanoparticles, namely, have advantageous properties like small size, and 
potentiate targeted drug delivery, features that make them feasible to cross BBB (Gilmore et 
al., 2008). Furthermore, polymeric and lipid-based nanoparticles, made from natural or highly 
biocompatible materials, are considered the least problematic regarding toxicity (Murthy, 
2007). When used as siRNA carriers, nanoparticles protect oligonucleotides from enzymatic 
degradation and target them to desired cells through surface functionalization. 
Using site-specific ligands it is possible to target particular cells/tissues and thus 
direct nanoparticles delivery (Gabathuler, 2010). Therefore, functionalizing nanoparticles 
surface with a peptide against transferrin receptor (TfR) would direct these systems to the 
BBB, since there is an over expression of transferrin receptors at this biological membrane, 
among other body regions (Gabathuler, 2010; Huang et al., 2007; Moos and Morgan, 2000). 
Gathering all this knowledge, this study proposes a nanosystem able to carry and 
control the release of siRNA against P-gp to the BBB, in order to further silence this protein 
receptor, temporarily transforming BBB in a more permeable membrane for P-gp substrates. 
The core aims of this study were the development and step-by-step improvement of lipid and 
polymeric nanoparticles loading siRNA, and functionalized with a TfR-peptide that enables 
the system to be more interactive with BBB cells. Different lipids and polymers were used to 
produce nanoparticles, and distinct functionalization processes were assessed to obtain 
better siRNA loaded and targeted carriers. The cytotoxicity of created particles was 
evaluated to ensure the safety of these nanoparticles promising future. 
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3. Materials and Methods 
 
3.1. Materials 
 
Poly(lactic-co-glycolic acid), PLGA 5004A, was purchased from Corbion – Purac, 
PLGA-PEG-NH2 from PolySciTech, Witepsol E85 from Gattefossé and Stearylamine from 
Sigma-Aldrich. Ethyl acetate was purchased from VWR, siRNA-FITC against P-gp from 
Santa Cruz Biotechnology, TfR-peptide from AnaSpec, TfR-peptide-Cys from Eurogentec, 
and SM(PEG)24 was from Thermo Scientific. Deuterated water was purchased from Sigma-
Aldrich. EBM-2 medium from Lonza and Triton X-100 from Spi-Chem. Several materials were 
purchased from Sigma: Tween 80, EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide), 
NHS (N-hydroxysuccinimide), MES (2-(N-morpholino)ethanesulfonic acid), hydrocortisone, 
ascorbic acid, HEPES, bFGF (basic fibroblast growth factor), MTT, DMSO and PFA 
(paraformaldehyde). Others were purchased from Invitrogen: Rhodamine 123, CellMask™ 
Orange, primary antibody against TfR (OX26, PA5-24661), and secondary antibody (A-
11070). From Gibco it was purchased FBS, penicillin-streotomycin, chemically defined lipid 
concentrate, HBSS, collagen I rat protein and trypsin-EDTA. 
 
3.2. Methods 
 
3.2.1. Nanoparticles production 
Nanoparticles (polymeric and solid lipid nanoparticles, SLN) were prepared through a 
modified solvent emulsification evaporation method based on the water-in-oil-in-water 
(w/o/w) double emulsion technique (Fonte et al., 2014; Soares et al., 2013). Twenty 
milligrams of polymer (PLGA) or lipid (Witepsol E85) were dissolved in ethyl acetate (500 
μL). Then, 100 μL of siRNA-FITC solution in RNAse free water (13.55 ng μL-1) were added 
and the solution was homogenized for 90 s using a Vibra-Cell™ ultrasonic processor. The 
primary formed emulsion (w/o) was then added into 2 mL of the surfactant solution, 2% of 
Tween 80 in deionized water, and homogenized again for 60 s. The second formed emulsion 
(w/o/w) was finally added to 6 mL of the same surfactant solution, and was left under 
magnetic stirring at 300 rpm for at least 3h for ethyl acetate evaporation. 
CHAPTER IV 
87 
 
Additional polymer (PLGA-PEG-NH2) and lipid (stearylamine) were added to 
polymeric and lipid systems, respectively, to allow further nanoparticle functionalization. 
Different ratios of PLGA:PLGA-PEG-NH2 were used, namely 100:0, 97.5:2.5 and 95:5 (% 
w/w), as well as of Witepsol E85:stearylamine, with 100:0, 99:1 and 98:2 (% w/w). 
After production, the nanoparticles were characterized regarding mean particle size, 
polydispersity index (PdI) and zeta potential by electrophorethic light scattering using a 
Malvern Zetasizer Nano ZS instrument (Malvern Instruments Ltd). For these measurements, 
samples were diluted in MilliQ-water. To determine the association efficiency (AE) of the 
developed nanosystems, the amount of siRNA-FITC associated to the nanoparticles was 
calculated by a fluorescence (ex. 494 nm, em. 517 nm) assay. AE was determined indirectly 
by the difference between the total amount of siRNA used to prepare the systems and the 
amount that remained in the aqueous phase after nanoparticles isolation by centrifugation 
(20,000  g, 4°C for 20 min for polymeric nanoparticles or 50,000  g, 4°C for 4 h for lipid 
nanoparticles), according to the following equation: 
 
 
 
3.2.2. siRNA release profile 
The in vitro release of siRNA-FITC from nanoparticles was evaluated using a dialysis 
bag diffusion technique. Previously washed nanoparticles (7 mL) were placed in cellulose 
dialysis bags with a 12-14 kDa MWCO and sealed at both ends. The dialysis bag was 
immersed in the receptor compartment containing PBS (70 mL, pH 7.4), which was kept 
stirring at 100 rpm over 24 hours. Aliquots of 200 μL were taken from the receptor 
compartment at pre-determined time points up to 24h, and the same volume of fresh buffer 
was added. The siRNA-FITC content of each sample was analyzed through fluorescence 
using a plate reader. 
 
3.2.3. Nanoparticles functionalization and characterization 
Two different approaches were followed to conjugate the peptide to nanoparticles 
surface and direct them to BBB: (1) the carbodiimide chemistry, to link an amine group to a 
carboxyl group (Araújo et al., 2015; Wang et al., 2015), using  a 12 amino acid peptide (Thr-
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His-Arg-Pro-Pro-Met-Trp-Ser-Pro-Val-Trp-Pro, named here as pept); or (2) the maleimide 
chemistry, to link an amine group to a sulfhydryl group (Esfandyari-Manesh et al., 2015; 
Zimmermann et al., 2010), using a 13 amino acid peptide (the same pept with an extra 
cysteine on the carboxyl termination; Thr-His-Arg-Pro-Pro-Met-Trp-Ser-Pro-Val-Trp-Pro-Cys, 
named here as pept-Cys). 
Nanoparticles were functionalized according to their ending functional groups: PLGA 
(carboxyl group) with pept (amine group); PLGA:PLGA-PEG-NH2(95:5) (amine group) with 
pept-Cys (sulfhydryl group); Witepsol E85:Stearylamine(99:1) (amine group) with pept 
(carboxyl group); Witepsol E85:Stearylamine(99:1) (amine group) with pept-Cys (sulfhydryl 
group). 
For the amide formation, the EDC/NHS coupling chemistry method was used. The 
activation of the carboxyl groups of polymeric nanoparticles was attained by using 1 mg of 
nanoparticles dispersed in 1 mL of MES solution (10 mM, pH~5.5). Then, EDC (3.14 μL, 17 
mM) and NHS (1.2 mg) were added to the dispersion and the pH was adjusted to 5.5. This 
mixture was stirred (300 rpm) for 30 min at room temperature. The pept (100 μL, 1 mg mL-1) 
was added and pH adjusted to 7.5. Finally, the mixture was kept stirring (300 rpm) at room 
temperature for 3h30. For lipid nanoparticles carbodiimide conjugation, the carboxyl groups 
of peptide (pept) were activated by a similar procedure. In this last case, nanoparticles were 
only added to the mixture after the addition of the peptide, and pH was kept at 5.5. Both 
described processes were performed in the dark. 
The maleimide conjugation chemistry was performed by dispersing 1 mg of amine 
terminated nanoparticles (polymeric particles with PLGA-PEG-NH2 and lipid particles with 
stearylamine) on 1 mL of PB solution (0.1 M, pH~7). The cross linker SM(PEG)24 was added 
(2 μL, 250 mM) and the mixture was stirred in the dark, at 300 rpm for 4h, at room 
temperature. Then, pept-Cys was added (50 μL, 6.2 mg mL-1) and the mixture was stirred for 
another 4h. 
Afterwards, nanoparticles were collected by centrifugation at 20,000  g, 4°C for 20 
min, for polymeric nanoparticles, or 50,000  g, 4°C for 4h, for lipid nanoparticles, and then 
washed with MilliQ-water. Functionalized nanoparticles were then analyzed by Zetasizer. 
 
3.2.4. Nanoparticles labeling 
The same protocol to produce siRNA-loaded nanoparticles was used to obtain 
fluorescent nanoparticles encapsulating rhodamine 123 (0.5% w/w loading) instead of siRNA, 
CHAPTER IV 
89 
 
as already described (das Neves et al., 2012). Nanoparticles were resuspended and purified 
three times with Milli-Q water by centrifugation to remove rhodamine 123 excess. Rhodamine 
123-loaded nanoparticles were measured with Zetasizer, AE was determined, rhodamine 
123 was detected through fluorescence (ex. 507 nm, em. 529 nm), and its release was 
studied. The release assay was performed with a dialysis membrane (cellulose dialysis bag 
with a 12-14 kDa MWCO). Rhodamine 123-loaded formulations were located inside the 
dialysis membrane, which was well closed at the top and bottom. Membrane was placed 
inside a flask with 70 mL of PBS solution (pH 7.4), with constant stirring at room temperature. 
Samples (200 μL) were taken at pre-determined time points up to 24h, and the same volume 
taken was added again (PBS). Samples were analyzed by fluorescence. 
 
3.2.5. 1H Nuclear Magnetic Resonance (1H NMR) 
Non-functionalized and functionalized nanoparticles, as well as respective peptides, 
were dissolved (1 mg) on deuterated water and placed on appropriate NMR tubes. Analysis 
were performed at room temperature on a Brüker AMX 300 spectrometer operating at 400.13 
MHz, with chemical shifts expressed in δ (ppm) values relative to tetramethylsilane (TMS) as 
internal reference. 
 
3.2.6. Cell culturing 
Immortalized human Cerebral Microvascular Endothelial Cell Line (hCMEC/D3 cell 
line) was purchased from Cedarlane (Canada). The cells (passage 35-41) were grown in 
tissue culture flasks (Orange Scientific), in EBM-2 medium supplemented with FBS (5%, v/v), 
penicillin-streotomycin (1%, v/v), hydrocortisone (1.4 μM), ascorbic acid (5 μg mL-1), 
chemically defined lipid concentrate (1/100, v/v), HEPES (10 mM) and bFGF (1 ng mL-1). 
This last supplement was added extemporaneously in the culture medium. Cells were 
maintained in an incubator (CellCulture CO2 incubator, ESCO) at 37°C with 5% CO2 in water 
saturated atmosphere. Cells were subcultured every 3-4 days using trypsin-EDTA to detach 
them from the flasks. The culture medium was replaced every other day. 
 
3.2.7. Nanoparticles safety – MTT assay 
Cells were seeded in a 96-well plate (4  104 cells/mL) in a supplemented EBM-2 
medium. After 24h of incubation, medium was removed and cells were washed twice with 
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200 μL PBS. Then, cells were incubated with different concentrations of nanoparticles 
(naked, siRNA-loaded, siRNA-loaded and functionalized) for 24h. Nanoparticles solution was 
discarded, cells were washed twice, and then were treated with 200 μL of MTT solution (0.5 
mg mL-1, in medium) per well, during 4h in the dark. Finally, MTT was removed and 200 μL of 
DMSO were added to dissolve MTT formazan crystals during a 10 min slight shake at room 
temperature. In the end, absorbance was measured at 590 and 630 nm. Metabolic activity 
(as described on the following equation) was expressed as a percentage compared to the 
cells incubated only with EBM-2 medium (negative control). Triton X-100 (1%, in medium) 
was used as the positive control, since the detergent action disrupts the cells. 
 
 
 
3.2.8. Cell-nanoparticle interaction 
Transferrin receptor expression 
To verify whether hCMEC/D3 cells express transferrin receptor, these cells were fixed 
with PFA 4% during 10 min. After washing, cells were incubated with a blocking solution 
(10% FBS in PBS, 30 min), and then seeded on a round bottom 96-well plate (0.1  106 
cells/well). The primary antibody (OX26, against TfR) was added (1:50 or 1:200) and 
incubated during 1h. Cells were washed thrice (1,500  g, 1 min) and then incubated with the 
secondary antibody (1:2,000) during 1h. After washing three times, cells were resuspended 
in blocking solution, filtered (70 μm) and placed in cytometer tubes. 
The quantification of the secondary antibody associated to the cells was evaluated 
using flow cytometry (FACS Calibur, two laser excitation (488 nm/635 nm)), where the 
labeled antibody was detected through the 488 nm channel. The results were analyzed using 
the software FlowJo vX.0.7. The fold increase parameter was calculated as the fluorescence 
geometric mean of all samples normalized to the control, as described on the following 
equation: 
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Fluorescence microscopy 
Cells were seeded in glass cover slips (2.5  105 cells/mL, 400 μL) pre-coated with 
type I collagen, and were allowed to attach overnight. Glass cover slips (14 mm) were placed 
inside a 24-well plate, one cover slip per well. The cells were washed twice with pre-warmed 
400 μL PBS pH 7.4, and then 200 μL of rhodamine 123-loaded nanoparticles (50 μg mL-1, in 
10 mM HBSS-HEPES) were added to each well and incubated for 15 min, 1h or 4h at 37°C. 
After incubation, the cells were washed twice with PBS. Afterwards, the plasma membrane 
was stained by adding 200 µL of CellMask™ Orange and incubated for 3 min at 37°C. The 
excess of staining solution was washed twice with pre-warmed fresh PBS (pH 7.4) and the 
cells were fixed using 4% PFA for 20 min. 
The interaction between nanoparticles and human brain endothelial cells was 
assessed through an inverted fluorescence microscope (Axiovert 200M from Zeiss), where 
nanoparticles were detected through the green channel, while cells through the red one. The 
control was cells without nanoparticles. 
Flow cytometry 
Cells were seeded in a 24-well plate (5  105 cells/mL, 200 μL) and were allowed to 
attach overnight. The cells were washed twice with pre-warmed 200 μL PBS pH 7.4, and 
then 200 μL of rhodamine 123-loaded nanoparticles (50 μg mL-1, in 10 mM HBSS-HEPES) 
were added to each well and incubated for 15 min, 1h or 4h at 37°C. After incubation, the 
cells were washed twice with PBS and detached with trypsin-EDTA. The cells were then 
washed with medium and PBS through centrifugation at 1,500  g during 1 min, and fixed 
with PFA 4% in PBS during 10 min. PFA was removed through centrifugation and cells were 
washed again. Finally, cells were resuspended in PBS, filtered (70 μm) and placed in 
cytometer tubes. 
The quantification of the nanoparticles associated to the cells was evaluated using 
flow cytometry (FACS Calibur, two laser excitation (488 nm/635 nm)), where nanoparticles 
were detected through the 488 nm channel. The results were analyzed using the software 
FlowJo vX.0.7. The fold increase parameter was calculated as the fluorescence geometric 
mean of all samples normalized to the control, as described previously. 
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3.2.9. Statistical analysis 
For the data analysis one-way analysis of variance (ANOVA) was performed to 
compare multiple groups. Differences between groups were compared with a post hoc test 
(Tukey’s honestly significant difference). Results are reported as mean ± standard deviation 
from a minimum of three independent experiments. Differences were considered significant 
at * p < 0.05, ** p < 0.01, or *** p < 0.001. All statistical analyses were performed with the 
software PASW Statistics 20 (IBM Corporation). 
 
4. Results and Discussion 
 
4.1. Nanoparticles production 
 
The development of targeted nanoparticles has been proposed as a more convenient 
and efficient strategy for take advantage of therapeutic drugs. Different kind of ligands can be 
anchored to the surface of nanoparticles, providing a receptor-mediated interaction with 
target cells. In the present approach, to functionalize nanoparticles to BBB, a peptide with 
affinity to bind to TfR was selected. Functional groups at nanoparticles surface are, thus, 
required, so PLGA-PEG-NH2 and stearylamine were added to bare nanoparticles to provide 
chemical bridges to ligands. On polymeric nanoparticles, regular PLGA carboxyl terminated 
was used in addition to the copolymer PLGA-PEG-NH2 in different ratios (100:0, 97.5:2.5 and 
95:5). For lipid nanoparticles, Witepsol E85 was used with stearylamine, a lipid with amine 
groups, in different ratios (100:0, 99:1 and 98:2). All nanoparticles were studied regarding 
mean size, PdI, zeta potential and siRNA association efficiency through Zetasizer and 
fluorescence methods (Table 4.1). 
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Table 4.1. Physicochemical characteristics of polymeric and lipid nanoparticles unloaded and loaded 
with siRNA. 
NP system 
siRNA 
Loading 
Mean Size 
[nm] 
PdI 
Zeta 
Potential 
[mV] 
Association 
Efficiency [%] 
PLGA 
No 114.1 ± 1.4 0.241 ± 0.012 -30.3 ± 2.5 - 
Yes 113.5 ± 1.7 0.233 ± 0.017 -31.9 ± 1.7 49.7 ± 0.6 
PLGA:PLGA-PEG-
NH2 (97.5:2.5) 
No 112.6 ± 2.7 0.226 ± 0.016 -32.3 ± 1.9 - 
Yes 113.0 ± 3.3 0.239 ± 0.014 -31.2 ± 1.1 48.9 ± 0.2 
PLGA:PLGA-PEG-
NH2 (95:5) 
No 117.6 ± 3.6 0.271 ±0.026 -30.5 ± 1.4 - 
Yes 118.1 ± 2.1 0.252 ± 0.014 -29.3 ± 0.5 50.3 ± 1.3 
Witepsol E85 
No 155.7 ± 5.7 0.451 ± 0.033 -21.2 ± 2.0 - 
Yes 152.8 ± 6.9 0.438 ± 0.024 -20.1 ± 2.9 * 18.2 ± 1.1 * 
Witepsol E85: 
Stearylamine (99:1) 
No 147.4 ± 7.6 0.425 ± 0.041 -7.6 ± 1.0 - 
Yes 144.1 ± 8.5 0.455 ± 0.037 -8.0 ± 0.4 * 30.8 ± 2.5 * 
Witepsol E85: 
Stearylamine (98:2) 
No 152.7 ± 6.9 0.471 ± 0.044 -2.5 ± 0.6 - 
Yes 150.1 ± 7.9 0.433 ± 0.039 -2.9 ± 0.7 * 51.5 ± 1.5 * 
PdI, polydispersity index; * p < 0.05 
 
Physicochemical characteristics of empty and siRNA-loaded nanoparticles were 
similar. Likewise, no differences were observed when the new polymer/lipid were added to 
the system matrices. Differences were only detected for surface charge of SLN, as amine 
groups from stearylamine originate an increase in charge, resulting in higher siRNA 
association efficiency. In previous studies, this charge-related stearylamine effect was also 
observed (Cui et al., 2015). Non-phospholipid liposomes composed of stearylamine and 
cholesterol had higher positive surface charge and enhanced particle stability than traditional 
phospholipid liposomes (Cui et al., 2015). In another previous work, SLN were used to 
promote saquinavir penetration through human brain endothelial cells; these systems were 
characterized as cationic due to stearylamine and dioctadecyldimethyl ammonium bromide 
used on nanoparticles preparation (Kuo and Chen, 2010). Additionally, stearylamine was 
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also used as a charge modifier for a SLN delivery system of clozapine (Venkateswarlu and 
Manjunath, 2004). Accordingly, siRNA AE also increased when stearylamine was included 
due to charge interactions between negative nucleotide and cationic lipid, which turned this 
association more stable and stronger. Stearylamine was already used to promote iloprost 
(which is a potent vasorelaxing agent negatively charged at physiological pH) encapsulation 
on liposomal nanoparticles. In fact, the use of this cationic lipid promoted iloprost 
encapsulation to at least more 50% (Jain et al., 2014). Regarding polymeric nanoparticles, 
siRNA AE reached 50% for all formulations tested, which was already a good achievement 
regarding its hydrophilic character. 
In order to have simple polymeric systems that already have carboxyl and amine 
terminal groups in their composition, nanoparticles of PLGA and PLGA:PLGA-PEG-
NH2(95:5) were chosen, respectively. Also, as mean particle size and AE results did not 
reveal any significant difference between the ratios 97.5:2.5 and 95:5, 95:5 was selected to 
guarantee that amine groups are present in significant amount. 
For lipid systems, since Witepsol E85 by itself does not contain any functional groups 
of interest, nanoparticles with stearylamine were chosen to proceed. Between 99:1 and 98:2, 
99:1 was selected since this quantity of the new lipid was already enough to increase zeta 
potential which means that amine groups are significantly present. Moreover, regarding 
toxicity issues already described for this cationic lipid, it would be advantageous to proceed 
with the lowest amount (Caldeira et al., 2015). 
 
4.2. siRNA release profile 
 
The siRNA release profile from previously selected nanoparticles was assessed and 
is depicted in Figure 4.1. It was found that the release kinetics was very similar to all 
formulations. During the first hour, a burst release was observed, following a slower release 
until 5h, and afterwards, a controlled, linear release was achieved, reaching around 60% 
after 24h. These profiles are consistent with sustained drug delivery systems, meaning that 
produced nanoparticles yield a prolonged and slowly release of siRNA from their matrices, 
which would further promote the desired siRNA prolonged effect (Li et al., 2014). 
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Figure 4.1. siRNA release profile from developed polymeric and lipid nanoparticles over 24h (PBS pH 
7.4). 
 
Generally, the release of the encapsulated molecule from nanoparticles depends 
on the physicochemical properties of the vehicle and the molecule employed (Kikwai et 
al., 2005). Both polymeric and lipid nanoparticles are characterized as biodegradable 
systems, which could promote siRNA release from them. However, in an in vitro study as 
this, siRNA release may occur mainly due to its diffusion through the system, rather than 
to the degradation of nanoparticles matrices. siRNA hydrophilic character may have a 
great role on its diffusion from a hydrophobic nanoparticle to a hydrophilic environment 
(Cruz et al., 2010; Qi et al., 2012). The same explanation can be extrapolated for the fact 
that siRNA was released faster and sooner from lipid nanoparticles than from polymeric 
ones, as these systems are obviously extremely lipophilic. 
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4.3. Nanoparticles functionalization and characterization 
 
In order to target BBB and, therefore, avoid unspecific delivery and potential side 
effects, nanoparticles were functionalized with a transferrin receptor-peptide. Two chemistry 
approaches were performed to try distinct methods to obtain a better functionalized 
nanosystem, with higher specificity. The way that the peptide binds to nanoparticles could 
influence crucial features for a future specific binding of the peptide to its target receptor, 
such as functional peptide availability and spatial distribution. 
Carbodiimide chemistry is less specific than maleimide one, since there are several 
carboxyl and amine groups at the pept, therefore different possibilities for the binding 
process. On the other hand, for the maleimide reaction, there is only one sulfhydryl group on 
pept-Cys, thus only one way (the correct one) to link the peptide to the nanoparticle. The 
functionalization of nanoparticles was evaluated by Zetasizer (Table 4.2). 
 
Table 4.2. Physicochemical characteristics of unloaded polymeric and lipid nanoparticles: non-
functionalized and functionalized with pept/pept-Cys. 
NP system Mean Size [nm] PdI Zeta Potential [mV] 
PLGA 114.1 ± 1.4 *** 0.241 ± 0.012 -30.3 ± 2.5 
PLGA with pept 321.3 ± 25.1 *** 0.447 ± 0.108 -19.8 ± 8.5 
PLGA:PLGA-PEG-NH2 (95:5) 117.6 ± 3.6 *** 0.271 ± 0.026 *** -30.5 ± 1.4 ** 
PLGA:PLGA-PEG-NH2 (95:5)  
with pept-Cys 
477.3 ± 29.5 *** 0.582 ± 0.027 *** -39.5 ± 2.3 ** 
Witepsol E85:Stearylamine (99:1) 147.4 ± 7.6 *** 0.425 ± 0.041 * -7.6 ± 1.0 
Witepsol E85:Stearylamine (99:1) 
with pept 
389.3 ± 18.8 *** 0.551 ± 0.046 * -10.4 ± 2.1 
Witepsol E85:Stearylamine (99:1) 147.4 ± 7.6 *** 0.425 ± 0.041 ** -7.6 ± 1.0 ** 
Witepsol E85:Stearylamine (99:1) 
with pept-Cys 
505.6 ± 28.9 *** 0.620 ± 0.018 ** -15.3 ± 1.8 ** 
PdI, polydispersity index; * p < 0.05, ** p < 0.01, *** p < 0.001 
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Functionalization significantly increased the nanoparticles mean size, from 114.1 to 
477.3 nm for polymeric nanoparticles, and 147.4 to 505.6 nm for lipid nanoparticles. Both 
lipid and polymeric nanoparticles with pept-Cys became larger than the ones with pept, which 
could be related to the different intermediate molecules size (the cross-linker used for the 
maleimide reaction has a PEG chain of 95.4 Å that leads to a higher particle hydrodynamic 
radius), as well as peptide size (pept-Cys has one more amino acid than pept). Similarly, PdI 
increased more for nanoparticles with this maleimide functionalization, and zeta potential 
became significantly more negative when pept-Cys was present. Moreover, the large size 
and PdI could have to do with some nanoparticles aggregation probably promoted by the 
amine groups (Bagwe et al., 2006). Changes on zeta potential values could be a 
consequence of different chemistries and intermediate molecules/reagents used. 
Previous studies already observed this nanoparticles size increase as a consequence 
of functionalization. As an example, Lamichhane and colleagues synthesized and 
characterized PLGA nanoparticles bearing glycosaminoglycans, namely hyaluronic acid. 
When PLGA nanoparticles were functionalized with hyaluronic acid, their mean size 
increased from ~150 to ~350 nm, depending on the ligand concentration (Lamichhane et al., 
2015). In another study, the same trend was monitored when PLGA nanoparticles mean size 
(~290 nm) increased after polymeric coating with PEG (~590 nm) or chitosan (~745 nm) onto 
their surface (Martin-Banderas et al., 2015). 
To confirm the attachment of peptide to nanoparticle surface, 1H NMR was used for 
the detection of differences on spectra from non-functionalized and functionalized 
nanoparticles (Figure 4.2). Regarding 1H NMR data for the polymeric nanoparticles (Figure 
4.2, spectra A and B), it was possible to verify the presence of characteristic signals related 
to PLGA at δ1.5 and δ5.4 ppm, which can be attributed to the hydrogens present in -CH- and 
-CH3, respectively (Hong et al., 2014). In addition, an intense signal related to Tween 80 
used for nanoparticles preparation was detected at δ3.7 ppm (Zhang et al., 2015). The signal 
commonly attributed to PEG methylene group (Hong et al., 2014), usually located around 
δ3.6 ppm, was not detected here probably due to PEG reduced concentration compared to 
free PLGA. Moreover, this PEG signal could also be masked behind the Tween 80 peak. 
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Figure 4.2. 
1
H NMR spectra of polymeric nanoparticles functionalized with pept (A) and pept-Cys (B), 
and lipid nanoparticles functionalized with pept (C) and pept-Cys (D). 
 
Interestingly, the spectra of functionalized nanoparticles, both with the pept and pept-
Cys, were not an overlap of spectra from respective non-functionalized particles plus the 
peptide. In fact, after functionalization the spectra showed new signals between δ2 and δ4 
ppm. These peaks could be related with the presence of MES and/or PB used during 
functionalization, which were probably adsorbed at particle surface (Bataineh et al., 2012). 
Moreover, a close spectra observation allowed us to conclude that the intensity of the peaks 
related with PLGA, Tween 80 and PEG have decreased. From the attained data it can be 
hypothesized that the presence of MES or PB at nanoparticle surface can act like a shell and 
contribute to this decreasing effect. Even though the amount of peptide used on 
functionalized samples was very limited compared to the polymer and lipid, the peak at δ-0.1 
ppm strongly suggest the presence of the pept and pept-Cys at the functionalized 
nanoparticles (Platzer et al., 2014). Thus, NMR data suggested the presence of the two 
different peptides on the nanoparticles surface, indicating their successful functionalization. 
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1H NMR has been commonly applied to characterize this kind of surface modification. 
Campbell and his research group functionalized polymeric nanoparticles with branched 
poly(ethylene-imine) and characterized this surface modification through 1H NMR, which was 
performed for non-functionalized and functionalized particles. Conclusions about the 
effectiveness of the functionalization process were taken after the comparison of NMR 
chemical shifts between these spectra, as they observed new peaks on modified particles 
(Campbell et al., 2015). 
 
4.4. Nanoparticles labeling 
 
Nanoparticles were labeled by rhodamine 123 entrapment in order to further detect 
them when performing cell studies (das Neves et al., 2012). General nanoparticles features 
were analyzed by Zetasizer, AE was calculated (Table 4.3) and rhodamine 123 release 
profile was determined (Figure 4.3). Both SLN and PLGA nanoparticles loaded with 
rhodamine 123 presented similar features as the ones loaded with siRNA. After 24h, only 
~2% of rhodamine 123 was released from both nanosystems, meaning that fluorescence 
observed on experiments where these nanoparticles were used corresponds to nanoparticles 
and not free fluorescent dye. 
 
Table 4.3. Physicochemical characteristics of polymeric (PLGA) and lipid (SLN, Witepsol E85) 
nanoparticles loaded with rhodamine 123. 
NP system 
Mean Size 
[nm] 
PdI 
Zeta Potential 
[mV] 
Association 
Efficiency [%] 
Rhodamine 123-PLGA 113.9 ± 1.4 0.243 ± 0.012 -30.3 ± 0.7 54.3 ± 1.8 
Rhodamine 123-SLN 152.2 ± 4.3 0.431 ± 0.032 -23.0 ± 2.5 71.1 ± 3.2 
PdI, polydispersity index 
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Figure 4.3. Rhodamine 123 release profile from polymeric (PLGA) and lipid (SLN) nanoparticles over 
24h (PBS pH 7.4). 
 
Moreover, the surface functionalization of nanoparticles is not expected to change 
rhodamine 123, as well as siRNA, release profile. Low amounts of short (12 or 13 amino 
acids) peptides were used to functionalize nanoparticles, which therefore are not 
believed to modify their nature and hydrophobicity character (Thamake et al., 2011). 
 
4.5. Nanoparticles safety 
 
Nanoparticles in vitro cytotoxicity was assessed by cell viability determination through 
a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in human brain 
endothelial cells (hCMEC/D3). A range of nanoparticle concentrations was tested on these 
cells, and then metabolic activity was determined. Metabolic activity of brain endothelial cells 
was found to be always above 80% when in contact with all nanoparticles at all evaluated 
concentrations, except for the two highest concentrations of SLN, which nevertheless led to a 
cellular metabolic activity never lower than 60% (Figure 4.4 and Figure 4.5). Moreover, the 
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highest concentration (1000 μg mL-1) of all polymeric carriers (Figure 4.4) was significantly 
different than the others, since it induced a significant decrease on cellular metabolic activity, 
suggesting that as a maximum concentration limit for the safe use of these nanoparticles. 
Therefore, it is possible to state that these studied systems are safe to be used with 
hCMEC/D3 cell line, which is commonly utilized as a BBB model (Weksler et al., 2013), 
particularly the polymeric-based ones at all tested concentrations and lipid-based ones for 
concentrations not higher than 10 μg mL-1. Unloaded and non-functionalized nanoparticles 
had cytotoxic profiles similar to siRNA-loaded and siRNA-loaded peptide-functionalized 
nanoparticles, indicating that both siRNA-loading and functionalization with pept or pept-Cys 
do not influence systems safety. 
 
 
 
Figure 4.4. Metabolic activity of brain endothelial cells (hCMEC/D3) when incubated with different 
concentrations of PLGA and PLGA:PLGA-PEG-NH2(95:5) nanoparticles during 24h. Nanoparticles 
concentrations were calculated based on polymer(s) concentrations. Naked nanoparticles were 
unloaded and non-functionalized; siRNA-loaded were loaded and non-functionalized; siRNA-loaded + 
peptide were loaded and functionalized with pept or pept-Cys. 
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Figure 4.5. Metabolic activity of brain endothelial cells (hCMEC/D3) when incubated with different 
concentrations of Witepsol E85:Stearylamine(99:1) nanoparticles during 24h. Nanoparticles 
concentrations were calculated based on lipids concentrations. Naked nanoparticles were unloaded 
and non-functionalized; siRNA-loaded were loaded and non-functionalized; siRNA-loaded + peptide 
were loaded and functionalized with pept or pept-Cys. 
 
Polymeric nanoparticles are known as biocompatible carriers that circumvent free-
drug toxicity by encapsulation. Copolymers are non-toxic materials as well, as Guo and 
colleagues also evaluated through the biocompatibility assessment of nanoparticles made of 
polyethylene glycol-poly L-lysine-poly lactic-co-glycolic acid (PEG-PLL-PLGA) copolymer 
(Guo et al., 2015). They observed low in vitro cytotoxicity of these nanoparticles on mouse 
fibroblast L929 cells, through MTT assay. Neves and colleagues observed SLN made of cetyl 
palmitate as safe carriers for hCMEC/D3 cell line at concentrations up to 1500 μg mL-1, not 
compromising the cell metabolic activity (Neves et al., 2015). This concentration is much 
higher than the maximum observed by us as safe when using lipid nanoparticles (10 μg mL-
1). The main reason for that could be the presence of stearylamine, which is an already 
described potentially toxic lipid (Hung et al., 2005). Accordingly, a study where 
nanoemulsions containing cholesterol and amphotericin B were assessed, the influence of 
stearylamine was evaluated. Authors observed that loaded and unloaded nanoemulsions 
without stearylamine were approximately 40-fold less toxic to J774 macrophages than the 
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nanoemulsions containing 0.1% stearylamine. That scenario was further highlighted when 
stearylamine was used at 0.2%, which emphasized this cationic lipid-related enhanced 
toxicity (Caldeira et al., 2015). 
 
4.6. Cell-nanoparticle interaction 
 
To verify whether the used cell line (hCMEC/D3) was expressing the receptor against 
which the nanoparticles were functionalized, a simple test where cells were immuno-labeled 
was performed. Two dilutions of the primary antibody (antibody against transferrin receptor) 
were assessed (Figure 4.6). The most concentrated condition (primary antibody at 1:50) 
showed a significant expression of 2.9-fold of the TfR-related signal intensity, compared to 
the unstained control. Negative control was also performed when only the labeled secondary 
antibody was added to the cells, to verify the inexistence of unspecific bindings and false 
positives results. 
 
Figure 4.6. Transferrin receptor labeling expression by the hCMEC/D3 cell line. Different conditions 
and controls were tested: unstained cells, with primary and secondary-labeled antibody, with 
secondary-labeled antibody only. All the samples were normalized to the unstained control. 
CHAPTER IV  
104 
 
This result testified the transferrin receptor expression on this cell line. Therefore, 
experiments proceeded to evaluate the interaction between cells and nanoparticles, mainly 
through transferrin receptor. 
The interaction between non-functionalized/functionalized nanoparticles and human 
brain endothelial cells was studied over time through fluorescence microscopy and cytometry 
(fluorescence-activated cell sorting, FACS). Fluorescence microscopy study was performed 
as a qualitative and visual analysis, using the same protocol as FACS experiments. 
Nanoparticles (labeled in green) were incubated with human brain endothelial cells (labeled 
in red) for 15 min, 1h and 4h, and their interaction was assessed. It was possible to observe 
that polymeric nanoparticles interacted with human brain endothelial cells in higher extent 
after functionalization (Figure 4.7), since they were observed in the close vicinity of the cell 
membranes. This difference was detected on both functionalized with pept and pept-Cys 
polymeric nanoparticles, meaning that both functionalization approaches were successful. 
 
 
Figure 4.7. Fluorescence microscope images representative of the interaction between polymeric 
nanoparticles (non-functionalized and functionalized) and human brain endothelial cells, after an 
incubation period of 4h. Cells were stained in red, nanoparticles in green. The control group was cells 
without nanoparticles. 
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For lipid systems this difference was not evident (data not shown), which may indicate 
an inefficient functionalization either due to a low yield binding chemistry process itself, or 
due to the lack of correct peptide availability for its receptor. Significant differences over time 
were also not observed, which is probably related to the lack of precision and accuracy of 
this technique, reason why it was used just to give a general view of what was happening. 
Nonetheless, these qualitative data suggest that functionalization processes reached their 
goals on polymeric nanoparticles, by increasing nanoparticles interaction with blood-brain 
barrier cells. 
To validate NMR and fluorescence microscope data, flow cytometry analysis was 
performed as a quantitative test. As a direct result, histograms were obtained and 
consequently the fold increase of the fluorescence geometric mean of all samples when 
compared to the control (cells without nanoparticles) was determined (Table 4.4). 
Correspondent histograms from polymeric nanoparticles with hCMEC/D3 cell line are present 
on Figure 4.8. 
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Table 4.4. Flow cytometry quantification of the interaction between labeled nanoparticles and 
hCMEC/D3 cells over time. The fold increase was related to the fluorescence comparison with 
unstained control (cells without nanoparticles), meaning the fold increase of the percentage of cells 
interacting with the nanoparticles. 
NP system 
Fold increase 
t = 15 min t = 1 h t = 4 h 
PLGA 2.34 ± 0.37 *** 
###
 5.44 ± 0.16 *** ### 9.29 ± 0.48 *** ### 
PLGA with pept 13.98 ± 0.87 *** 16.35 ± 0.47 *** 32.73 ± 2.04 *** ### 
PLGA:PLGA-PEG-NH2 (95:5) 2.58 ± 0.42 *** 
#
 4.27 ± 0.34 *** 5.63 ± 0.88 *** 
PLGA:PLGA-PEG-NH2 (95:5)  
with pept-Cys 
9.77 ± 0.19 *** 12.33 ± 0.32 *** 21.26 ± 2.51 *** ## 
Witepsol E85:Stearylamine (99:1) 1.10 ± 0.12 ** 1.11 ± 0.11 *** 1.42 ± 0.39 ** 
Witepsol E85:Stearylamine (99:1) 
with pept 
2.48 ± 0.27 ** # 3.30 ± 0.24 *** # 4.17 ± 0.17 ** ## 
Witepsol E85:Stearylamine (99:1) 1.10 ± 0.12 ** 1.11 ± 0.11 *** 1.42 ± 0.39 ** 
Witepsol E85:Stearylamine (99:1) 
with pept-Cys 
2.34 ± 0.30 ** # 3.13 ± 0.11 *** # 4.37 ± 0.47 ** ## 
** p < 0.01, *** p < 0.001 – For the comparison within the same time point 
#
 p < 0.05, 
##
 p < 0.01, 
###
 p < 0.001 – For the comparison within the same NP system 
 
CHAPTER IV 
107 
 
 
Figure 4.8. Representative flow cytometry histograms of polymeric nanoparticles (non-functionalized 
and functionalized) with human brain endothelial cells over time. The control was the unstained line 
(cells without nanoparticles). 
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For all the studied labeled systems, when incubated with hCMEC/D3 cells, an 
increase of fluorescence over time was observed due to an increased interaction and further 
binding to the surface and/or internalization of nanoparticles into cells, as expected but not 
detected on fluorescence microscope analysis. This increment was even higher for 
nanoparticles with the peptide at their surface, reaching significantly higher values of 
fluorescence fold increase after 4h. By comparison between non-functionalized and 
functionalized nanoparticles, FACS results corroborate NMR and fluorescence microscope 
evidences. Polymeric nanoparticles were successful functionalized, since fluorescence was 
significantly higher when functionalized nanoparticles were used rather than non-
functionalized, meaning that functionalized nanoparticles interacted more with cell 
membranes. On histograms, these differences were detected by the observation of peak 
shifts to the right (increased fluorescence direction) between samples over time and between 
non-functionalized and functionalized nanoparticles. From these representative histograms 
shown on Figure 4.8, it was possible to quantify that, after 4h of incubation with fluorescent 
nanoparticles, 94.4% of cells were attached to functionalized PLGA nanoparticles, while 
58.2% of cells were attached to non-modified PLGA nanoparticles. As well, 88.9% of cells 
were interacting with functionalized PLGA:PLGA-PEG-NH2(95:5) nanoparticles, while only 
7.34% interacted with non-functionalized PLGA:PLGA-PEG-NH2(95:5) nanoparticles. This 
means that the proper attachment between nanoparticles and BBB cells was significantly 
increased when these systems were functionalized. Moreover, the same trend was observed 
for lipid systems. However, the fluorescence obtained for these lipid functionalized particles 
after 4h of incubation with cells, although much higher than the obtained for non-
functionalized ones, corresponded to low values of fluorescence after all (much lower than 
the ones obtained for polymeric nanoparticles), which explains why differences were not 
detected through the fluorescence microscope. This may suggest that the functionalization 
process on lipid nanoparticles may not have been as successful as for polymeric systems. As 
it was mentioned before, a functionalization process has several critical steps, such the 
spatial peptide orientation on these lipid systems that could made it unavailable for the 
receptor or the possible low functionalization yield for these carriers. Furthermore, non-
functionalized polymeric nanoparticles interacted more with cells than non-functionalized lipid 
ones did, which could indicate that even before functionalization the ability of these lipid 
nanoparticles to interact with cells is not that promising. Therefore, besides functionalization 
and targeting success, nanoparticles matrix composition could also influence their interaction 
with cells. 
Functionalization process improved the potential efficacy of nanoparticles, mainly the 
polymeric ones, since they became more attracted and capable to interact with their target 
CHAPTER IV 
109 
 
cells, being more bonded to their surface and/or internalized compared to non-functionalized 
ones. Both peptides, using both chemistries, resulted on a significantly higher interaction with 
BBB cells compared to non-functionalized nanoparticles, 3.5-fold with pept and 3.8-fold with 
pept-Cys, after 4h in contact with cells. For lipid systems, lipid nanoparticles with pept 
improve the interaction with cells by 2.9-fold while lipid nanoparticles with pept-Cys 3.1-fold, 
compared to respective non-functionalized nanoparticles. Therefore, FACS results 
complement NMR spectra and fluorescence microscope images, confirming the presence of 
peptides on nanoparticles surface and the increased nanoparticle-cell interaction after 
functionalization. 
Araújo and co-workers assessed the interaction of PLGA nanoparticles modified with 
chitosan and a cell penetrating peptide with Caco-2 and HT29-MTX cells (Araújo et al., 
2015). They observed by confocal microscopy no significant interaction for both unmodified 
nanoparticles. However, when nanoparticles were further functionalized with cell penetrating 
peptide, cell-nanoparticle interactions were higher, as more particles were associated and 
internalized by the cells. In the same study, quantitative flow cytometry experiments 
demonstrated that functionalized nanoparticles presented a 5.6-fold  increase in the 
interaction with the intestinal cells, compared to the unmodified nanoparticles (Araújo et al., 
2015). These values are similar to the ones obtained by our functionalized polymeric 
nanoparticles. 
Kang and his group developed a nanosystem aimed to treat glioblastoma. For that, to 
achieve BBB, polymeric nanoparticles (PLGA-PEG) were functionalized with a cyclic nine 
amino acid peptide (named as CRT peptide), an iron-mimic moiety targeting the transferrin-
receptor (TfR). The main aim of this study was to compare this CRT functionalization with Tf-
modified nanoparticles and unmodified ones. Cell-nanoparticle interactions were assessed 
using brain capillary endothelial cell line (BCEC) and rat C6 glioma cell line over expressing 
TfR. Fluorescence microscope images showed an increased fluorescence intensity of CRT-
nanoparticles compared to unmodified nanoparticles, in BCEC cells and C6 cells. 
Additionally, quantitative experiments determined that, in BCEC cells, the fluorescence signal 
related to CRT-nanoparticles was 1.9-fold higher than for unmodified particles, which is a 
value significantly lower than the obtained in the present study. As well, the fluorescence 
signal of Tf-nanoparticles was 1.6-fold and 1.8-fold higher than on unmodified particles after 
1 and 4h, respectively. Similar data were obtained for C6 cells, highlighting the advantages of 
CRT and Tf functionalization over unmodified nanoparticles on cell-nanoparticle interaction 
(Kang et al., 2015). 
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Additionally, it is important to highlight how functionalization is a delicate issue. 
Nanoparticles surface, either charge, coating or conjugated molecules, have an impact on 
their behavior, namely on cellular interaction and uptake. Increased ligand concentrations on 
nanoparticle surfaces can result in serum protein binding and enhance rapid clearance or 
diminish the ability of the ligands to interact with their target receptors. Therefore, the 
number, density, and orientation of targeting ligands on the surface of nanoparticles are 
important factors for an effective targeting (Amin et al., 2015). Specifically, the active site of 
the ligand must be available in the correct three-dimensional arrangement to correctly bind to 
the receptor. In this study, the possibility to have a side-oriented covalent link of transferrin-
receptor peptide needs to be considered, since it is correlated with further cell interaction 
and, therefore, could be critical for nanoparticles efficacy. This could be the reason why lipid 
nanoparticles had low binding values to BBB cells. 
 
5. Conclusions 
 
Worldwide spread brain disorders are an actual problem that our society faces 
nowadays. Surpass BBB is the main common key for all brain disorders, which could in the 
future lead to improved therapies and maybe cures. Regarding that, this work aimed to 
develop a nanosystem able to transport siRNA against P-gp towards the brain endothelial 
cells. Basic lipid and polymeric nanoparticles were produced and, as a first step, functional 
groups were added via the addition of a new lipid/polymer to regular systems in order to 
promote the functionalization process, namely the peptide binding to nanoparticles surface. 
siRNA was loaded and its association efficiency reached 50% on PLGA:PLGA-PEG-
NH2(95:5) nanoparticles. These systems enabled a prolonged release of siRNA from their 
matrices, reaching around 60% after 24h. Two peptides against transferrin-receptor were 
tested through two chemically distinct approaches (carbodiimide and maleimide), planning to 
further choose the one that attains better results after the functionalization procedure. 
Obtained functionalized nanoparticles had an increased size and NMR new peaks when 
compared to non-functionalized samples, which suggest the successful presence of peptides 
on all developed systems. Nanoparticles (unloaded, siRNA-loaded, siRNA-loaded and 
functionalized) were found to have no cytotoxicity on a cell line generally utilized as a BBB 
model, once used up to concentrations of 1000 μg mL-1 for polymeric systems and 10 μg mL-
1 for lipid ones. Again, cell-nanoparticle interaction data suggest that both functionalization 
processes achieved their goals on polymeric nanoparticles, by making these modified 
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systems more attracted and capable to interact (3.5 to 3.8-fold more) with targeted TfR-
expressing BBB cells than non-functionalized ones. 
Therefore, this study focused on nanoparticles improvement and highlighted the 
importance of carriers, namely correctly functionalized carriers, to obtain better outcomes. 
The best systems obtained through these experiments were polymeric nanoparticles (PLGA 
and PLGA:PLGA-PEG-NH2 (95:5)), which were effectively functionalized with TfR-peptides. 
This great achievement supports and encourages their promising potential. By interacting 
more and more specifically with their target cells, this nanoparticles approach will further 
improve their ability to successfully permeate and deliver siRNA on these cells, ending with a 
likely more permeable BBB needed to reach drug therapeutic concentrations in brain. 
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Delivery of siRNA silencing P-glycoprotein in peptide-
functionalized nanoparticles causes efflux modulation at a 
human blood-brain barrier model 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter was based on the following submitted paper: 
- Gomes, M.J., Kennedy, P.J., Martins, S. and Sarmento, B. 2017. Delivery of siRNA 
silencing P-glycoprotein in peptide-functionalized nanoparticles causes efflux modulation 
at a human blood-brain barrier model. Submitted.  
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1. Abstract 
 
As a tightly organized layer of endothelial cells, blood-brain barrier (BBB) has 
distinctive features that limit the capacity of drugs to enter the brain and reach therapeutic 
targets. One of the most effective BBB-related obstacles is the P-glycoprotein (P-gp), which 
acts as an efflux pump. Silencing this protein expression via siRNA constitutes a potential 
way to triumph over BBB blockade, improving delivery of drugs to the brain. In this work, new 
functionalized nanoparticles via different peptide linkage bridges, targeted to transferrin 
receptor, were developed to deliver P-gp silencing siRNA to brain endothelial cells. Both 
carbodiimide and maleimide approaches were used to anchor a peptide to the surface of 
PLGA-COOH and PLGA-PEG-NH2 materials, respectively, assuring target effect and 
prolonged blood circulation of siRNA-containing nanoparticles. Beyond their ability to improve 
siRNA permeability through the BBB by 2-fold, it was shown that, 96h post transfection, 
maleimide functionalized PLGA:PLGA-PEG-NH2 nanoparticles successfully induced 
reduction of P-gp mRNA expression up to 52%, compared to non-functionalized systems. 
Subsequently, increase on rhodamine 123 permeability through the human BBB model up to 
27% was detected. In this fashion, such values reveal the brightness of this approach to 
possibly enable drugs to reach brain in higher and therapeutic concentrations. 
 
KEYWORDS: Blood-brain barrier; P-glycoprotein; siRNA; Targeted nanoparticles; Transferrin-
receptor binding peptide 
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2. Introduction 
 
The incidence of central nervous system (CNS) related diseases is continuously 
increasing due to ageing population along with an increased average life expectancy (Gomes 
et al., 2015). Therefore, CNS disorders are a worldwide concern to individuals, their families 
and societies in general. Existing therapies for CNS diseases are mainly blocked by BBB 
related obstacles, which hampers more than 98% of candidate drugs, presenting a major 
challenge for the pharmaceutical industry (Anand et al., 2015). As a result, current treatments 
are failing their meaningful purpose, which creates an opportunity for nanomedicine to arise 
as an alternative pathway to circumvent BBB handicaps. 
BBB, as a tightly packed layer of endothelial cells surrounded by pericytes, astrocytes 
and microglial cells, presents molecular and receptor structures able to mediate the transport 
of substances in and out of the brain.  In a first approach, BBB restricts the passage of 
foreign substances into the brain. Additionally, efflux transporters like P-gp are one of the 
main contributors for brain penetration limitations, pumping drugs back to the blood stream 
(Abbott et al., 2010; Bhaskar et al., 2010). P-gp is a phosphorylated glycoprotein expressed 
in multiple cell types with relevant activity at the luminal plasma membrane of the capillary 
brain endothelium (Mahringer et al., 2011). This efflux pump is often over-expressed in tumor 
cells which contributes to the multi-drug resistant phenotype commonly observed in cancer 
cells (Fisher et al., 2007). 
Nanoparticle-based drug delivery systems have a potentially customized surface that 
promotes not only their targeting but also their cellular uptake by endogenous transport 
systems acting as “Trojan horse” (Gao et al., 2017). Thus, nanoparticles (NPs) should act as 
biocompatible and biodegradable materials with surface functional groups where targeting 
ligands could be anchored, directing these systems to specific cells or tissues and 
decreasing their off-targets effects. 
Efflux transporters are considered attractive targets to be inhibited and improve drug 
passage across the BBB (Mahringer et al., 2011). Nanoparticles, on the other hand, have 
shown their ability to be addressed to the BBB (Gomes et al., 2016). Therefore, by combining 
these concepts with the ability of specific small interfering RNA (siRNA) sequences to 
transient and reversibly silence P-gp, this arises as a possible solution to surpass BBB. Gene 
silencing through siRNA offers a specific deactivation of genes since it specifically binds to 
complementary messenger RNA (mRNA) sequences, leading to degradation of the target 
mRNA, and following down-regulation of protein synthesis (Malmo et al., 2013). Hence, 
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siRNA against P-gp is capable to specific and directly down-regulate P-gp expression and 
subsequent transport activity, helping to improve its substrates permeability through the BBB. 
Simultaneously, nanoparticles protect the siRNA from enzymatic degradation and may direct 
it to brain endothelial cells through surface functionalization, thus improving siRNA cellular 
delivery. 
This study proposes a peptide-functionalized nanomaterial to transport siRNA against 
human P-gp (P-gp-siRNA) specifically to the BBB, temporarily reducing drug efflux, and 
increasing drug permeability kinetics in the CNS. This system, based on merging poly(lactic-
co-glycolic acid) (PLGA) and PEGylated PLGA, was firstly directed to the BBB through 
surface modification in a site-oriented manner with a peptide against transferrin receptor 
(TfR) over expressed at the BBB (Gabathuler, 2010), derivative of transferrin itself (Gomes et 
al., 2016). In addition, a BBB monolayer model was created with human brain endothelial 
cells, hCMEC/D3 (Weksler et al., 2013), in order to assess permeability kinetics of siRNA 
itself. The same cell line was treated with siRNA-loaded nanoparticles to further evaluation of 
their effect on P-gp expression. Moreover, the permeability of a model P-gp substrate 
(rhodamine 123) was also assessed, after P-gp down-regulation, to understand its influence 
on drug efflux. 
 
3. Materials and Methods 
 
3.1. Materials 
 
PLGA 5004A, was purchased from Corbion – Purac, PLGA-PEG-NH2 from 
PolySciTech. Ethyl acetate was purchased from VWR, siRNA-FITC against P-gp, siRNA 
against P-gp and scrambled siRNA from Santa Cruz Biotechnology, TfR-peptide from 
AnaSpec, TfR-peptide-Cys from Eurogentec, and SM(PEG)24 was from Thermo Scientific. 
EBM-2 medium from Lonza, 12-well plate PET inserts 0.4 μm from Corning BD, Vectashield 
and DAPI from Vector Laboratories Inc, and ScreenFectA from InCella. Several materials 
were purchased from Sigma: Tween 80, EDC (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide), NHS (N-hydroxysuccinimide), MES (2-(N-
morpholino)ethanesulfonic acid), hydrocortisone, ascorbic acid, HEPES, bFGF (basic 
fibroblast growth factor), verapamil hydrochloride and paraformaldehyde. Others were 
purchased from Invitrogen: Rhodamine 123, WGA Alexa Fluor 594, P-gp and YWHAZ 
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primers. From Gibco it was purchased FBS, penicillin-streptomycin, chemically defined lipid 
concentrate, HBSS, collagen I rat protein and trypsin-EDTA. 
 
3.2. Methods 
 
3.2.1. Nanoparticles production 
Polymeric nanoparticles were prepared through a modified solvent emulsification 
evaporation method based on the water-in-oil-in-water (w/o/w) double emulsion technique 
(Fonte et al., 2014; Soares et al., 2013), already described by us (Gomes et al., 2016). 
Briefly, twenty milligrams of polymer (PLGA and/or PLGA-PEG-NH2) were dissolved in ethyl 
acetate, siRNA (13.55 ng μL-1) was added, and the solution was homogenized using a Vibra-
Cell™ ultrasonic processor. The primary formed emulsion (w/o) was then added into the 
surfactant solution, 2% of Tween 80, and homogenized again for 60s. The second formed 
emulsion (w/o/w) was finally added to another solution of the same surfactant, and was left 
under magnetic stirring at 300 rpm for at least 3h for ethyl acetate evaporation. In the end, 
two types of systems were obtained: PLGA and PLGA:PLGA-PEG-NH2 (95:5) (% w/w). 
To conjugate the peptide to nanoparticles surface, two approaches were followed: (1) 
the carbodiimide chemistry, to link an amine group to a carboxyl group (Araújo et al., 2015; 
Wang et al., 2015), using  a 12 amino acid peptide (Thr-His-Arg-Pro-Pro-Met-Trp-Ser-Pro-
Val-Trp-Pro, named here as pept); or (2) the maleimide chemistry, to link an amine group to 
a sulfhydryl group (Esfandyari-Manesh et al., 2015; Zimmermann et al., 2010), using a 13 
amino acid peptide (the same pept with an extra cysteine on the carboxyl termination; Thr-
His-Arg-Pro-Pro-Met-Trp-Ser-Pro-Val-Trp-Pro-Cys, named here as pept-Cys). 
The peptide was conjugated to the surface of the nanoparticles following our previous 
described method (Gomes et al., 2016). In brief, for the amide formation, the EDC/NHS 
coupling chemistry method was used. Carboxyl groups from PLGA nanoparticles diluted on a 
MES solution (10 mM, pH~5.5) were activated by EDC (3.14 μL, 17 mM) and NHS (1.2 mg), 
during 30 min. The pept (100 μL, 1 mg mL-1) was then added and pH adjusted to 7.5. Finally, 
the mixture was kept stirring (300 rpm) at room temperature for 3h30. Process described was 
performed in the dark. Meanwhile, for the maleimide conjugation chemistry, PLGA:PLGA-
PEG-NH2 (95:5) nanoparticles were diluted on a PB solution (0.1 M, pH~7). The cross linker 
SM(PEG)24 was added (2 μL, 250 mM) and the mixture was stirred in the dark, at 300 rpm for 
CHAPTER V 
123 
 
4h. Then, pept-Cys was added (50 μL, 6.2 mg mL-1) and the mixture was stirred for another 
4h. 
Afterwards, nanoparticles were collected by centrifugation at 20,000  g, 4°C for 20 
min and washed with MilliQ-water. Functionalized nanoparticles were then analyzed by 
Zetasizer and fluorescence. 
 
3.2.2. Nanoparticles characterization 
After production, nanoparticles were characterized for their average particle size, 
polydispersity index (PdI) and average zeta potential by electrophorethic light scattering 
using a Malvern Zetasizer Nano ZS instrument (Malvern Instruments Ltd). For these 
measurements, samples were diluted in MilliQ-water. To determine the association efficiency 
(AE) of the developed nanosystems, the amount of siRNA-FITC associated to the 
nanoparticles was calculated by a fluorescent assay (ex. 494 nm, em. 517 nm). AE was 
determined indirectly by the difference between the total amount of siRNA used to prepare 
the systems and the amount that remained in the aqueous phase after nanoparticles isolation 
by centrifugation (20,000  g, 4°C for 20 min), according to the following equation: 
 
 
 
3.2.3. Cell culture 
Immortalized human Cerebral Microvascular Endothelial Cell Line (hCMEC/D3 cell 
line) was purchased from Cedarlane (Canada). The cells (passage 35-41) were grown in 
tissue culture flasks (Orange Scientific), in EBM-2 medium supplemented with FBS (5%, v/v), 
penicillin-streptomycin (1%, v/v), hydrocortisone (1.4 μM), ascorbic acid (5 μg mL-1), 
chemically defined lipid concentrate (1/100, v/v), HEPES (10 mM) and bFGF (1 ng mL-1). 
This last supplement was added extemporaneously in the culture medium. Cells were 
maintained in an incubator (Binder) at 37°C with 5% CO2 in water saturated atmosphere. 
Cells were subcultured every 3-4 days using trypsin-EDTA to detach them from the flasks. 
The culture medium was replaced every other day. 
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3.2.4. Blood-brain barrier in vitro model setup and characterization 
The BBB in vitro model was based on a previous work from our group (Mendes et al., 
2015) with some minor modifications. Briefly, the membrane of a 12-well plate Transwell® 
system was coated with rat tail collagen type I (50 μg mL-1) for 1h at 37°C before seeding the 
cells. hCMEC/D3 cells were then cultured at the desired density on the apical side (500 μL) 
of the semi-permeable filter (insert), and the well was filled with 1.5 mL of medium. The 
system was maintained in the incubator at 37°C with 5% CO2 during 8 or 12 days. Cell 
culture medium was changed on days 2, 4, 6, 8 and 10. Cell monolayer integrity was 
periodically monitored by determining the transendothelial electrical resistance (TEER) using 
an endothelial volt-ohm meter (Millicell® ERS-2 (Millipore, USA)). The resistance value (Ω 
cm2) of an empty filter was subtracted from each measurement. 
To assess the development of a BBB monoculture membrane, at culture day 8 a 
staining was performed on the Transwell® adherent cells. Briefly, cells were fixed with 4% 
paraformaldehyde at room temperature. Upon washing, cells were maintained in the dark 
and labeled with WGA Alexa Fluor 594 (for cell membranes, 5 μg mL-1) during 10 min at 
room temperature. After washing with PBS, DAPI was added (for nuclei, 1 μg mL-1), 
incubated 3 min at room temperature, and the excess was removed. Labeled membrane was 
moved to a microscope slide using the mounting medium Vectashield and photographed 
using an inverted fluorescence microscope (Axiovert 200M from Zeiss). 
 
3.2.5. siRNA permeability 
When the BBB membrane was established (day 8), siRNA permeability was 
determined either as a free compound or loaded in nanoparticles. First, medium was 
removed from inserts and wells which were then washed with PBS, and HBSS (1.5 mL) was 
added to the receptor chamber (basolateral side). On the apical side, siRNA (free or loaded 
in nanoparticles) solution in HBSS (40.5 nM; 500 μL) was added, and the Transwell® systems 
were moved to an orbital shaker kept at 100 rpm and 37°C during 3h. Samples (200 μL) were 
taken from all wells to a microtiter plate (Microplate Costar 96) at predetermined time points 
(15 min, 30 min, 45 min, 1h, 1h30, 2h and 3h), and the same volume of fresh buffer was 
added. siRNA-FITC that crossed the membrane over time was quantified through 
fluorescence with a plate reader (ex. 494 nm, em. 517 nm). The apparent permeability 
(Papp) of siRNA was calculated by the following equation: 
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where dm/dt is the permeated mass over time, c0 the initial concentration at the apical 
compartment, and A the surface area of the membrane (0.9 cm2). The percentage of siRNA 
permeated mass was calculated based on the relation between mass that crossed and the 
total initial theoretical mass at the apical side. 
Cell-seeded inserts with HBSS only were also used as permeability blanks. TEER 
was measured at the beginning and at the end of this assay to check membrane integrity. 
To evaluate the effectiveness of receptor-mediated endocytosis, siRNA-loaded 
functionalized nanoparticles permeability was also tested after blocking transferrin receptor. 
An excess of the peptide used on those functionalized nanoparticles (50 molar excess 
relative to the peptide on nanoparticles surface (Pridgen et al., 2013)) was used during 30 
min to block the receptor. 
 
3.2.6. hCMEC/D3 cells transfection 
Cells were seeded (0.1  106 cells/well) on a 24-well plate and allowed to attach 
overnight. Then, medium was removed and siRNA (50 nM) complexed with a transfection 
agent or loaded in nanoparticles was added (500 μL). For the controls, same calculations and 
protocol were performed, but without siRNA. Transfection was kept during 6h. After that time, 
cells were gently washed with PBS and fresh medium was added. At different time points 
(24, 48 and 96h) RNA was extracted and analyzed. 
ScreenFectA was the transfection agent used as a control cationic lipid able to form 
liposomes and act as liposomal vector for oligonucleotides transfection (Enlund et al., 2014; 
Li et al., 2015). siRNA complexes were produced following manufacturer’s instructions. 
 
3.2.7. P-gp mRNA expression in hCMEC/D3 cells 
RNA was extracted, isolated and purified from previously transfected hCMEC/D3 
samples using the Quick-RNA MicroPrep kit (R1050, Zymo Research) according to the 
manufacturer’s instructions. Total purified RNA was quantified by Nanodrop (ND1000). P-gp 
mRNA expression was analyzed by quantitative reverse transcription polymerase chain 
reaction (qRT-PCR) using the SYBR Green One Step qPCR kit (B25002, Biotool) according 
to manufacturer’s instructions. Primers for P-gp (forward: 5’-CCCATCATTGCAATAGCAGG-
3’, reverse: 5’-GTTCAAACTTCTGCTCCTGA-3’ (Kim et al., 2008)) and reference gene 
YWHAZ (forward: 5’–GATGAAGCCATTGCTGAACTTG-3’, reverse: 5’-
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GTCTCCTTGGGTATCCGATGTC-3’ (Nelissen et al., 2010)) were used at 250 nM final 
concentration. Around 50 ng of RNA was mixed with the SYBR green and enzyme mixes in a 
20 µL total reaction volume in 96-well plate format and fluorescence was monitored with the 
iQ5 real time PCR detection system (Bio-Rad). Quality control measures (e.g. melt curve 
analysis and no template controls) were always implemented. The iQ5 optical system 
software (Bio-Rad) was used to evaluate the relative expression levels (ddCt algorithm) 
incorporating the efficiency of the reaction as determined by a 3 log-fold dilution series 
standard curve. The unloaded ScreenFectA or nanoparticles from the 24h time point was 
implemented as the expression control. 
 
3.2.8. Functional assay through rhodamine 123 permeability 
At day 8 of the developed BBB membrane, medium on the apical and basolateral 
compartments was removed and the cells were treated with the nanoparticles (unloaded, 
siRNA-loaded and siRNA-loaded functionalized). In order to have a siRNA final concentration 
of 50 nM, nanoparticles in medium were added. For the controls, same calculations and 
protocol were performed, but without siRNA or nanoparticles. After 6h, both compartments 
were washed and fresh medium was added. At a predetermined time point (96h, day 12) 
rhodamine 123 permeability was assessed. 
At day 12, inserts with non-previously treated BBB membranes were used to 
chemically inhibit P-gp using verapamil (Jahne et al., 2016), as a positive control. Medium on 
the apical and basolateral compartments was removed and replaced by verapamil solution 
(50 μM, in HBSS). Transwell® systems were incubated 1h at 37°C. Then, both compartments 
were washed and rhodamine 123 permeability was tested. 
For the rhodamine 123 permeability study at day 12, the protocol performed was the 
same used for siRNA permeability already described here, except for the following details. 
The tested solution was rhodamine 123 at 2.5 μM in HBSS. To quantify rhodamine 123 a 
fluorescence plate reader was used (ex. 507 nm, em. 529 nm). 
 
3.2.9. Statistical analysis 
For the data analysis one-way analysis of variance (ANOVA) was performed to 
compare multiple groups. Differences between groups were compared with a post hoc test 
(Tukey’s honestly significant difference). Results are reported as mean ± standard deviation 
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from a minimum of three independent experiments. Differences were considered significant 
at * p < 0.05, ** p < 0.01, or *** p < 0.001. All statistical analyses were performed with the 
software PASW Statistics 20 (IBM Corporation). 
 
4. Results and Discussion 
 
4.1. Nanoparticles characterization 
 
Polymeric nanoparticles have been demonstrate to load gene material as siRNA and 
engineered for a straightforward BBB targeting, with specificity and reduced toxicity to 
surrounding tissues (Tam et al., 2016). In this work, new ligands based on transferrin-mimetic 
peptides were selected to be anchored to the surface of PLGA and PLGA:PLGA-PEG 
nanoparticles and target the BBB. 
PLGA-based nanoparticles with different bulk compositions (regular PLGA and a co-
polymer mixture PLGA:PLGA-PEG-NH2) were produced aiming to surface modification 
through different functionalization chemistries and peptides. Both peptides (pept and pept-
Cys) were used according the functional groups available at the surface of nanoparticles and 
bound by two distinct approaches, carbodiimide and maleimide, respectively, as previously 
described (Gomes et al., 2016). Nanoparticles were evaluated regarding mean size, PdI, 
surface charge and siRNA association efficiency (Table 5.1). 
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Table 5.1. Physicochemical characteristics of polymeric nanoparticles: unloaded and siRNA-loaded, 
non-functionalized and functionalized with pept or pept-Cys. 
NP system 
Mean Size 
[nm] 
PdI 
Zeta Potential 
[mV] 
Association 
Efficiency [%] 
Unloaded-PLGA 116.3 ± 1.0 0.262 ± 0.013 -31.3 ± 1.6 - 
siRNA-PLGA 113.3 ± 1.9 0.238 ± 0.014 -33.8 ± 1.6 49.1 ± 1.1 
siRNA-PLGA-pept 313.1 ± 17.5 *** 0.464 ± 0.076 ** -23.4 ± 7.3 48.4 ± 1.5 
Unloaded-PLGA:PLGA-
PEG-NH2 (95:5) 
115.0 ± 4.6 0.274 ± 0.020 -29.6 ± 1.3 - 
siRNA-PLGA:PLGA-PEG-
NH2 (95:5) 
116.9 ± 2.9 0.259 ± 0.026 -29.0 ± 1.4 49.6 ± 1.1 
siRNA-PLGA:PLGA-PEG-
NH2 (95:5)-pept-Cys 
482.4 ± 33.0 *** 0.607 ± 0.042 *** -41.2 ± 2.7 ** 50.7 ± 2.0 
PdI, polydispersity index; ** p < 0.01, *** p < 0.001 
 
The loading of siRNA did not change the physicochemical properties of bare PLGA 
and PLGA:PLGA-PEG nanoparticles, resulting in mean particle size around 115 nm and 
charge of -30 mV. The association efficiency of siRNA was close to 50%, a satisfying value 
considering the hydrophilic nature of the siRNA molecule. The functionalization increased the 
mean particle size of nanoparticles, in agreement with our previous findings (Gomes et al., 
2016), although surface charge and association efficiency were retained. Functionalized 
PLGA:PLGA-PEG nanoparticles were larger than functionalized PLGA nanoparticles (mean 
sizes around 482.4 nm and 313.1 nm, respectively), which may be related with the chemistry 
used for binding the peptide. The maleimide approach applied to the co-polymer systems 
used a cross-linker that has a PEG chain of 95.4 Å, enhancing particle hydrodynamic radius. 
The particle size enlargement has been observed in different nanosystems surface-
functionalized with peptides (Englert et al., 2016). Moreover, the large size and PdI could 
have to do with some nanoparticles aggregation probably promoted by the amine groups 
(Bagwe et al., 2006). 
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4.2. Blood-brain barrier model 
 
The BBB is a tightly packed layer of endothelial cells commonly modeled in vitro by 
the human brain endothelial capillary cell line hCMEC/D3 (Poller et al., 2008). Here, several 
endothelial cell concentrations on the apical side of the semi-permeable filter were tested, 
namely 1.25, 2.5, 5, 10 and 15  104 cells/cm2 (D1 to D5, respectively) and their integrity was 
tracked by TEER measurements, until day 12 in culture. An increase in TEER values would 
indicate a superior monolayer confluence and, thus, integrity. High initial densities (D3 to D5) 
led to faster confluence, which could probably be the reason why relatively high resistance 
values were achieved in early stages (day 4, Figure 5.1). However, after being maintained 
during a short period, these values started to decrease over time (Figure 5.1). On the other 
hand, the two lowest initial cell densities (D1 and D2) developed membranes which 
resistance increased more until day 8, reaching the most high values, and then slightly 
decreased or stabilized. Furthermore, as initial cell density increased, the monolayer was 
less straight and thin (data not shown), due to cells growing on top of each other. It is 
believed that the number of cells surpassed the available area for a confluent monolayer, 
starting to detach and decreasing transendothelial resistance and cell membrane integrity. 
The highest TEER value (29.4 ± 2.3 Ωcm2) was achieved with an initial endothelial cell 
density of 2.5  104 cells/cm2 (D2) and after 8 days in monoculture on a Transwell® (Figure 
5.1). Therefore, since a stable membrane of human brain endothelial cells was obtained on 
these conditions, they were used in the following procedures. 
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Figure 5.1. TEER measurements for all membranes developed with different initial cell densities (1.25 
 10
4
 cells/cm
2
 D1, 2.5  10
4
 cells/cm
2
 D2, 5  10
4
 cells/cm
2
 D3, 10  10
4
 cells/cm
2
 D4, 15  10
4
 
cells/cm
2
 D5), over 12 days in culture on Transwell
®
. TEER values of D1 are significantly different from 
D5 at days 8 (
**
), 10 (
**
) and 12 (
*
). D2 is significantly different from D5 at day 6 (
*
). At days 8, 10 and 
12, D2 is significantly different from D1 (
*
, 
**
, 
*
, respectively) and from all the other densities (
**
, 
***
, 
***
, 
respectively). 
 
Choosing these cell density and time based on obtained TEER values is also related 
to what is known from literature. Previous work from our group already showed 33 Ωcm2 as 
the highest TEER value achieved after seven days in monoculture, which is similar to 
selected conditions (Mendes et al., 2015). Moreover, it is commonly accepted that 
mammalian systems show high BBB in vivo TEER values, above 1,000 Ωcm2 (Weksler et al., 
2013). However, such values are difficult to achieve with in vitro models. hCMEC/D3 
monolayers usually obtain TEER around 30-50 Ωcm2, as several studies report (Qosa et al., 
2014; Ragnaill et al., 2011; Weksler et al., 2013). To complement TEER results, BBB 
monoculture membrane was labeled and visualized at the microscope to verify the 
development of a robust monolayer through the selected conditions. Long cells with parallel 
growth creating a whole and confluent membrane at culture day 8 were visualized (Figure 
5.2). 
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Figure 5.2. Fluorescence microscope images of human brain endothelial cell monolayer, after 8 days 
in culture on Transwell
®
; scale bar of 50 μm for (A) and 20 μm for (B). Cell membranes were stained in 
red, and nuclei in blue. 
 
4.3. siRNA permeability 
 
Permeability studies were performed in order to evaluate the influence of 
nanoparticles to promote the crossing of siRNA through a human BBB cell-based model. 
TfR-targeted nanoparticles resulted in a two-fold increase of siRNA permeability compared to 
non-functionalized nanoparticles, either for PLGA or PLGA:PLGA-PEG-NH2 nanosystems 
(Figure 5.3 A). Interestingly, siRNA permeability was 1.3-fold higher for siRNA-PLGA:PLGA-
PEG-NH2-pept-Cys compared to siRNA-PLGA-pept nanoparticles, which may indicate that 
selected peptide orientation achieved through the maleimide binding approach is more 
effective to improve cellular interaction than the carbodiimide chemistry used for PLGA 
nanoparticles. In a similar approach, Park and colleagues developed a targeted 
polyethylenimine-based system to deliver siRNA against beta-secretase 1 through the BBB 
(Park et al., 2015). The permeability of functionalized siRNA complexes was 2.2-fold higher 
than non-functionalized ones, indicating the efficacy of surface modification on the BBB 
permeability. 
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Figure 5.3. (A) siRNA apparent permeability values obtained 3h after the siRNA-loaded in the different 
systems have crossed the BBB membrane. (B) Percentage of siRNA mass permeated through the 
BBB membrane using siRNA-loaded in all studied nanoparticles (with and without blocked transferrin 
receptor), during 3h. 
 
On the other hand, by blocking the transferrin receptor with the peptide 30 minutes 
prior the permeability assay, it was clear a decrease on the amount of siRNA that reached 
the basolateral side. Hence, for TfR-targeted nanoparticles without receptor blockage, siRNA 
permeability was 1.4 to 1.6-fold higher than when receptor was blocked. These results 
endorse the active role of the receptor on the active transport mechanism. It is known that 
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transferrin receptor involves clathrin-mediated endocytosis (Damm et al., 2005; Fekri et al., 
2016). Thus, functionalized nanoparticles get in the cells through transferrin receptor, which 
is initiated with ligand binding and receptor activation. This complex diffuses through the 
plasma membrane and is captured by a forming clathrin-coated pit that then forms a clathrin-
coated vesicle which will fuse to an early endosome. After this, the endocytosed cargo will be 
sorted to lysosomes, recycling, or other cellular pathways (Fekri et al., 2016). Several other 
works also demonstrate nanoparticles internalization through receptor blocking assays. Park 
and co-workers observed a 65% significant reduced permeability of modified complexes 
when the receptor was blocked by the used peptide (Park et al., 2015). Moreover, and also in 
accordance with our results, Pridgen et al studied nanoparticles targeted to the neonatal Fc 
receptor (Pridgen et al., 2013). They observed that the enhanced transport achieved through 
targeted nanoparticles was significantly reduced when the Fc receptor was blocked, meaning 
that it was largely mediated by this receptor. Although only a modest increase in targeting 
was observed in the in vitro model, this translated to significant in vivo function (Pridgen et 
al., 2013). As such, this suggests that our NPs could also yield promising results in vivo as 
well. 
When comparing the permeability of siRNA loaded into different nanoparticles (mean 
values ranging between 4.0 – 8.5  10-7 cm s-1) and in solution (2.7  10-6 ± 2.3  10-7 cm s-1), 
the free siRNA was able to cross the BBB more extensively than loaded into non-
functionalized or even functionalized nanoparticles. Differences in free and loaded siRNA 
might be expected, as the size and low flexibility of nanocarriers are against the physical 
barrier that BBB provides. Also, we previously demonstrated that siRNA releases slowly from 
nanoparticles (Chapter IV from this thesis), which is in agreement with the overall siRNA that 
reaches the basolateral compartment. Moreover, in an in vivo situation, free siRNA would not 
be able to reach BBB due to harsh in vivo conditions such as enzymatic degradation (Choi et 
al., 2014) and absence of targeting moiety for the BBB. 
Regarding the siRNA permeation profile (Figure 5.3 B), the permeability kinetics was 
very similar among all used systems: initially, on the first hour, it increased faster than during 
later time points, which could probably be associated with the slow release profile of siRNA 
from nanoparticles (Chapter IV from this thesis). After 3h, the siRNA permeability from 
siRNA-PLGA:PLGA-PEG-NH2-pept-Cys nanoparticles was significantly higher than from the 
non-functionalized and functionalized nanoparticles with previous blocked receptor. These 
results are in accordance with apparent permeability values (Figure 5.3 A). 
Overall, PLGA:PLGA-PEG nanoparticles obtained more promising results than 
regular PLGA systems. When TfR-targeted, they significantly improve their capability to 
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interact with human brain endothelial cells, and consequently siRNA permeability. This may 
be related to the presence of PEG on the surface of nanoparticles, as it not only enhances 
biocompatibility by inhibiting interaction with serum proteins (Rahme et al., 2015; Tam et al., 
2016), but also makes the bounded peptide to be more spatially available to its receptor. As 
well, the maleimide chemistry used to bind the peptide to the nanoparticle surface could also 
have some influence on these greater results, as already mentioned. This chemical method 
improved specificity and correct peptide orientation when compared to carbodiimide used 
approach from regular PLGA functionalization system (Gomes et al., 2016). Thus, siRNA-
PLGA:PLGA-PEG-NH2-pept-Cys formulation was selected for further experiments. Still, the 
rational for this approach is to retain the siRNA inside brain endothelial cells, where it is 
desired to act by silencing P-gp, and not to cross the BBB. Consequently and according to 
latest data, in general, siRNA low permeability through the human BBB model was achieved 
and confirmed considering that only less than 2% crossed the membrane, which hints that 
siRNA was being retained on cells. 
 
4.4. P-gp mRNA expression in hCMEC/D3 cells 
 
In order to check the silencing efficiency of the siRNA sequence used in this work, 
human BBB cells were transfected with siRNA against P-gp (P-gp-siRNA) by using a 
transfection agent, ScreenFectA. This agent is known to boost up siRNA silence effect, 
acting as a siRNA-specific positive control (Enlund et al., 2014), along with high transfection 
efficiency and low cytotoxicity (Li et al., 2015). 
Down-regulation was quantified at the mRNA level through qRT-PCR at different time 
points after transfection (Figure 5.4). It was found that, 24h post transfection, P-gp-siRNA 
significantly decreased P-gp mRNA expression levels on 45% compared to the treatment 
with transfection agent only. On the other hand, treatment with non-targeted siRNA 
(scrambled-siRNA) did not induce any silencing effect, eliminating non-specific effects from 
nanoparticles. Additionally, following time points (48h and 96h) did not reveal any difference 
between cell treatments, meaning that the P-gp-siRNA knockdown action was only noticed at 
24h post transfection. This probably occurred due to the fast siRNA ability to enter in the cells 
and transfect them, which could be promoted by the transfection agent features already 
mentioned, and further cell recovery over a transient oligonucleotide silencing effect. 
 
CHAPTER V 
135 
 
 
Figure 5.4. Expression of P-gp mRNA at several time points, after hCMEC/D3 cells transfection with 
different type of transfection agent combinations: transfection agent only (negative control), scrambled-
siRNA transfection agent (negative control), and P-gp-siRNA transfection agent. Fold expression was 
normalized to the transfection agent only control at 24h. 
 
P-gp mRNA expression data stressed up the already studied increased expression of 
P-gp on higher cell densities, related with the increased P-gp half-life detected under this 
condition (Muller et al., 1995; Stierle et al., 2004), which is the reason why P-gp mRNA levels 
increased over time, within the same transfection type. 
Previous works also studied siRNA-mediated gene down-regulation in BBB cells. For 
example, the organic cation/carnitine transporter (OCTN2) knockdown was evaluated in 
hCMEC/D3 cells (Higuchi et al., 2015). Authors reported that OCTN2-siRNA (5 nM) 
treatment decreased OCTN2 mRNA expression by 90%, 48h after transfection using 
Lipofectamine RNAiMAX (Higuchi et al., 2015). Another study was performed to understand 
the interaction between caveolin-1 (Cav-1) and P-gp transport activity in a rat brain 
endothelial cell line (Barakat et al., 2007). Authors found that Cav-1-siRNA (50 nM) 
transfection induced a strong 90% of Cav-1 down-regulation, 48h post transfection using 
HiPerFect transfection agent. Interestingly, accumulation of P-gp substrates were reduced up 
to 40% in transfected cells, suggesting that down-regulation of Cav-1 enhanced P-gp 
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transport activity (Barakat et al., 2007). Although these preceding examples stated higher 
silenced expressions when using commercially available transfection agents than the one 
obtained here (90% versus 45%), as well as at a different time point (48h versus 24h post 
transfection), that does not depreciate P-gp-siRNA knockdown results. Maximum silencing 
efficiency depends on several factors like the target protein half-life, cell line used, cell health, 
viability and confluency, as well as the media, serum presence, antibiotics, transfection agent 
and method, and siRNA sequence itself (Gu et al., 2016). 
To verify siRNA-loaded nanoparticles ability to silence P-gp from human brain 
endothelial cells, cells were transfected with unloaded nanoparticles (negative control), P-gp-
siRNA-loaded nanoparticles, and P-gp-siRNA-loaded nanoparticles functionalized with a 
peptide toward the BBB. At different time points post transfection (24h, 48h and 96h) P-gp 
mRNA expression was evaluated (Figure 5.5). 
 
Figure 5.5. Expression of P-gp mRNA at different time points, after cell transfection with different type 
of nanoparticles (unloaded, P-gp-siRNA-loaded and P-gp-siRNA-loaded targeting BBB). Fold 
expression was normalized to the unloaded nanoparticles control at 24h. 
 
At 24h post transfection, functionalized nanoparticles induced a P-gp mRNA 
expression 15% inferior than unloaded nanoparticles did. This value is much lower than the 
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45% observed for P-gp-siRNA on the transfection agent experiment (Figure 5.4), which 
could be justified through the improved transfection enabled by the commercial transfection 
agent, plus the more controlled release of siRNA by the nanoparticles that avoided its burst 
silencing effect. 
In order to compare nanoparticle’s and transfection agent’s efficiency, a study where 
polyethylenimine-PEG nanoparticles were developed to evaluate their DNA transfection 
ability for mammalian cells was performed (Nimesh et al., 2006). These particles were 
compared to lipofectin (transfection agent) on the transfection of luciferase gene (150 mM). 
48h post transfection, authors claimed that co-polymer nanoparticles were found to be the 
most efficient on luciferase transfection, yielding 11-fold higher levels of luciferase activity 
(Nimesh et al., 2006). Another group assessed the ability of cationic multi-shell calcium 
phosphate nanoparticles and the transfection agent Lipofectamine to transfect DNA encoding 
GFP (0.2-0.3 μg per well) on several cell lines (Neuhaus et al., 2016). Researchers stated 
Lipofectamine as the most efficient transfection agent (Neuhaus et al., 2016). Gathering all 
these published data, it is possible to verify that transfection efficiency of nanoparticles 
versus commercial transfection agents does not follow a rationale trend, as it depends on 
numerous factors; inclusively, it has been related to the size of transfection polymer and its 
cytotoxicity. Usually, high molecular weight polymers reported superior transfection efficiency 
(Nimesh et al., 2006), which in turn is often correlated with low cell viability (Neuhaus et al., 
2016). Furthermore, nanoparticles aggregation has been associated with decreased 
transfection efficiency (Ota et al., 2013), which could be affecting the developed system as 
Zetasizer results might suggest. 
At 48h post transfection, no differences were detected (Figure 5.5). As well, no 
significant differences were observed between mRNA levels when cells were treated with 
unloaded and siRNA-loaded nanoparticles. This could be associated with the diminished 
ability of these non-functionalized particles to interact with brain endothelial cells (Gomes et 
al., 2016), and resulting reduced siRNA capacity to get in the cells and silence its target 
protein on a quantifiable extension. 
P-gp mRNA quantification results (Figure 5.5) showed that 96h after transfection, 
when siRNA-loaded TfR-targeted nanoparticles were used, the P-gp mRNA expression was 
reduced. Such down-regulation corresponded to an expression 32 to 52% lower compared to 
unloaded nanoparticles and siRNA-loaded nanoparticles, respectively. Therefore, although 
P-gp mRNA expression increased over time while cell density also increased (Muller et al., 
1995; Stierle et al., 2004), there was a P-gp silencing effect when siRNA-loaded 
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functionalized nanoparticles were used, which was highlighted at 96h. Consequently, this 
was the selected time point for the functional assay permeability experiment. 
A delayed P-gp down-regulation was observed, from 24h post transfection when a 
commercial transfection agent was used to 96h post transfection when the produced 
nanosystem was applied. This time gap could be justified due to nanoparticles-related siRNA 
more controlled release, which extend and retard its effect. 
To study drug resistance on breast cancer cells, P-gp-siRNA complexed with 
polyethylenimine substituted with lipids was tested by Aliabadi and colleagues (Aliabadi et 
al., 2013). 48h post transfection (54 nM siRNA), the P-gp mRNA levels decreased around 
50% compared to values obtained for scrambled-siRNA control (Aliabadi et al., 2013). PLGA 
has also been utilized to conquer tumor drug resistance as P-gp-siRNA carrier functionalized 
with biotin for active tumor targeting (Patil et al., 2010). Adenocarcinoma cells were 
transfected with siRNA-loaded PLGA nanoparticles (0.2 nM siRNA), resulting in about 50% 
decrease of P-gp mRNA expression levels 72h post transfection, when compared with 
control treatments (Patil et al., 2010). Moreover, chitosan nanoparticles complexed with P-
gp-siRNA were used to transfect a rat BBB model cell line (Malmo et al., 2013). 48h post 
transfection (100 nM siRNA), P-gp mRNA levels were 20% reduced compared to the 
untreated cells. From the transfection with chitosan only or scrambled-siRNA, no significant 
change in mRNA expression was detected, indicating absence of non-specific effects from 
chitosan or nanoparticles, respectively (Malmo et al., 2013). 
These P-gp knockdown values and respective post transfection selected times are 
mostly in accordance with the obtained results, but none of them were performed on human 
brain endothelial cells, highlighting this work novelty with the hCMEC/D3 cell line. 
Additionally, P-gp-siRNA transfection, targeted to these cells through a specific peptide-
oriented chemistry, constitutes an innovative application of such functionalization method. 
Furthermore, down-regulation percentages and times depend on nanoparticles composition 
and siRNA release profile, in addition to the already mentioned factors. 
 
4.5. Functional assay through rhodamine 123 permeability 
 
To quantify the effects of siRNA-mediated silencing on P-gp function, the permeability 
of a well-established P-gp substrate (rhodamine 123 (Lee et al., 2013)) was tested on a 
human BBB in vitro membrane 96h after cells treatment. BBB models were subjected to 
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different treatments: no transfection/inhibition; transfection with unloaded nanoparticles, 
siRNA-loaded nanoparticles and siRNA-loaded TfR-targeted nanoparticles; and P-gp 
chemical inhibition. Rhodamine 123 apparent permeability was calculated (Figure 5.6 A), as 
well as the permeation profile (Figure 5.6 B). 
No cellular treatment and treatment with unloaded nanoparticles induced similar 
rhodamine 123 permeability values through the BBB model, indicating that these systems by 
themselves did not interfere with cellular efflux. However, P-gp-siRNA-loaded nanoparticles 
treatment brought an increased rhodamine permeability of 11 to 12% compared to no 
treatment and unloaded nanoparticles treatment, respectively. This slight increase was not 
predicted by the P-gp mRNA expression assay, although siRNA silencing action was noticed 
by this functional experiment. Following this, cells treated with P-gp-siRNA-loaded 
functionalized nanoparticles enabled a significant increase on rhodamine permeability – 26, 
27 and 17% higher than values obtained for non-treated cells, unloaded nanoparticles and 
siRNA-loaded nanoparticles treatments, respectively. Those differences have a close relation 
with the reduced P-gp mRNA expression obtained for these nanosystems 96h post 
transfection. When P-gp as an ABC transporter is down-regulated, a weaker efflux made by 
this protein is reached, and thus also an increased uptake/permeability of its substrates such 
as rhodamine 123 is attained. 
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Figure 5.6. (A) Rhodamine 123 apparent permeability values obtained 3h after crossing through a 
BBB model membrane previously treated with: any transfection/inhibition, unloaded nanoparticles, P-
gp-siRNA-loaded nanoparticles, P-gp-siRNA-loaded TfR-targeted nanoparticles, and P-gp chemical 
inhibitor (verapamil). (B) Percentage of rhodamine 123 mass permeated through the previously treated 
BBB membrane, over 3h. 
 
Since TfR-targeted, P-gp siRNA-loaded nanoparticles caused a decrease on P-gp 
mRNA expression between 32 and 52%, as already discussed. Therefore, an equivalent 
increase on rhodamine 123 permeability could be expected. However, P-gp efflux kinetics 
has a maximum transport rate related with its saturation nature and substrate-concentration 
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dependence (Sjostedt et al., 2014). Hence, although rhodamine permeability had, in fact, 
increased after functionalized nanoparticles treatment, it is not feasible or correct to 
quantitatively correlate P-gp expression with P-gp substrates permeability. 
Rhodamine permeability rose even more significantly when P-gp was inhibited 
through a chemical way – it was 49, 50, 43 and 31% higher than permeability obtained when 
cells were treated without any agent, with unloaded nanoparticles, siRNA-loaded 
nanoparticles, and siRNA-loaded functionalized nanoparticles, respectively. This was 
expected since chemical inhibition tends to be more powerful than a transfection dependent 
on siRNA silencing capacity (Duan et al., 2004). Still, siRNA has several advantages such as 
a transient and reversible action, reduced toxicity towards non-specific tissues (which is 
related to the TfR-targeting of used nanoparticles), and high specificity (Navarro et al., 2012). 
On the other hand, chemical inhibitors as verapamil could easily promote side effects related 
to interactions with the second drug that would be further administered to cross the barrier 
(Navarro et al., 2012). 
In a previous study, to investigate the effects of drugs on the function and expression 
of P-gp, rhodamine 123 efflux assays were performed in Caco-2 cells (Abbasi et al., 2016). 
After verapamil (300 μM) and posterior rhodamine 123 (5 μM) incubation, authors found the 
mean intracellular concentration of rhodamine 123 on the verapamil-treated cells to be 2-fold 
higher than on non-treated cells (Abbasi et al., 2016). These results highlighted the already 
known P-gp inhibitors capacity. 
In accordance with apparent permeability values, rhodamine permeated mass 
through a cellular membrane pre-treated with P-gp-siRNA-loaded functionalized 
nanoparticles was significantly higher from all other particles over all time points (Figure 5.6 
B). As well, verapamil treatment led to the same conclusion, with a more noticeable effect. At 
the 3h time point, the P-gp-siRNA-loaded nanoparticles treatment also significantly enhanced 
the rhodamine permeated mass. 
In a study where P-gp-siRNA-loaded chitosan nanoparticles were investigated as a 
potential way to silence P-gp in a rat BBB model, doxorubicin (50 μM) was used for a 
functional assay as a P-gp substrate (Malmo et al., 2013). In addition to the effective P-gp 
knockdown observed after P-gp-siRNA (100 nM) transfection, authors described a decrease 
in doxorubicin efflux, and subsequent 60% metabolic activity reduction caused by this drug 
action. These results meant increased cellular delivery and efficacy of P-gp model substrate 
when this transporter was silenced (Malmo et al., 2013). In another previous study, after a 
single P-gp-siRNA (200 nM) transfection, Caco-2 cells expressed lower amounts of P-gp 
mRNA (Lee et al., 2013). Subsequently, rhodamine 123 efflux decreased, increasing its 
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intracellular accumulation. Authors obtained consistent results through both P-gp-siRNA and 
a well established P-gp inhibitor, LY335979 (Lee et al., 2013). Caco-2 cell line used by Lee 
had also been used by Klein with the same purpose. However, Klein treated cells with both 
silicon quantum dots complexed with P-gp-siRNA and P-gp-siRNA-Lipofectamine 2000 (Klein 
et al., 2009). After that, cells were incubated with rhodamine 123 (0.1 mM) and results stated 
that, from day 0 to day 8 post transfection, the P-gp transporter efficiency for the rhodamine 
123 dropped continuously for both type of transfection carriers, revealing the siRNA silencing 
capacity (Klein et al., 2009). 
In agreement with obtained rhodamine 123 permeability results, previously published 
works, as discussed, also state the significant increase of this P-gp substrate permeability 
when P-gp is down-regulated. However, again, the present study stands out from all the 
others already performed in the P-gp-siRNA and P-gp substrate permeability field by the use 
of targeted systems to a human brain endothelial cell line. This cell line, hCMEC/D3, is being 
nowadays the most commonly selected for the development of in vitro BBB models (Weksler 
et al., 2013). 
It is important to highlight that TEER was kept constant from culture day 8 (cell 
treatment) until day 12 (permeability experiment 96h later), meaning that membrane integrity 
was not lost (data not shown). 
Overall, results from this work suggest that developed anti-P-gp siRNA-loaded TfR-
targeted co-polymer carriers could be a promising strategy to circumvent a human BBB huge 
obstacle like drug efflux transport, improving drugs ability to cross this biological barrier. 
 
5. Conclusions 
 
Surpassing the BBB is the main common trick for brain therapies success due to its 
physiological restrictive features that creates a CNS unique environment. Therefore, this 
work focused on establishing a new platform to silence P-gp, facilitating P-gp substrates 
transport across this biological membrane. Hence, siRNA against P-gp was used and 
targeted to human brain endothelial cells through TfR-targeted peptide-functionalized 
polymeric nanoparticles. Maleimide functionalized PLGA:PLGA-PEG-NH2 (95:5) 
nanoparticles successfully targeted the BBB and led to a significant 2-fold increase on the 
siRNA permeability through the BBB model, compared to the non-functionalized systems. 
When transferrin receptor was previously blocked, the permeability of siRNA-loaded 
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functionalized nanoparticles decreased to values similar to the ones obtained for non-
functionalized nanoparticles. This emphasized the transcellular pathway that TfR-targeted 
particles also took to cross the membrane, proving the existence of receptor-mediated 
endocytosis through transferrin receptor. Beyond their ability to improve siRNA permeability, 
functionalized nanoparticles also decreased P-gp mRNA expression in endothelial cells. 96h 
post transfection, the expression of P-gp mRNA was 52% reduced when cells were treated 
with functionalized compared to non-functionalized siRNA-loaded nanoparticles. 
Subsequently, the permeability of rhodamine 123, a P-gp substrate, across a cell-based BBB 
model was 17% higher after 6h treatment with functionalized siRNA-loaded nanoparticles. 
Instead of siRNA, verapamil, a P-gp chemical inhibitor, was also tested, which drove 
rhodamine permeability to increase 31% more than the values achieved when siRNA-loaded 
functionalized nanoparticles were used. Still, chemical inhibitors are not as specific as siRNA 
and have potential side effects problems related to drug-drug interactions when the drug that 
needs to cross the BBB is also administered (Navarro et al., 2012). 
TfR-targeted siRNA-loaded co-polymer nanoparticles had been underlined during this 
work since they profitably induced P-gp silencing and consequent rhodamine 123 
permeability enhancement through a human BBB model. Therefore, these results suggest 
that developed anti-P-gp siRNA-loaded functionalized carriers could be a promising 
approach to temporarily disrupt the human BBB to enable drugs to reach the CNS in 
therapeutic concentrations. Concurrently, by adjusting the targeting ligands attached to the 
nanoparticles surface, this siRNA against P-gp system could be translated to other fields as 
cancer, by addressing drug-resistance in tumors characterized as P-gp over expressing 
tissues. 
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1. General discussion and conclusions 
 
Bioengineering, as a functional, innovative and trendy field, has been of 
growing importance for the pharmaceutical and biomedical research. Along with 
the progress of more fundamental fields, such as biology and biochemistry, which promote a 
deeper knowledge of human body function, the evolution of biotechnology is enticing modern 
society to believe in an improved efficiency of treatments. Indeed, drug and gene delivery 
systems, engineered to specifically target desired cells or tissues, are diamonds ready to be 
polished, that could become meaningful for the increasing incidence of central nervous 
system (CNS) disorders. Similarly, the development of membranes mimicking biological 
barriers, as blood-brain barrier (BBB), is of topmost significance to predict the in vivo 
behavior of delivery systems. Therefore, the rational of this thesis work followed a 
compromise between nanotechnology, BBB models and their interaction, in order to end up 
by achieving a successful optimized system for the modulation of drug efflux at the human 
BBB. 
As discussed in this thesis work, nanoparticles based on lipid or polymeric matrices, 
already known for their ability to carry oligonucleotides, were implemented as an anti P-
glycoprotein (P-gp) small interfering RNA (siRNA) protective and delivery system. These 
carriers were further surface-modified, through polyethylene glycol coating (PEGylation) and 
receptor-targeted functionalization, to upgrade their functional characteristics. 
Simultaneously, the development of BBB models, phospholipid- and cell-based ones, 
enabled the assessment of nanoparticles feasibility and potential, as well as their ability to 
interact with human brain endothelial cells and inflect brain-to-blood drug efflux. 
Therefore, firstly, a new BBB phospholipid-based model was implemented through a 
phospholipid vesicle-based permeability assay (PVPA) method. BBB-PVPA, made of a 
phosphatidylcholine and phosphatidylethanolamine mixture, only addressed passive 
transcellular-like diffusion and intended to be an alternative and/or complement to cellular 
models. Membranes produced through this method were easy to develop by a short-time 
consuming protocol, leading to similar permeability data as other in vitro BBB models. These 
advantages light up this model as an excellent way for high throughput screening of 
permeability properties. Thus, potential drug/nanosystem candidates, early in the 
development process, could be screened using this model, inspiring a pre-selection of the 
best drug/nanosystem before continue to in vitro and in vivo studies. One of the main 
objectives of the barrier developed through this method was to enable results extrapolation 
and prediction. Consequently, it was used to test the permeability of siRNA, as a free 
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biomolecule and loaded in simple lipid (Witepsol E85) and polymeric (poly(lactic-co-glycolic 
acid); PLGA) nanoparticles. 
To promote BBB crossing, it is often argued that the ideal size for a non-targeted 
system is up to 200 nm (Chen et al., 2004). Thus, rapidly uptake by the reticuloendothelial 
system is avoided and, therefore, blood circulation time and nanoparticles contact time with 
the BBB are increased (Chen et al., 2004; Kaur et al., 2008). Developed siRNA-loaded 
nanoparticles accomplished this prerequisite since they had a mean size of 140 nm and were 
slightly negative (-10 mV). In general, nanocarriers, especially solid lipid nanoparticles (SLN), 
improved the siRNA transport across the non-cellular barrier. Their hydrophobic composition 
with high affinity to lipid membranes made of liposomes enabled siRNA permeability to 
increase from 10% (free-siRNA) to 14 and 19% (siRNA-loaded polymeric and lipid 
nanoparticles, respectively). Therefore, nanoparticles were found to be able to interact with 
BBB-PVPA liposomes, passively crossing the barrier, revealing capability to interact with 
BBB-like cellular membranes. Afterwards, nanoparticles were improved by changing the 
surfactant and combining an additional lipid/polymer envisioning further functionalization 
processes. siRNA reached association efficiency (AE) of 50% for the polymeric systems and 
31% for the selected SLN, while retaining a prolonged release from nanoparticles matrices 
(60% released after 24h). Two distinct chemical approaches, carbodiimide and maleimide, 
promoted surface modification with a peptide against transferrin-receptor (TfR), which was 
physicochemical confirmed by the increase of mean particles size and by nuclear magnetic 
resonance peptide-related new peaks. Most importantly, the interaction between human 
brain endothelial cells and non-cytotoxic nanoparticles, evaluated through fluorescence 
microscopy and flow cytometry, revealed that functionalization improved 4-fold the capability 
of polymeric nanoparticles to interact with cells. Hence, polymeric nanocarriers have proved 
to be crucial to potentiate siRNA efficiency, by promoting its targeted brain delivery and 
subsequent uptake. More specifically, the maleimide functionalization of a polymeric system, 
developed with both PLGA and PLGA-PEG amine terminated, improved siRNA permeability 
(2-fold) through a BBB cell-based model, compared to non-functionalized systems. This 
same system led to 52% reduction of P-gp messenger RNA (mRNA) expression in human 
brain endothelial cells 96h post transfection, which drove to a 17% increase of rhodamine 
123, as a P-gp substrate, permeability. 
As siRNA permeability was tested in two distinct BBB models, the final comparison 
between obtained results is imperative. On one hand, permeability of free-siRNA was similar 
for BBB-PVPA and cell-based model, indicating that PVPA was a good method to predict the 
permeability of a biomolecule as siRNA and, potentially, other biopharmaceutical hydrophilic 
drugs. On the other hand, the same trend was not observed for siRNA when loaded in 
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nanoparticles. When BBB-PVPA was used, siRNA-PLGA nanoparticles had apparent 
permeability values around 5.5  10-6 cm s-1, which were higher than the ones obtained for 
the cell-based model, 4.0 – 8.5  10-7 cm s-1. Among the factors that could explain this 
difference are the BBB-PVPA membrane hydrophobicity and the biochemistry complexity of 
BBB cells. Since BBB-PVPA consisted of liposomes, lacking any hydrophilic structure as 
cytoplasm or extracellular matrix, this membrane was more hydrophobic than the cell-based 
one, which could cause an increased affinity and interaction with apolar nanoparticles, 
leading to higher siRNA-loaded permeability. Although the selected BBB-PVPA barrier 
reached transendothelial electrical resistance values above 2,000 Ωcm2 on the same day of 
production, these also highly decreased on 50% during the permeability experiment, 
meaning that tested drugs/molecules may open some spaces within the membrane. That 
may actually caused an augment of the paracellular permeability of molecules and justify the 
difference obtained for siRNA-loaded nanoparticles on BBB-PVPA versus BBB cell-based 
model. Moreover, other possible reason is related to the difference of tested nanoparticles on 
both models. Developed systems were improved along the project, by changing the 
surfactant and surface functionalization, which led them to become larger and that could 
have reduced their ability to permeate the membrane. Finally, as a biologic system, cell-
based membrane addressed both passive and active transports. As so, it also had other 
obstacles (missing on the BBB-PVPA model) that nanoparticles needed to overcome, which 
may have hampered their crossing ability. 
Through functionalization, nanoparticles were targeted to the TfR which is over 
expressed at the BBB. This receptor is both temperature and energy dependent (Harding et 
al., 1983). When uptaking transferrin, as well as other possible ligands such functionalized 
nanoparticles, TfR is also internalized. It is well known that TfR involves clathrin-mediated 
endocytosis (Damm et al., 2005; Fekri et al., 2016). Thus, functionalized nanoparticles get in 
the cells through binding and receptor activation. The complex TfR plus nanoparticles 
diffuses through the plasma membrane and is captured by a forming clathrin-coated pit that 
then forms a clathrin-coated vesicle which will fuse to an early endosome. After this, the 
receptor is recycled back to the plasma membrane, which normally requires previous 
passage through early endosomes and recycling endosomes (Harding et al., 1983; Sheff et 
al., 2002; van Dam et al., 2002). Consequently, TfR recycling enables the continuous 
internalization of functionalized nanoparticles. 
Subsequently, after a successful siRNA transport until reach the brain endothelial 
cells due to nanoparticles engineering, siRNA is released from its biodegradable carriers. 
This stage is a key step for the oligonucleotide since, during its intracellular trafficking into the 
cytoplasm, it has to escape from endosomes and avoid lysosomes to be able to silence its 
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target protein (Ma, 2014). However, since clathrin-mediated endocytosis commonly directs 
the entry agent to lysosomal compartments (Rejman et al., 2005), most likely, some of P-gp-
siRNA was degraded by the lysosomal content, where various nucleases within an acidic 
environment are located. The efficient and successful siRNA, that circumvented these 
vesicles and went to the cytosol, can then associate with the RNA-induced silencing complex 
(RISC), directing the cleavage of mRNA complementary sequences (Fountaine et al., 2005; 
Martinez and Tuschl, 2004). 
When loaded in functionalized polymeric nanoparticles, P-gp-siRNA has silenced 
52% of P-gp mRNA expression in human brain endothelial cells, 96h post transfection. 
Therefore, it is hypothesized that P-gp production was not completely depleted. Although not 
being the presumed theoretical goal of such assay, it was somehow a plus. Indeed, normal 
cell trafficking, as metabolites excretion, involves P-gp transport (Thiebaut et al., 1987). 
Moreover, P-gp-siRNA treatments promote a transient P-gp down-regulation. After treatment 
interruption and according to P-gp turnover, the silencing effect is discontinued and P-gp 
production comes back to normal (Gomes et al., 2015). 
Overall, this project ended up with an efficient TfR-targeted anti-P-gp siRNA-loaded 
nanosystem whose promising results pointed out that it could be the trigger to down-regulate 
P-gp at the BBB, ending with numerous drug reaching brain advantages. Consequently, any 
P-gp substrate drug that is desired to achieve the CNS in therapeutic concentrations would 
benefit from this transient opportunity. Concomitantly, the giant power of this siRNA against 
P-gp system could be translated to other fields as cancer, by addressing drug-resistance in 
tumors characterized as P-gp over expressing tissues, through simply adjusting the targeting 
ligands attached to the nanoparticles surface. 
 
2. Future perspectives 
 
Nanoparticles developed to carry siRNA to a specific location arise through the 
convergence of bioengineering, technology and pharmaceutical fields to fill medicine needs. 
This was exactly the great goal of this thesis work, achieved by the refinement of a siRNA 
delivery system designed to surpass BBB obstacles. Nonetheless, when caught by the 
scientific research area, the possibilities for “what you can do next” are endless. The 
continuous knowledge evolution does not allow future perspectives to decline. 
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siRNA-loaded carriers may still be improved by enhancing its AE and refining its 
release profile. Through siRNA association with natural polyamines (like spermidine and 
putrescine), which are small positive charged molecules that strongly bind to negative 
phosphate groups from nucleic acids, the oligonucleotide become more stable and robust. 
Hence, complexed siRNA association to nanoparticles happens to be stronger and its 
release from them harder to attain. As demonstrated on previous studies (Woodrow et al., 
2009), we have already obtained promising preliminary results where PLGA nanoparticles 
with higher AE were produced after complex siRNA with polyamines. siRNA AE increased, 
from 50% to 55% and 67%, when spermidine and putrescine were used, respectively. 
Accordingly, these systems attained an interesting siRNA release profile, mainly 
characterized by a diminished initial burst release. Complexed siRNA could be advantageous 
in different ways, however, due to these molecules amine composition, toxicity arises as a 
serious possible problem. Therefore, assays regarding their cytotoxicity and further 
transfection efficiency should be performed. 
Unlike clathrin-mediated endocytosis, the caveolae-dependent endocytosis could 
bypass lysosomes, avoiding entry molecules degradation (Kou et al., 2013). Therefore, a 
topic that could be further explored is the nanoparticles targeting mechanism. Using a ligand 
that targets a caveolae-dependent receptor, the siRNA early degradation would be 
circumvented. At the BBB, low density lipoprotein receptors are proposed to operate through 
the caveolar mechanism (Georgieva et al., 2014), which makes apolipoprotein E a great 
promising ligand for nanoparticles surface. 
Still regarding nanosystems production, an interest aspect that could be optimized is 
adapting the production method to smooth the progress of its scale-up to an industrial level. 
Replacing double emulsion conventional method with microfluidics technique could be a 
great bottom line to also reduce the production time. 
Furthermore, anti-P-gp siRNA silencing efficiency evaluation may be deeper 
assessed, besides the P-gp mRNA expression. Following the transcription and translation 
path, P-gp levels should also be determined through Western Blot analysis. Thus, the 
functional assay timing could be updated regarding the post transfection time when the 
protein itself is silenced and less expressed. 
Moreover, translate this approach to an in vivo study would be the icing on the cake. 
Healthy adult male Wistar rats would be intravenously administered with free-siRNA or 
siRNA-loaded nanoparticles prior to a P-gp substrate (as paclitaxel or rhodamine 123) 
administration. Afterwards, rats would be euthanized at different time points, followed by 
brain removal, P-gp substrate detection, mRNA and protein extraction and quantification. 
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Immunohistochemistry on brain histological slides would also monitor P-gp expression 
reduction. As reported by in vitro results, drug accumulation in the brain is expected to 
increase in rats injected with TfR-targeted siRNA-loaded nanoparticles. After the in vivo proof 
of concept, the therapeutic relevance of modulating the BBB efflux with developed siRNA 
carriers could, in the future, be determined through simultaneous administration of these 
nanoparticles with anticancer compounds in rats with induced brain tumors, or 
neuroprotective agents in rats with induced stress. 
Finally, regarding cancer as one of the most central research fields nowadays, the 
developed siRNA against P-gp system may be applied to cancer-related therapy. This could 
have great advantages due to the known drug-resistance in tumors characterized as P-gp 
over expressing tissues. By adjusting the targeting ligands attached to the nanoparticles 
surface, different targets could be addressed. 
As hereby described, several aspects are ready to be optimized pursuing successful 
and effective targeted anti-P-gp siRNA delivery systems. 
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